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Conventional exercise training in chronic heart failure (CHF) is safe and beneficial.
Training is therefore recommended in a number of guidelines although the data upon
which these recommendations are based are drawn from trials enrolling highly selected
groups of CHF patients. Extrapolation of these data to a wider CHF population is
difficult. Additionally, the optimal mode of training and the timing of introduction of
training during a CHF patient's illness pathway is unclear. Applicability of conventional
training regimes to the wider population is uncertain. This thesis explores the differing
characteristics of trial and general CHF populations and describes the utility of a novel
form of exercise training, neuromuscular electrical stimulation of the legs for both stable
patients and those with recently decompensated symptoms, a group normally excluded
from exercise training trials.
Methods.
Studies 1-3 randomise stable patients to conventional bicycle training (Bike) or
neuromuscular stimulation (NMS) of quadriceps and gastrocnemius leg muscles. A 6-
week training programme is undertaken with functional performance assessed by 6-
minute walk (6MW), quadriceps strength and fatigue testing, cardiopulmonary exercise
testing and quality of life scoring. Body composition is assessed further in study 2 using
dual-energy X-ray absorptionometry. Inflammatory markers are assessed before and
after training in study 3. Study 4 is a controlled trial ofNMS and Bike training including
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stable (S-CHF) and recently decompensated (RD-CHF) patients, with performance
testing before and after a period of training. Study 5 explores the characteristics of a
large group of CHF patients admitted to hospital with heart failure and compares the
characteristics of these patients with those included in the exercise training trial
described in study 4 and also with those patients included in a recent meta-analysis of
exercise training trials.
Results.
Improvements in 6MW, treadmill exercise time, quadriceps strength and fatigue were
observed following both Bike and NMS training for stable patients in study 1. In study
2, a significant improvement in peak VO2 following bike training but not NMS was
observed when corrected for lean muscle mass. No change in body composition
following training was observed. Pro-inflammatory state was attenuated following
conventional training with a significant fall in sTNFar2 in the Bike group only. NMS
t
training resulted in significant improvement in NT-pro BNP when compared with
controls and Bike patients in study 4. Overall, exercise training appeared to be effective
when RD-CHF patients were included. Study 5 demonstrated that only 6.7% of the
screened population was suitable for inclusion in the exercise training trial in study 4.
Eligible patients were younger, more likely to be male, had fewer comorbidities and
were on more optimal CHF medication than the non-eligible patients despite similar




NMS exercise training appears safe and effective in stable CHF patients, although it
differs from Bike training in its effects on markers of inflammation. Body composition
did not change following training despite functional improvements, implying qualitative
changes in peripheral muscle. RD-CHF patients may benefit from training but
recruitment into a trial of exercise training is difficult. NMS is more easily delivered
than Bike training and it may be a useful alternative or bridging therapy for those who
cannot exercise conventionally. Extrapolation of data presented in this thesis and that
published in the literature needs to be viewed critically in the context of the wider CHF
population as standard inclusion and exclusion criteria application in addition to the
psychosocial features of those volunteering for trials results in substantially different
population characteristics.
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Conventional exercise training is safe in chronic heart failure (CHF) and beneficial for a
wide range of outcome measures including exercise performance, aerobic capacity and
quality of life. From one randomised study, one meta-analysis and a Cochrane review,
there is emerging evidence of a possible mortality benefit and reduction in
hospitalisation following training which may attenuate the major socioeconomic burden
that heart failure presents. Training is recommended in a number of guideline documents
but data on which these recommendations are based are drawn from trials of highly
selected patients. Translation of findings to a wider heart failure population is difficult.
In this thesis, data are presented exploring a novel method of exercise delivery,
neuromuscular electrical stimulation (NMS). Study 1 is a pilot study ofNMS vs. bicycle
exercise in stable CHF patients. Study 2 explores the differing effects of NMS and
conventional training on body composition and exercise performance to investigate the
hypothesis that quantitative changes in muscle are responsible at least in part for the
functional gains ubseived. Study 3 explores the role of NMS training in the attenuation
of the pro-inflammatory response in CHF. Study 4 is a randomised controlled trial of
NMS and conventional exercise and follows on from the pilot study, study 1. Patients
who have recently been discharged from hospital following an acute decompensation of
their heart failure, a group previously not considered for training, are included and
outcomes compared with the stable patient, the group traditionally enrolled in training
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studies. Study 5 explores the characteristics of stable, recently-decompensated and
published trial populations of heart failure patients compared with the wider CHF
population from which they are recruited as substantial differences are likely to exist,
limiting the interpretation of published findings.
1.2 Methods
Studies 1-3 randomised stable patients to conventional bicycle ergometer training or
neuromuscular stimulation of the quadriceps and gastrocnemius muscles of the legs.
Exercise was performed daily for 6 weeks. Functional performance was assessed by 6-
minute walk (6MW), quadriceps strength and fatigue measurement and cardiopulmonary
exercise test. Quality of life was assessed with the Minnesota 'Living with Heart
Failure' questionnaire. Body composition was measured by dual-energy X-ray
absorptionometry (DEXA scanning). Inflammatory state was assessed by measurement
of interleukin-6 (IL-6), high sensitivity C-reactive protein (hs-CRP), tumour necrosis
factor a (TNFa) and the soluble TNFa receptors, sTNFari and sTNFar2. Studies 4 and 5
recruited patients following a recent decompensation of their heart failure (RD-CHF) in
addition to stable CHF patients (S-CHF). RD-CHF commenced NMS or conventional
cycle ergometer training within 4 weeks of hospital discharge according to the same
protocol as S-CHF patients. In study 5, 672 CHF patients were screened either following
hospital admission or following attendance at a hospital clinic. Baseline characteristics
of patients scrutinised in a recent meta-analysis of CHF exercise training trials were
compared with the screened population and the S-CHF and RD-CHF groups.
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1.3 Results
In study l, 46 stable patients were randomised. Conventional cycle ergometer exercise
and NMS resulted in significant improvement in 6MW, treadmill exercise time,
quadriceps strength and fatigue. Peak VO2 in both groups was unaltered following
*
training.
In study 2, 36 stable patients were randomised. Significant improvement in peak VO2
corrected for lean muscle mass was seen following conventional cycle ergometer
training but not NMS. Both forms of training resulted in similar improvements in
treadmill exercise time, leg strength and 6MW. No significant alteration following
training was observed in body composition.
In study 3, 46 stable patients were randomised. Pro-inflammatory state appeared to be
attenuated by conventional cycle ergometer training but not by NMS, with a significant
decrease in sTNFar2 in the bike group only.
In study 4, 40 patients were recruited (15 S-CHF and 25 RD-CHF). Exercise training
with conventional cycle ergometer or NMS resulted in significant gains in NYHA
functional class, 6MW, VO2 at anaerobic threshold, oxygen uptake efficiency slope,
VE/VCO2 slope, NT-pro BNP, quadriceps strength and treadmill exercise time when
compared with controls. NMS training for RD-CHF patients appeared to result in a
greater reduction in NT-pro BNP in the NMS group compared with conventional
training and control patients.
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In study 5, 672 patients were screened. Only 6.7% were eligible to participate in a trial
of conventional vs. NMS exercise training when standard inclusion and exclusion
criteria were applied. Of the 5.06% subsequently randomised only 3.42% of the
originally screened population were able to complete the study. Eligible patients were
younger, had similar NYHA class, had fewer comorbidities and were more likely to be
treated with ACEi, B-blockers, aldosterone antagonists and digoxin than the non-eligible
population. Younger and male patients were over-represented in the published meta¬
analysis also.
1.4 Conclusions
NMS exercise training appears safe and effective in stable CHF patients, although it
does differ from conventional cycle ergometer training in its effects on markers of
inflammation. No change in body composition was observed following either form of
training in stable patients despite functional improvements, implying qualitative rather
than quantitative changes in peripheral muscle. RD-CHF patients may benefit from
training but recruitment into and maintenance within a trial of exercise training is
difficult. NMS appears to be a more practical training modality than conventional cycle
ergometer training and benefits for RD-CF1F patients following NMS are observed.
NMS may be a useful alternative for those CHF patients who cannot exercise
conventionally due to limited functional capacity. Alternatively, it could be useful as a
bridging therapy before a more conventional regime can be adopted. The role of early
exercise training for the recently decompensated patient remains uncertain.
Extrapolation of the trail data presented in this thesis and that published in the literature
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needs to be viewed critically in the context of the wider CHF population as standard
inclusion and exclusion criteria application in addition to the psychosocial features of
those volunteering for trials results in substantially different population characteristics.
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2 Introduction
Heart failure is common and lethal. It represents a major health care burden for the 21st
century as the population ages and patients with ischaemic heart disease show improved
survival. Yet the mechanisms by which the syndrome develops and progresses are
incompletely understood. Advances have been made over the past 20 years in the
treatment of heart failure, particularly with respect to the angiotensin converting enzyme
inhibitor and beta-blocker classes of drugs; more recently, advances have been made
with cardiac resynchronisation therapy and automated implantable defibrillators. Despite
this however, the mortality in heart failure remains very high and rivals the mortality
associated with some neoplasms. Clearly, our understanding of this condition remains
incomplete and other as yet unidentified pathological mechanisms exist in heart failure
which contribute to the progression of this debilitating syndrome. Research continues
around the globe to promote our understanding in all aspects of heart failure, from basic
science and genetic studies through to population based data.
A key feature of the syndrome of heart failure is exercise intolerance, due to fatigue and
breathlessness. Over the last 10 years or so, preliminary evidence has emerged
suggesting the symptomatic benefit of exercise training for patients with heart failure.
Issues regarding the potential role for training in certain patient groups form the main
focus for this thesis. Exercise training regimes undertaken in previously published work
differ, but mainly involve conventional forms of training. A major drawback, of course,
is the difficulty in targeting appropriate patient groups for exercise prescription given the
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elderly, detrained and demotivated nature of the heart failure population and
conventional forms of exercise are unsuitable for those patients with more advanced
disease. Non-conventional forms of exercise training which require less physical effort
on the part of the participant may be of particular use in this circumstance and research
on this topic will be presented below. To begin with, however, the syndrome of heart
failure will be introduced and defined, following which the current knowledge regarding
epidemiology and pathogenesis will be detailed. Subsequently, the current evidence for
exercise training in heart failure will be presented and the rationale for the design of
studies presented in this thesis will be explained.
2.1 Definition
2.1.1 Basic definitions
Heart failure is a complex clinical syndrome rather than a disease in itself and manifests
with symptoms of fatigue, exercise intolerance, breathlessness, oedema and sometimes
cachexia. It can be defined as a condition in which the heart loses its ability to efficiently
eject sufficient blood to meet the metabolic demands of the body. The inefficiency can
be due to impaired contraction of the ventricles during systole secondary to disease of
the myocardium (systolic heart failure) or due to impaired relaxation of the ventricles
preventing adequate filling (diastolic heart failure). Aetiologies of heart failure are
diverse and include ischaemic heart disease, cardiomyopathy, valvular heart disease and
hypertension (Table 2.1). Simply put, heart failure is a syndrome which results from any
structural or functional cardiac disorder which impairs the ability of the ventricle to fill
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with or eject blood.
The terms right heart failure and left ventricular failure are sometimes used to indicate
impairment of predominantly the right or left ventricle, respectively. Right heart failure
is a clinical syndrome characterised by tissue congestion (including a raised jugular
venous pressure, peripheral oedema, ascites and abdominal organ enlargement) with







• Hypertrophic / obstructive
• Restrictive-for example, amyloidosis, sarcoidosis, haemochromatosis
• Obliterative
Valvular and congenital heart disease
• Mitral valve disease
• Aortic valve disease
• Atrial septal defect, ventricular septal defect
Arrhythmias
• Tachycardia
• Bradycardia (complete heart block, sick sinus syndrome)
• Loss of atrial transport-for example, atrial fibrillation
Alcohol and drugs
• Alcohol
• Cardiac depressant drugs (e.g. calcium antagonists)
"High output"failure





• Pulmonary hypertension e.g., pulmonary embolism, cor pulmonale, primary
pulmonary hypertension
• Right ventricular infarction
» Tricuspid incompetence
Table 2.1. Aetiology of heart failure
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ventricular dilatation and severe tricuspid regurgitation. There are multiple causes
including severe left heart failure, severe lung disease with pulmonary hypertension,
primary pulmonary hypertension and right ventricular infarction.
Heart failure can also be classified as either acute or chronic and the term
'decompensated heart failure' is sometimes used to describe the worsening of previously
stable chronic heart failure with the development of acute symptoms.
In summary, heart failure is a general term which encompasses multiple aetiologies,
pathophysiological mechanisms and clinical presentations.
2.1.2 Staging and severity
Two methods of defining the severity of heart failure are generally used in clinical





Slight limitation of physical activity.
Comfortable at rest, but ordinary physical
activity results in fatigue or dyspnoea.
Marked limitation of physical activity.
Comfortable at rest, but less than ordinary
activity causes fatigue or dyspnoea.
Unable to carry out any physical activity
without discomfort. Symptoms of c ardiac
insufficiency at rest. Ifany physical activity is
undertaken, discomfort is increased.
No limitation ofphysical activity.
Ordinary physical activity does not cause
undue fatigue or dyspnoea
Figure 2.1. New York Heart Association classification of symptom severity
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New York Heart Association (NYHA) classification (The Criteria Committee of the
New York Heart Association, 1964, Figure 2.1). This classification is widely used to
describe the functional capacity of patients with heart failure, i.e. symptoms, but gives
no indication of the progression or aetiology of the syndrome. Critics of the NYHA
system argue that the assessment of a patient's symptoms is subjective and varies
between observers, and that symptoms for an individual patient can vary over short
periods of time without necessarily indicating significant progression of the syndrome.
Additionally, the classes of drugs used as therapy for heart failure are broadly similar
between the NYHA classes. As such the American College of Cardiology / American
Heat Association task force have recently proposed an additional staging system which
takes account of the progressive nature of the syndrome and identifies stages at which
specific therapies are appropriate (Hunt et al., 2001). This scheme is designed to
complement the NYHA symptom classification and is unidirectional - the syndrome
will inevitably progress to stage D (Figure 2.2).
2.2 Epidemiology
Since a common definition is difficult to establish in heart failure, the epidemiology of
the syndrome is difficult to fully delineate. Heart failure can be considered as a clinical
entity, based on symptoms such as fatigue and breathlessness which, as discussed above,
may be highly variable during an individual's disease course, or it can be considered
with respect to the underlying pathology i.e. systolic or diastolic ventricular dysfunction.
Asymptomatic patients with left ventricular systolic dysfunction are at risk of
developing the syndrome of heart failure and represent an additional group. As such, it is
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critical when discussing both the epidemiology of heart failure and the outcomes
reported in clinical studies to be absolutely clear how heart failure has been defined,
particularly given that patient groups involved in therapeutic intervention trials rarely
have characteristics identical to that of the real disease population in the community.
This is particularly true of trials involving exercise training, an issue which will be
discussed further in chapter 8.
Stage Group Therapy












-with a family history of
cardiomyopathy
Treat hypertension, lipid disorders.
Discourage alcohol, stop smoking
and illicit drug use.
Regular exercise














As section A plus
-ACE inhibitors for appropriate
patients
































As sections A, B and C plus
-mechanical assist devices
-heart transplantation
-continuous iv inotropic support
-hospice care
Figure 2.2. AHA/ACC staging system for chronic heart failure.
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2.2.1 Prevalence
2.2.1.1 Clinical heart failure
Contemporary estimates of the prevalence of heart failure are sobering although the
figures themselves should be interpreted with some caution. In the UK, prevalence is
probably around 1% overall and Figure 2.3 summarises some reported prevalence rates.
It can been seen from this that estimates do vary, primarily due to differing
methodologies of data collection, and differing definitions of what heart failure actually
is. An example of this problem is seen with the frequently quoted statistics from
America: it is estimated that 4790000 individuals in the USA currently have heart
failure. This is based on self reporting from the period 1988-1994 with correction for
under-reporting and extrapolation to current population figures (National Health and
Nutrition Examination Survey III, 1994). A more up-to-date self-reporting study from
1999 estimates that 2.4 million people in the US had been told they had heart failure (Ni,
2003). This was also based on questionnaire data; positive responses to a question
asking if subjects had ever been told they had 'congestive heart failure' were seen in
0.1%, 1.1%, 3.6% and 5.5% of American people aged 18-39, 40-64, 65-74, 75-105,
respectively. Naturally, these kinds of self-reporting based research are crude ways of
estimating prevalence and methodological problems probably explain the wide variation
in prevalence. A more recent American survey has estimated the prevalence of LV
systolic impairment as 6% (moderate or severe LV systolic dysfunction 2%) and mild
diastolic dysfunction as 21%, moderate or severe diastolic dysfunction as 7% (Redfield
et al., 2003).
43
The increasing prevalence of heart failure with increasing age is important to note,
however, as this observation is made consistently in epidemiological studies of heart
failure, for instance the data from the Framingham study reported in McKee, et al.
(1971) where there was an estimated prevalence in the age groups 50-59, 60-69, 70-79
and >80 of 8, 23, 49 and 91 per 1000 - these figures were based on more robust clinical
criteria (compared with questionnaire self-reporting) but reservations do exist regarding
the ethnic homogeneity of the Framingham population and the era in which the data
were collected (i.e. predating the modern trends in ischaemic heart disease survival and
heart failure therapy). Again, similar age-related trends are seen with general
practitioner-based observation studies (Parameshwar et al., 1992) and population studies
(Remes et al., 1992; Rodeheffer et al., 1993), although in only a small proportion of
cases in these studies was a diagnosis of heart failure based on an objective
measurement of left ventricular (LV) function. With more strict assessment of LV
systolic dysfunction using echocardiography, the trend for increasing prevalence has
been demonstrated in a Scottish population also (McDonagh et al., 1997). Age-related
trends have been confirmed in the latest report from the AHA statistics committee, as
shown in Figure 2.3 (Rosamond et al., 2007).
2.2.1.2 Systolic dysfunction.
Studies assessing the prevalence of LV systolic dysfunction have been carried out. In
north Glasgow, the prevalence of LV systolic dysfunction, as defined as an ejection
fraction of less than 30%, in a randomly selected population of men and women aged
25-74 was 2.9% overall (McDonagh et al., 1997). Prevalence increased with age and
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was more common in men than women (6.4% of men aged 65-74 compared with 4.9%
ofwomen). Overall, only 1.5% of those with LV systolic dysfunction had symptoms and
this is an important issue as discussed in section 2.2.1.4.
2.2.1.3 Diastolic dysfunction.
Prevalence of diastolic dysfunction in the community is even harder to estimate as
criteria for the definition of this subset of heart failure varies. Previously, diastolic
dysfunction has been a diagnosis of exclusion, i.e., symptoms and clinical signs
consistent with heart failure, but no objective evidence of abnormal left ventricular
systolic function. Prevalence estimates vary (Vasan et al., 1995) but a recent interim
study analysis using echocardiographic criteria reports that in an American population
over the age of 45 years and with an ejection fraction of greater than 50%, 5.3% of
subjects had moderate to severe diastolic dysfunction and 16.6% had mild dysfunction
























20-39 40-59 60-79 80+
□ Men □ Women
Figure 2.3. Age-related trends in heart failure prevelance. Adapted from Rosamond, et al. (2007)
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(2003) identified mild diastolic dysfunction in 20.8%, moderate diastolic dysfunction in
6.6% and severe diastolic dysfunction in 0.7% of screened subjects, making diastolic
dysfunction approximately as common as systolic dusfunction. However, diastolic
dysfunction in these subjects was not commonly associated with symptoms despite
being predictive of all cause mortality. The precise relation between these data and
clinical syndromes and outcomes remains unclear, but early identification diastolic
dysfunction may allow earlier treatment and perhaps delay or prevent progression from
stage B to stage C of the heart failure syndrome.
2.2.1.4 Asymptomatic LV systolic dysfunction.
Asymptomatic LV systolic dysfunction is common and is probably as prevalent as
symptomatic LV systolic dysfunction, although the estimates do vary and depend on a
number of factors in the study design including the particular cut-off level of ejection
fraction used to define dysfunction (Davies et al., 2001; Devereux et al., 2001; Mosterd
et al., 1999; Redfield et al., 2003; Schunkert et at, 1998) or whether qualitative
assessments were used (Gottdiener et al., 2002). For instance, in the North Glasgow
study, 1.4% of the participants who had an ejection fraction less than 30% had no
symptoms, increasing to 5.9% of those with an ejection fraction less than 35%
(McDonagh et al., 1997). Similarly, a recent assessment of the original and offspring
Framingham cohorts over 40 years old and with no history of heart failure identified that
3% of participants overall had an ejection fraction of less than 50% (Wang et al., 2003).
In males it was more common (6%) compared with females (0.8%), probably due to an
increased burden of ischaemic heart disease in men. There was increasing prevalence
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with age (14.3% of those male subjects aged 80 and over).
The importance of asymptomatic LV systolic dysfunction lies in the natural history of
this condition. In the above study of the Framingham cohorts, 26% of those with
asymptomatic LV systolic dysfunction developed symptoms of heart failure over a mean
follow-up period of 5 years and there was a clearly increased risk of death - age- and
sex-adjusted hazard ratios for asymptomatic subjects with ejection fractions less than
50% and less than 40% were 1.9 and 3.1, respectively, compared with subjects without
asymptomatic LV dysfunction. For comparison, subjects with symptomatic heart failure
at baseline had a mortality hazard ratio of 5. Interestingly, 56% of those subjects with
asymptomatic LV dysfunction at baseline who subsequently died had not developed
symptomatic heart failure in the interim.
Other studies of the natural history of asymptomatic LV systolic dysfunction also
identify increased cardiovascular or all-cause mortality in this group although event
rates were low overall (Gottdiener et al., 2002; McDonagh et al., 2001). For large trials
involving patients post-myocardial infarction and with degrees of LV systolic
dysfunction, increased progression to symptomatic heart failure is also seen with
mortality rates intermediate between those individuals with preserved LV systolic
function and those with symptomatic heart failure at baseline (Kober et al., 2000; Pfeffer
et al., 1992; Sharpe et al., 1990; SOLVD Investigators, 1992).
These data highlight the importance of the inclusion of stage B in the American Heart
Association guidelines as discussed in section 2.1.2. Treatments directed towards this
47
group may be helpful in preventing or delaying the progression to symptomatic heart
failure and may reduce hospitalisation or death.
2.2.2 Incidence
Less contemporary data is available overall for heart failure incidence. Extrapolation of
the Framingham data suggested that there are around half a million new cases of heart
failure per year in the US (American Heart Association, 2001; Ho et al., 1993). Current
analysis of the Framingham data suggest an incidence of around 10 per thousand after
the age of 65 and that at the age of 40, the lifetime risk of developing heart failure is 1 in
5 for both men and women (Lloyd-Jones et al., 2002). As with the prevalence estimates,
there is a marked increase in the incidence of heart failure with age - <2 per 1000 patient
years for those aged under 60 rising to 10 per 1000 patient years in the age group 70-79
and 25 per 1000 patient years for those aged over 80. The incidence is greater for men,
but greater survival in females leads to approximately the same point prevalence for the
sexes (Table 2.2).
A lower overall incidence was observed in the Rochester study during 1981 of 1.1 per
1000 patient years, with the same age and sex trends as the Framingham data
(Rodeheffer et al., 1993). More recently, in the UK, based on the numbers of patients




Table 2.2. Incidence of heart failure per 1000 patient years (Framingham data).
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overall annual incidence was calculated as 1.85 per 1000 patient years (Cowie et al.,
1999). From American data, CHF incidence has not declined over the past 2 decades
although overall survival has improved following disease onset (Roger et al., 2004).
2.2.3 Heart failure hospitalisation
2.2.3.1 Admission trends
As with prevalence, incidence data will vary depending on the definition of heart failure,
the study population and the era in which the data is gathered. As such, data pertaining
to hospital admissions may be more useful in determining current trends. Heart failure is
the most common primary diagnosis for those hospitalised over the age of 65 and some
data exist for the trends in hospitalisation for heart failure in Europe, the USA and New
Zealand over the last two decades (Doughty et al., 1995; Ghali et al., 1990; Gillum,
1993; Haldeman et al., 1999; McMurray et al., 1993b; Reitsma et al., 1996; Rodriguez-
Artalejo et al., 1997; Ryden-Bergsten and Andersson, 1999). Admissions increase with
age, are more commonly female patients than men and female patients tend to be older
than male patients when admitted (Blackledge et al., 2003). Figure 2.4 shows the general
trend for increased rates of admission either as a primary or secondary diagnosis up until
1993 in developed countries.
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Figure 2.4. Heart failure admissions 1978-1993 per 10000 population at risk per annum. Adapted
from (McMurray et al., 1998).
However, there is some evidence that heart failure admissions may not be continuing to
rise. Scottish data for the period 1980-1990 identified the number of hospitalisations
with a principle diagnosis of heart failure rose from 1.3 to 2.12 per 1000 of the
population, although it should be noted that these data are obtained from routine hospital
discharge coding which may not be fully accurate. Subsequent data has shown an
increase in admission rates, rising to a peak in 1993/1994 of 2.3 per 1000 for men and
2.4 for women (Stewart et al., 2001b) but a lack of further increase beyond then. A
similar trend, with admission rates reaching a plateau in the late 1990's was observed in
a study from Leicestershire (Blackledge et al., 2003). This is interesting and contrasts
with the prediction of increased heart failure prevalence, but it may be linked to the
observation that heart failure may now be less common in the post myocardial infarct
group than previously, perhaps due to more widespread use of secondary prevention
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therapy (Guidry et al., 1999; Hellermann et al., 2003). Alternatively, it may reflect better
care of heart failure patients with more widespread use of ACE inhibitors and beta-
blockers, or it may indeed reflect a change in the accuracy of diagnosis.
2.2.3.2 Seasonal Variations
My own experience in clinical practice would suggest that heart failure admissions occur
more commonly in the winter months and in fact the seasonal variation in admission
rates is well documented. For instance, in a recent Spanish study, hospitalisations were
25% above average in wintei and 33% below aveiage in the summer (Martinez-Selles el
al., 2002). This compares with other reports of seasonal variation in France (Boulay et
al., 1999) and the USA (Allegra et al., 2001). A similar picture is seen in Scotland
particularly in the elderly, with an associated seasonal variation in mortality (Stewart et
al., 2002b). This variation in admission rates could be explained by seasonal variations
in blood pressure, cardiac arrhythmias and neurohormonal state secondary to
temperature. Alternatively, it may be related to seasonal trends in rates of myocardial
infarction or respiratory disease, particularly viral upper respiratory tract infections.
2.2.4 Mortality
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Figure 2.5. Cumulative mortality in a meta-analysis of trials of ACE-inhibitor therapy for
patients with impaired left ventricular systolic function. Adapted from Flather et al. (2000).
Even in clinical trials this is demonstrated. For instance, Figure 2.5 shows the meta¬
analysis of mortality data for patients randomised to receive either placebo or an ACE
inhibitor in five large clinical trials for subjects with reduced ejection fraction (the
SAVE (Pfeffer et al., 1992), AIRE (The Acute Infarction Ramipri! Efficacy (AIRE)
Study Investigators, 1993) and TRACE (Kober et al., 1995) trials of post myocardial
infarction heart failure) combined with the data from the prevention and treatment
components of the SOLVD study (SOLVD Investigators, 1991; SOLVD Investigators,
1992), most of whom had had a previous myocardial infarction (Flather et al., 2000).
Despite the young average age of the patients of 61 years and the likelihood of otherwise
optimised medical therapy for hypertension and ischaemic heart disease, there is an
overall mortality of around 30% at 4 years. Even in the CHARM study, a major clinical
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trial performed in the era of modern pharmacological therapy for heart failure, and
including relatively young patients with a mean age of 65 years, the all-cause mortality
over 2 years in the placebo group was 21% and was 31% over 3.5 years (Young et al.,
2004). These disease populations do not reflect the true spectrum of heart failure in the
community, however. From community prevalence and incidence studies discussed in
sections 2.2.1 and 2.2.2, we know that the average age of the heart failure patient is older
and at least half the patients are female - in the above meta-analysis of the ACE-
inhibitor trials, however, only 19% were female (Flather et al., 2000). As such, it is more
realistic to look at data from community-based prospective observational studies.
For instance, a report from 4 decades of data from the Framingham cohorts (1950s -
1980s) identified 1 and 5 year survival rates of 57% and 25% for men and 64% and 38%
for women, respectively (Kannel et al., 1994). Increasing age was associated with a
poorer prognosis. Little change was seen over these four decades despite improvements
in treatment for coronary artery disease. The mortality rates above are notably high and,
as a comparison, during the period 1979-1984, the 5-year survival rate from all cancers
in the US was reported as 50% (Fraumeni et al., 1989).
More recent data from the Rochester epidemiology project are similar. The same
diagnostic criteria as the Framingham study were used and identified overall 1 and 5
year mortality rates of 28% and 66% in a cohort recruited in 1981, and 23% and 67% in
a cohort recruited in 1991 (Senni et al., 1999). As such, little change in mortality was
seen over the period studied, perhaps indicating that ACE inhibitors were not being
widely used in the community in the early to mid 1990s.
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A recent analysis of the Framingham Heart Survey data suggests that 80% of men and
70% of women under the age of 65 with a diagnosis of heart failure will die within 8
years; the one year mortality rate is around 20% and the risk of sudden cardiac death is
between 6 and 9 times higher than those without a diagnosis of CHF (Lloyd-Jones et al.,
2002).
Data from 1991 obtained from the Scottish Morbidity Record Scheme has identified a 5-
year survival rate of 25%, poorer than most forms of cancer at that time, with lung
cancer being the only malignancy with a poorer outcome (Stewart et al., 2001a). Other
Scottish crude survival data for those patients admitted to hospital between 1986 and
1995 are equally sobering (Table 2.3, Maclntyre et al., 2000).
There is some evidence of improvement during the 1990's however. In Leicestershire, 1-
year survival was estimated at 45% in 1993/1994 compared with 62% in 2000/2001,
although this means that there is still about 40% mortality 1 year following an
admission, which is still very poor (Blackledge et al., 2003). Data from Scotland show a
modest improvement in 1-year case fatality between 1986 and 1995 - from 46.7% to









Table 2.3. Crude case fatality rates following hospitalisation in Scotland with a primary
diagnosis of heart failure 1986 -1996.
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42.4%, with an overall median survival increase from 1.23 years to 1.64 years
(Maclntyre et al., 2000). These data have been mirrored in other recent reports from
developed countries and, again, absolute benefits in mortality are quite modest (Raker el
al., 2003; Feinglass et al., 2003). These trends are positive but do represent small
changes - the improved survival in Scotland quoted above for instance is only around 3
months overall. It is templing to attribute these improved survival lates to improved drug
treatment, particularly with ACE inhibitors and, more latterly, beta-blockers. However,
admission thresholds and disease recognition may have changed over the last 10 years -
as such, the mildly improved survival trends may simply represent the better survival in
a group of patients with milder disease, or the increased likelihood of diagnosis of
milder disease using modern techniques.
2.2.5 Cost of heart failure
Heart failure is a major public health problem and in a study from 1990 / 1991 it was
estimated that heart failure was responsible for 1.2% of all NHS expenditure in the UK
(McMurray et al., 1993a). These costs were mirrored in other Western countries
including the US where 1.5% of healthcare costs or 20 billion dollars was spent in
1999/2000 (American Heart Association, 1999).
Data for an analysis of costs incurred in both primary and secondary care for 1995
concluded that £716 million (1.8% of the total healthcare budget) in the UK was spent
on heart failure, 69% of this being due to the cost of hospitalisation alone (around £'A
billion). This high cost of institutionalisation in fact rises to £1.26 billion if the cost
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nursing home care and admissions with heart failure listed as a secondary diagnosis are
taken into account (Stewart et al., 2002a). Although there is potential for polypharmacy
in heart failure, drugs accounted for only 18% of costs in this study.
In the future, more expensive drug and device therapies will be introduced which will
potentially increase expenditure. However, newer treatments are likely to reduce
hospitalisation and may therefore prove to be cost effective. An alternative view is that
newer therapies which reduce mortality will only serve to increase prevalence of the
syndrome and may in fact increase the costs associated with drugs and out-patient care
as more patients survive. Certainly, therapies which involve hospitalisation for initiation
(i.e. placement of biventricular pacing devices) need to be carefully considered for their
true cost effectiveness.
2.2.6 Future trends
Few formal projections exist for heart failure and vary considerably. In Scotland,
hospitalisation is predicted to increase by 34% for males and by 12% for females by
2020 (Stewart et al., 2003). In the Netherlands, incidence is expected to increase by 70%
by 2010 (Bonneux et al., 1994). Projections for Australia are similar (Kelly, 1997).
Although these projections cannot account for the variation in prevalence of heart failure
which may be occurring currently due to changes in incidence post MI, introduction of
new therapies for heart failure and an increased awareness of the potential benefits of
treatments in stages A and B of the syndrome which may favourably affect the clinical
course of the syndrome, they do indicate a likelihood of an increased burden of heart
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failure in the future.
2.2.7 Summary and observations
The above statistics are certainly troubling and despite the scope for error and variation
generated by differing methodologies in data acquisition, there is no doubt that heart
failure is common and is set to become even more so. There have been modest
improvements in survival with the introduction of new therapies, in particular ACE
inhibitors and beta-blockers, but the condition remains highly lethal. Costs associated
with heart failure, predominantly due to hospitalisation, are set to rise and already
consume a substantial proportion of the healthcare budget.
The epidemiology shows us that heart failure is a disease of the elderly and females
account for more hospitalisations than men. Incidence of the disease is higher for men
but the prevalence is approximately equal for both sexes owing to the greater longevity
of women. Comorbidities are common in heart failure and are related to higher
healthcare expenditure (Zhang et al., 2003). What is striking, however, is how these
demographics differ from those of the patients studied in clinical trials. Patients recruited
in these large trials are generally younger, predominantly male and with few
comorbidities. Medical therapy is usually optimally managed and this is reflected
perhaps in the substantially lower mortality rates seen in the placebo arms of controlled
trials when compared with the rates identified from population surveys. Despite this,
survival is still relatively poor in these trials also.
Most published data relate to patients from Western nations. Limited epidemiological
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data are available for the Indo-Asia region or for the developing world. In Hong Kong,
incidence rates are similar to Western Europe and the US (Sanderson et al., 1995) and is
high in Africa (Oyoo and Ogola, 1999), South America (Mendez and Cowie, 2001) and
Oman (Agarwal et al., 2001). Aetiologies vary around the world. For instance,
hypertensive heart failure is common in Nigeria (Rotimi et al., 1998) and Chagas disease
in South America (Mendez and Cowie, 2001), contrasting with the predominance of
ischaemic heart disease as the most common aetiology in the Western world. However,
there is a global epidemic of coronary artery disease and diabetes occurring, particularly
involving the developing world and increased in part by the lifestyle changes associated
with industrialisation and urbanisation (Yusuf et al., 2001). Diabetes is common in the
Indian subcontinent and it is troubling that very little data exist regarding therapeutic
interventions in Chinese and Indian regions where approximately half of the world's
population live.
These issues are of key importance in the specialised area of exercise training, a topic
which will be discussed further in section 2.3.2. We know that heart failure patients are
elderly and include at least equal numbers of females as males. We need to be sure that
any intervention, particularly exercise training, is applicable to 'real' populations. A
degree of motivation on behalf of the subject is required for exercise training and
exercise is culturally acceptable in Western society. Few data exist for training in non-
Caucasian populations and exercise is probably less acceptable culturally in these
populations. Our understanding of the potential benefits of this particular treatment need
to be viewed in a world-wide context.
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2.2.8 Pathophysiology
The pathophysiology of heart failure is characterised by three things. Firstly, there is an
initial insult impairing the heart's ability to fill with or eject blood, leading to a reduced
ability to increase cardiac output as the body's metabolic needs increase. Secondly, there
are a number of adaptive responses which act in the short term to maintain an
appropriate cardiac output. Thirdly, over time, these adaptive changes result in
detrimental changes which exacerbate symptoms and promote the progression of the
syndrome and further reduction of cardiac reserve.
The adaptive and maladaptive responses will be discussed below, with particular
emphasis on those changes which are responsible for exercise intolerance and which
may be modified potentially by exercise training.
Although the majority of data on pathogenesis in heart failure relate to experimental
work on systolic left ventricular dysfunction, the maladaptive changes equally apply to
diastolic dysfunction as they occur in response to a reduction in the ability of the heart to
maintain an appropriate cardiac output as metabolic demands increase.
2.2.8.1 Myocardial changes
The initial insult to the heart can be considered as a loss of functioning myocardium (e.g.
infarction or coronary artery disease) or due to excessive overload (e.g. hypertension or
valve disease). The development of the syndrome of heart failure occurs over time and it
is useful to consider the process in separate stages. Of course, the process is a continuum
rather than discrete stages with several mechanisms interacting. However, if one
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considers the acute situation, as the ventricle fails, it is unable to eject a normal volume
of blood during a single beat. As such, the volume at the end of systole (end systolic
volume, ESV) is increased. Consequently, as the ventricle refills during diastole, a
normal quantity of blood is added which then results in an increased volume in the
ventricle at the end of diastole (increased end diastolic volume, EDV; movement from
point A to B, Figure 2.6). This represents an increased preload for the subsequent beat
and in accordance with the Frank-Starling mechanism, stroke volume (SV) increases for
the next systole (Starling E.H., 1918). The increased contractility is due to sarcomere
lengthening resulting in more optimal overlap and closer apposition of actin and myosin
9+
filaments, and increased Ca" sensitivity. Over time, the left ventricle may dilate and
remodel, with the result that EDV is further increased. This increase in EDV occurs
despite little change in EDP (movement from point A to C, Figure 2.6). Subsequent
increases in EDP may then produce little change in diastolic volume, either due to
ventricular stiffening or due to near maximal dilatation of the ventricle. As such, the
failing heart is less able to use the Frank-Starling mechanism to maintain SV. This is
diagrammatically represented in Figure 2.7 which shows the Frank-Starling curve for a
normal heart, with large increases seen for relatively small changes in EDP but in heart
failure a curve which is depressed and flattened, resulting in a relatively fixed stroke
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Figure 2.6. Relationship between left ventricular end diastolic volume and pressure in the
failing heart.
As such, ventricular dilatation leads to initial compensation for reduced cardiac output
but over time results in a blunting of the Frank-Starling mechanism. Left ventricular
dilatation also results in further progression of the heart failure syndrome due to
increased wall tension and over-stretch which requires greater energy expenditure for
contraction and can result in diffuse myocyte apoptosis (Cheng et al., 1995).
Additionally, functional mitral regurgitation may develop, particularly during exertion
thereby further reducing forward cardiac output.
Another important factor regarding the failing ventricle is also illustrated in Figure 2.7.
SV in the failing ventricle is markedly affected by afterload and less affected by changes
in preload in contrast to the healthy ventricle. This is important when considering other
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maladaptive responses which will be discussed further below.
Cardiac output (CO), which is a function of stroke volume and heart rate, is reduced in
heart failure both at rest and during exercise. Normally, CO increases during exercise
due to a combination of increased heart rate and increased stroke volume, itself
secondary to increased EDV and reduced ESV. In heart failure there is an attenuated
ability to increase EDV due to ventricular stiffness or dilatation as described above, and
a decreased ability to reduce ESV due to impaired contractility, decreased P-receptor
responsiveness, increased systemic vascular resistance (secondary to increased
sympathetic tone and activation of the renin-angiotensin system) and blunted arterial
LVEDP Afterload
Figure 2.7. Frank-Starling mechanism in the normal and failing heart.
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vasodilatory response to exercise (described below). As such, the heart relies more on an
increase in heart rate to maintain an appropriate increase in cardiac output in heart
failure during exertion. However, maximum heart rate is mildly decreased in heart
failure and the heart rate reserve is markedly decreased owing to a higher resting heart
rate, mostly due to the loss of parasympathetic vagal tone. This impairment of heart rate
reserve is documented in heart failure and again, although initially beneficial, the resting
tachycardia reduces the reserve available upon commencement of exertion.
The compensatory changes which occur in response to depressed cardiac function are
protective and serve to increase cardiac output and hence tissue perfusion. In the chronic
state they are deleterious, however, and result in progression of the syndrome, increased
symptoms and organ damage.
2.2.8.2 Neurohormonal system
Vasoconstriction and salt/water retention are well recognised features of heart failure.
Arterial hypoperfusion secondary to reduced cardiac output or systemic vascular
resistance results in the activation of a number of reflexes which serve to retain salt and
water. The reduction in perfusion may be sensed by mechanoreceptors in the left
ventricle, carotid sinus, aortic arch and renal afferent arterioles with subsequent
sympathetic activation, activation of the renal-angiotensin-aldosterone system, and
release of arginine vasopressin. With the increase in circulating volume, filling pressure
will increase which will serve to increase cardiac output (Schrier and Abraham, 1999).
The counter-regulatory proteins atrial naturetic peptide (ANP), brain naturetic peptide
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(BNP) and clearance naturetic peptide (CNP) are also released, which enhance sodium
excretion, aldosterone secretion and reduce sympathetic drive, systemic vascular
resistance and right atrial pressure (Levin et al., 1998). However, in more advanced
heart failure, the vasoconstriction and salt/water retention of the neurohormonal
responses predominate and form the basis for manipulation with modern
pharmacological treatment.
2.2.8.2.1 Autonomic nervous system
There is an increase in sympathetic activity in heart failure which serves to maintain
cardiac output acutely. Increased circulating levels of norepinephrine have been
recognised for some time in heart failure (Chidsey et al., 1962) and levels correlate with
disease severity (Thomas and Marks, 1978). In the heart, catecholamines increase heart
rate and myocardial contractility, and promote more rapid ventricular relaxation during
diastole. Although individuals with severe end-stage heart failure may be dependent on
the sympathetic drive for maintenance of cardiac output, there is no doubt that during the
course of the syndrome, increased levels of norepinephrine are detrimental with toxicity
to the myocardium (Mann et al., 1992), promotion of arrhythmias and left ventricular
hypertrophy and remodelling. Peripherally, arterial and venous vasoconstriction will
serve to increase afterload and preload, respectively (Packer, 1992) and, as described
earlier, increased afterload is detrimental in chronic heart failure. Additionally, as the
syndrome progresses, there is decreased sensitivity of the heart to catecholamines and
down-regulation of P-adrenoreceptors (Bristow et al., 1982).
2.2.8.2.2 Renin-angiotensin-aldosterone system
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Multiple mechanisms are responsible for the activation of this key system in chronic
heart failure, the initial stage of which is renin release (Francis et al., 1984). These
mechanisms include sympathetic activity, hypoperfusion and delivery of hyponatraemic
perfusate to the macula densa, diuretic use and low sodium diet, which both result in a
relative reduction of circulating volume and also stimulate renin release. Renin is a
proteolytic enzyme which promotes the cleavage of angiotensinogen to angiotensin I.
Angiotensin converting enzyme (ACE) cleaves angiotensin I to form angiotensin II,
which has a range of biological activities. Angiotensin II itself stimulates aldosterone
release from the adrenal cortex which promotes sodium and water retention, and AVP
release.
Angiotensin II acts primarily via the ATI receptor resulting in arterial vasoconstriction,
myocyte apoptosis, ventricular remodelling, polydypsia, norepinephrine release and
sensitisation of blood vessels to norepinephrine.
Again, the initial activation of the system provides beneficial support in maintaining
cardiac output and organ perfusion, but is detrimental in the long term.
2.2.8.2.3 Arginine Vasopressin
Arginine vasopressin (AVP) released from the hypothalamus or
hypothalamoneurohypohyseal tract in response to activation of carotid baroreceptors
during low circulatory pressure states reduces the excretion of water in the kidney at the
collecting duct, again serving to increase circulatory volume. Normally, hyponatraemia
would result in the discontinuation of AVP release but dysregulation of AVP occurs in
the low pressure state of heart failure resulting in selective retention of water and
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hyponatraemia. AVP is found in high levels in the circulation of hyponatraemic patients
with heart failure (Szatalowicz et a/., 1981) and there is an ongoing assessment of the
benefits of AVP blockade via vasopressin receptor antagonists. Additionally, AVP may
contribute to myocardial dysfunction and increased vascular resistance promoting
further progression of the syndrome.
2.2.8.2.4 Endothelin
Endothelin 1 (ET-1), the best characterised of the vascular endothelins and produced in
response to external stimuli by vascular endothelial cells is a powerful vasoconstrictor
and has emerged as a potentially important contributor to the syndrome of heart failure.
Synthesis is enhanced by a number of factors associated with heart failure including
angiotensin II, norepinephrine and hypoxia and elevated concentrations of ET-1
correlate with poorer clinical state (Kiowski et al., 1995) and outcome (Pacher et ai,
1996). The bioactivity of ET-1 is mediated by 2 receptors - ET-A, found mainly in
vascular smooth muscle and responsible for vasoconstriction and cell proliferation /
hypertrophy, and ET-B, found predominantly on vascular endothelium and which
mediates vasodilatation (Haynes and Webb, 1998).
2.2.8.2.5 Natriuretic peptides
This family of peptide hormones incorporates atrial or A-type natriuretic peptide (ANP),
brain or B-type natriuretic peptide (BNP) and clearance natriuretic peptide (CNP). ANP
and BNP have similar physiological actions including natriuresis, diuresis,
vasodilatation, improved diastolic relaxation and reduced myocardial fibrosis. ANP acts
as the predominant of the two circulating hormones in healthy individuals, is secreted in
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response to atrial stretch and is more rapidly cleared than BNP. BNP is released by the
ventricles in response to LV wall stress and dysfunction (Mukoyama et al., 1991). This
and BNP's longer half life results in BNP being the more useful biomarker in heart
failure (Doust et al., 2004). Both ANP and BNP are synthesised as larger pro-molecules
with subsequent proteolytic cleavage into active and inactive fragments. The inactive N-
terminal pro-BNP (NT-pro BNP) has a longer half-life than the active BNP and as such
is often used in preference to BNP as a biological marker in research studies.
There is a close relationship between the degree of LV impairment and BNP (Richards
et al., 1993) and also NT-pro BNP (Hunt et al., 1997). There is a clear association of
BNP with symptoms of heart failure (Wieczorek et al., 2002) and also with
asymptomatic LV dysfunction (Mueller et al., 2004).
BNP has been demonstrated to be useful as a highly specific aid to differentiate heart
failure due to LV systolic impairment from other causes of breathlessness (Davis et al.,
1994; Maisel et al., 2002) and, recently, NT-pro BNP has been shown to be perhaps
more discriminating in this regard (Lainchbury et al., 2003). BNP is also elevated in
right ventricular impairment associated with pulmonary embolism (Kruger et al., 2004)
and primary pulmonary hypertension (Leuchte et al., 2004), diastolic heart failure
(Redfield et al., 2004) and acute coronary syndromes (Wiviott et al., 2004). BNP is also
associated with worse prognosis (de Lemos et al., 2003) and predictive of sudden
cardiac death (Berger et al., 2002). NT-pro BNP levels also predict worse outcomes and
the need for more urgent cardiac transplantation (Gardner et al., 2003; Richards et al.,
2001).
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Importantly, BNP and NT-pro BNP can be used to monitor clinical progression in heart
failure and these biomarkers have been used in clinical trials to assess outcome
following an intervention. The converse is also true - NT-pro BNP guided therapy has
been shown to be more effective than clinical monitoring in reducing cardiovascular
events in heart failure patients (Troughton et al., 2000). The longer half-life of NT-pro
BNP and the availability of a rapid assay makes the use of this particular biomarker
attractive both for study design and clinical management.
2.2.8.3 Peripheral changes
The central haemodynamic changes described in the preceding sections are only part of
the pathophysiological change responsible for the generation of the syndrome of chronic
heart failure. Abnormalities of ventilatory function, peripheral haemodynamics and
skeletal muscle function have been identified and are key to the generation of symptoms
in heart failure and perhaps also to disease progression. It is well recognised that ejection
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Figure 2.8. Relationship between ejection fraction and peak oxygen consumption. Adapted
from (Minotti et al., 1991).
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Figure 2.8, Minotti et al., 1991), the increment in ejection fraction during exercise does
not relate to peak VO2 (Higginbotham et al., 1983; Szlachcic et al., 1985) and that acute
improvements in central haemodynamics do not result in rapid improvement in exercise
capacity (Marzo et al., 1993; Wilson et al., 1984).
2.2.8.3.1 Skeletal muscle abnormalities
Decrease muscle strength and early fatigue are recognised in CHF and are in part due to
muscle atrophy which may occur early in the course of disease progression (Buller et al.,
1991; Lipkin et al., 1988; Mancini et al., 1992). Although this may be due to disuse,
other causative factors include the pro-inflammatory state observed in heart failure and
abnormal skeletal muscle blood flow. Cytokines which promote a catabolic state are
found in increased levels in heart failure, e.g., tumour necrosis factor a (TNFa),
interleukin (1L) 2 and IL-6 (Adamopoulos et al., 2002; Levine et al., 1990; Marriott et
al., 1996). Decreased skeletal muscle blood flow observed in CHF patients (Zelis et al.,
1974) is unlikely to be directly due to the low cardiac output state during exercise in
heart failure, again as acute changes in central haemodynamics following ACF.i therapy
(Drexler et al., 1989) or transplantation (Sinoway et al., 1988) do not result in
immediate improvements in exercise capacity. The vascular endothelium regulates
vasomotor tone and is recognised to be abnormal in CHF (Drexler et al., 1992a).
Endothelial function is closely involved in the control of tissue perfusion (Henderson,
1991) and dysfunction is associated with increased mortality (Fischer et al., 2005; Katz
et al., 2005). Impaired vasodilatation secondary to endothelial dysfunction and the
elevated concentration of peripheral vasoconstrictor neurohormones such as
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Figure 2.9. Muscle biopsy and myofibrillar ATPase stain. Light staining - type I fibre, dark
staining - type II fibre, A - normal, B - CHF patient.
noradrenaline, renin, angiotensin II and vasopressin as described in section 2.2.8.2 is
likely to play a significant contributory role.
Atrophy alone, however, is not the explanation for reduced muscle strength and early
fatigue in CHF. There is a reduction in strength per unit muscle (Harrington et al., 1997)
which suggests qualitative changes also. Histologically, type I 'slow-twitch' muscle
fibres are replaced by type lib glycolytic fast twitch fibres which have a low capacity for
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aerobic metabolism and hence may contribute to early fatigability (Drexler et al., 1992b;
Lipkin et al., 1988). Figure 2.9 shows muscle biopsy specimens for normal and CHF
patients stained for myosin ATPase with dark-stained type II muscle fibres over-
represented in the CHF sample. Myosin heavy chain type I isoforms are reduced in CHF
patients with reduction in proportion to decreased peak VO2 (Sullivan et al., 1997). At
the ultrastructural and enzymatic level, mitochondrial volume density and surface
density of christae (associated with peak VO2 at anaerobic threshold) are reduced
(Drexler et al., 1989) along with oxidative mitochondrial enzyme activity (reduced
cytochrome oxidase, citrate synthase and succinate dehydrogenase, Sullivan et al.,
1990). These changes place more reliance on anaerobic metabolism in the skeletal
muscle of CHF patients and help explain the early fatigue and early lactate production
they experience (Weber and Janicki, 1985).
2.2.8.3.2 Ventilatory abnormalities
Breathlessness is a common symptom in CHF. For a given level of exercise, ventilation
is abnormally increased and this is demonstrated by the abnormal relationship of
ventilatory equivelant (VE) to CO2 production (VCO2), i.e., VE/VCO2 slope (Fink et al.,
1986; Sullivan et al., 1988b). The VE/VCO2 slope is increased in heart failure and has
been demonstrated to be an independent predictor of mortality and closely associated
with disease severity (Corra et al., 2002; Guazzi et al., 2003). VCO2 itself is not thought
drive ventilation during exercise, but rather that VCO2 is driven by VE and that there is a
non-pulmonary ventilatory stimulus (Franciosa et al., 1984; Rubin et al., 1982). The
small afferent ergoreceptors found in skeletal muscle are sensitive to the type of
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metabolic changes observed in CHF and their activity is enhanced compared to control
subjects (Piepoli et al., 1996; Ponikowski et al., 2001; Scott et ah, 2002). Ergoreceptor
activation results in an exaggerated sympathetic and ventilatory response to exercise and
may therefore be a link between metabolic peripheral muscular changes and exertional
breathlessness.
2.3 Therapy
2.3.1 Pharmacological and device therapy
There is an overwhelming evidence base for pharmacological treatment in heart failure
and an emerging evidence base for device therapy, i.e., cardiac resynchronisation
therapy with or without automated defibrillator function. These therapies do not directly
relate to the trials performed during the course of my research and will not be discussed
further. Position statements and guidelines from the European Society of Cardiology and
American College of Cardiology / American Heart Association have been published and
review the evidence (Hunt et al., 2005; Nieminen et al., 2005).
2.3.2 Exercise training
Historically, it was believed that exercise therapy was detrimental in CHF and until the
late I970's / early I980's it was not encouraged Uncontrolled studies around that time
suggested exercise tolerance could be improved by training (Conn et al., 1982; Lee et
al., 1979; Letac et al., 1977) although conflicting outcomes were described during the
1980's with respect to LV remodelling post-anterior myocardial infarction following
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low-intensity training (Jugdutt et al., 1988). Since then, many studies have been
performed looking at every known aspect of pathological change in CHF and have
largely demonstrated benefit following training and this has led to the adoption of
training in the current guidelines for CHF management (Hunt et al., 2001; Remme and
Swedberg, 2002; Scottish Intercollegiate Guidelines Network, 2002; Working Group on
Cardiac Rehabilitation & Exercise Physiology and Working Group on Heart Failure of
the European Society of Cardiology, 2001). A review of some of the influential studies
performed during the last 2 decades which have demonstrated improvements following
training is given below.
2.3.2.1 Central haemodynamics
Although the majority of benefit from training is likely to be due to peripheral
adaptations, improvement in central haemodynamic variables has been observed. There
is minimal or no change in ejection fraction following training (Belardinelli et al.,
1995a; Belardinelli et al., 1998b; Sullivan et al., 1988a) but small improvements in
cardiac output are observed during exercise following a period of training (Belardinelli
et al., 1995b; Dubach et al., 1997b; Dubach et al., 1997a; Hambrecht et al., 1995). This
small increase in cardiac output can be attributed to a small increase in maximal heart
rate (around 4-8%) and small increases in stroke volume coupled with a small reduction
in systemic vascular resistance. One study has shown an improvement in the diastolic
filling rate following training with improvements correlating with increased cardiac
index at peak exercise (Belardinelli et al., 1996). There is no evidence of significant
ventricular remodelling following exercise training (Dubach et al., 1997b; Giannuzzi et
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al., 1993; Jette et al., 1991; Klecha et al., 2007; Myers et al., 2000a), and in fact one
study has suggested an adverse effect on remodelling post MI following training
(Jugdutt et al., 1988). There may be some improvement in perfusion and contractility
following training as assessed following a short period of training by dobutamine stress
echocardiography and thallium perfusion scintigraphy (Belardinelli et al., 1998a) where
an approximately 30% improvement in contractility and thallium uptake was observed.
This contrasts with other studies where LV contractility at rest and during exercise was
unchanged following training (Dubach et al., 1997b; Giannuzzi et al., 1997; Giannuzzi
et al., 1993).
2.3.2.2 Neuroendocrine function
Results from studies measuring catecholoamine spill-over are inconsistent with some
studies showing reduced noradrenaline levels following training (Coats et al., 1992;
Hambrecht et al., 1995; Tyni-Lenne et al., 2001), but not others (Kiilavuori et al., 1999).
Improvement in heart rate variability and reduction in resting heart rate which indicate
reduced sympathetic drive and increased vagal tone have also been demonstrated
following training (Coats et al., 1992; Larsen et al., 2004).
2.3.2.3 Endothelial function
Improvement in oxygen delivery and extraction by improved peripheral circulation has
been proposed as a mechanism for improved exercise capacity following training. Leg
blood flow has been seen to increase following 4-6 months of exercise training with
improvement in oxygen extraction peripherally and reduced lactate formation at
74
submaximal exercise (Sullivan et al., 1988a). Additionally, peak leg blood flow response
has been shown to improve following training with reduced leg vascular resistance at
submaximal and peak exercise (Hambrecht et al., 1995). To explore this further, a
number of studies have investigated the effect of training on the vascular endothelium.
Endothelial dependent relaxation of upper-limb vessels in response to flow is improved
following upper limb exercise in CHF patients (Hornig et al., 1996) and lower limb
training improves leg blood flow via endothelial-dependent vasodilatation with
improvements correlating with increases in peak VO2 (Hambrecht et al., 1998).
Improvement in epicardial endothelial dysfunction has also been demonstrated in one
small study following a short period of exercise training (Hambrecht et al., 2000b).
2.3.2.4 Exercise capacity and cardiopulmonary data
Peak oxygen consumption (peak VO2) during exercise is a reliable indicator of exercise
capacity in heart failure and is closely associated with prognosis (Myers et al., 2000b).
Allowing for methodological differences between studies examining effects of exercise
in heart failure, specifically mode and duration of training, many studies demonstrate
clear improvement in peak VO2, with increases between 12% and 31% (Table 2.4).
Some uncertainty exists regarding the required duration of training, but it is likely that
continued training is required to maintain benefit (Meyer et al., 1996; Tenenbaum et al.,
2006) and that supervision may be required (McKelvie et al., 2002).
It is possible that aetiology of heart failure is important in determining response to
training with one study suggesting greater benefit for patients with non-ischaemic heart
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failure (Keteyian et al., 1996) although ischaemic patients with evidence of hibernating
myocardium on dobutamine stress echocardiography may benefit most (Belardinelli et
al., 1998b).
Submaximal exercise parameters are commonly assessed in exercise training studies
also, including 6-minute walk distance (6MW) and exercise duration. Improvements in
6MW distance have consistently been seen in trained subjects e.g., (Freimark et al.,
Authors No. of Exercise Programme %V02 Increase
Reference Patients (trained vs.
Duration, wk Mode of training control patients)
Jette, et al. 18 4 Mon-Fri. am: Jog at 70% to 80% max HR for 22 in group with
(1991) 5 min 3x/wk; calisthenics 30 min; cycle 15 min EF <30%
at 70% to 80% max HR. pm: Walk 30 to 60
Belardinelli, et 20 8
min.
Cycle at 40% peak Vo2 3x/wk. 20
al. (1992)
Coats, et al. 17 8 Cycle 20 min at 60% to 80% max HR 3x/wk. 18
(1992)
Belardinelli, et 55 8 Cycle 40 min at 60% Vo2max 3x/wk. 12
al. (1995a)
Hambrecht, et 22 3 Walk 10 min 6x/d at 70% Vo2max 2x/wk. 31
al. (1995)
Keteyian, et al. 29 24 Rating of perceived exertion, 12-14. 16.3
(1996) Treadmill, cycle, rowing, and arm ergometer at
60% exercise capacity for 33 min 3x/wk.
Radaelli, et al. 6 5 Cycle 20 min 5 d/wk. 15
(1996)
Dubach, et al. 25 4 Walk 60 min 2x/d; cycle 40 min 4x/wk at 80% 26
(1997b) Vo2max.
Tyni-Lenne, et 16 8 Knee extensor: 60 repeats/min for 15 min for 8 14
al. (1997a) wk (at 65% peak work rate for 4 wk and then
75% peak work rate for 4 wk).
Callaerts-Vegh, 17 8 Walk 1 h, 2x/d; cycle 45 min at 70% to 80% 30.9
etal. (1998) HR reserve 4x/wk.
Reinhart, et al. 25 8 Cycle 40 min at 70% to 80% max capacity 29
(1998) 4x/wk; walk 1 hour 2x/d.
Belardinelli, et 99 8 (plus Cycle at 60% peak Vo23x/wk for 8 wk. 18 at 2 mo; 23 at
al. (1999) maintenance) Maintenance: 2x/wk for 12 mo. 14 mo
Taylor (1999) 8 8 Train 30 min at 45% to 70% peak Vo23x/wk. 17.6
Sturm, et al. 26 12 (plus Step aerobics and cycle at 50% capacity for 12 23.3
(1999) maintenance) wk; then step aerobics 100 min/wk and cycle
50 min/wk.
Keteyian, et al. 43 24 Treadmill, cycle, and arm ergometer at 60% to 14.3
(1999) 80% max HR for 33 min 3x/wk.
Table 2.4. Effects of exercise training on V02 in CHF patients.
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2007; McKelvie et al., 2002) as have improvements in exercise duration (Wielenga et
al., 1999). The usefulness of the 6MW test as a submaximal marker of exercise capacity
is discussed further in section 3.3.2.
Another submaximal exercise parameter is the anaerobic threshold (AT) measured
during cardiopulmonary exercise testing. The terms anaerobic threshold, ventilatory
threshold and lactate threshold are often used interchangably in the literature although
the processes they describe are subtly different; the AT, however, does relate to the point
where there is a sustained switch to predominantly anaerobic metabolism during
exercise. The measurement and interpretation of AT during cardiopulmonary exercise
testing differs between studies and is discussed further in section 3.3.4.3. Low VCL at
AT is associated with poorer outcome (Gitt et al., 2002) and exercise training has been
shown to significantly increase VCL at AT (Hambrecht et al., 1995; Wielenga et al.,
1999). Alleinatively, the lactate threshold can be measured directly with venous blood
sampling during incremental exercise testing and VCL at lactate threshold has been
shown to improve following training (Belardinelli et al., 1992; Dubach et al., 1997a);
venous lactate concentrations were lower in one study for trained subjects during
submaximal exercise testing, indicating delayed progression to anaerobic metabolism
(Hambrecht et al., 1995).
Ventilatory abnormalities indicated by the exaggerated VE/VCCL slope (discussed in
section 3.3.4.4) are improved following training (Coats et al., 1992; Guazzi et al., 2004).
Mechanisms are likely to relate to improved skeletal muscle characteristics and delayed
onset of lactate accumulation, although enhanced ventilation / perfusion matching and
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reduced ergoreceptor activation have been proposed (Clark et al., 1996; Mancini et al.,
1995; Piepoli et al., 1996). The effectiveness of specific respiratory muscle training has
also been examined and maximal ventilatory capacity and inspiratory / expiratory
muscle strength improve with targeted respiratory training (Mancini et al., 1995).
2.3.2.5 Skeletal muscle
The abnormalities in skeletal muscle function described in section 2.2.8.3.1 can be at
least partially reversed by training. Belardinelli, et al. demonstrated increased cross
sectional area of both type I and type II fibres following an 8-week training programme
(Belardinelli et al., 1995b). The fibre-type switch was reversed following a longer period
of training which may improve the early fatigue of CHF patients during exercise
(Hambrecht et al., 1997).
Beneficial changes in oxidative capacity have also been observed following training.
Belardinelli, et al. observed a 22% increase in volume density of mitochondria following
training, which was correlated to peak VO2 (r = 0.77, p < 0.0002) and lactate threshold (r
= 0.81, p < 0.0001, Belardinelli et al., 1995b). The mitochondrial total volume density
and volume density of cytochrome c oxidase-positive mitochondria increased
significantly, whereas volume density of cytochrome c oxidase-negative mitochondria
remained unchanged following training with increased oxidative capacity highly
correlated with improvement in peak VO2 (Hambrecht et al., 1995; Hambrecht et al.,
1997). Additionally, Hambrecht, et al. (1997) demonstrated a 92% increase in surface
density of mitochondrial inner border membrane and an increase in the surface density
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of cytochrome c oxidase-positive mitochondrial cristae.
Early reliance on anaerobic metabolism can be assessed by 31P-MRI scanning to
measure phosphocreatinine depletion. It has been shown that training results in a
reduced depletion of phosphocreatinine during exercise and an accelerated recovery of
phosphocreatinine following exercise, indicating less reliance on anaerobic metabolism
during exercise and an increased rate of mitochondrial ATP synthesis (Adamopoulos et
al., 1993). Minotti, et al. demonstrated that there was a two- to three-fold increase in
endurance following training associated with a slower increase in inorganic phosphate
(Pi) and decline in phosphocreatine (PCr) and a beneficial change in the Pi/PCr ratio to
workload regression slope, implying improved oxidative metabolism (Minotti et al.,
1990).
Catabolism induced by pro-inflammatory cytokines is a possible mechanism for skeletal
muscle atrophy in heart failure and an attenuated pro-inflammatory state following
training has been demonstrated (Adamopoulos et al., 2002).
2.3.2.6 Quality of life
Not all training studies address quality of life and those that do vary in methodology and
results. Table 2.5 summarises trial data and methodology for those studies that have
reported on quality of life outcomes. The optimal quality of life assessment tool is
uncertain at present and some studies have used multiple assessment tools. The majority
of the studies listed in Table 2.5 do show a positive effect for quality of life although
some others showed no benefit (Cider et al., 1997; Johnson et al., 1998; Owen and
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Croucher, 2000). It is not surprising that short-term quality of life scores improve
following short-term training regimes in unblinded trials and the long term effects on
quality of life following training still requires evaluation, although the results from
Belardinelli, et al. (1999) are encouraging, suggesting a sustained improvement in
quality of life at follow-up.
2.3.2.7 Morbidity and mortality
Exercise training studies have tended to enrol only small numbers of patients and, as
Author Interval Assessment tool Outcome
Belardinelli, et al.
(1999)
Cider, et al. (1997)
Coats, et al. (1992)
Johnson, et al. (1998)
Kavanagh, et al. (1996)
Koch, et al. (1992)
Oka, et al. (2000)
Owen and Croucher
(2000)
Quittan, et al. (1999b)









Wielenga, et al. (1999)
Willenheimer, et al.
(1998)
Baseline, 2, 14, 26
months
MLWHF
Positive at 2 months,
stable thereafter
NHP: positive in
Baseline, 20 weeks NHP, QLQ-HF control group. QLQ-
HF - no change
8 weeks crossover Likert scale Positive
Baseline, 8 weeks CHFQ No change
Baseline, 16, 26, 52
weeks CHFQ, SG Trend for improvement
Baseline, 12 weeks Visual scale
Uncertain - no statistics
reported
PositiveBaseline, 12 weeks CHFQ
Baseline, 12, 26 weeks MLWHF No change
Baseline, 12 weeks SF-36 Positive
Baseline, 16 weeks CHFQ, SG Positive
Baseline, 8 weeks SIP, SOC
SIP - positive, SOC -
no change
Baseline, 8 weeks SIP, SOC Positive
Baseline, 8, 16 weeks SIP, SOC
SIP - positive, SOC -
no change
Baseline, 8 weeks SIP, SOC, MLWHF
MLWHF - positive.
SIP, SOC - no change
Baseline, 12 weeks HPPQ, SAGWB
SAGWB - positive.
HPPQ - trend only.
Baseline, 16 weeks DFI, Global QoL, PAS Positive
Table 2.5. Quality of life outcomes following CHF exercise training trials.
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such, event rates are low. The studies have not, therefore, been adequately powered to
assess hospitalisation rates and mortality data. The older studies predate the widespread
use of cardioselective beta-blocker therapy and this makes interpretation of morbidity /
mortality data harder. The EXERT trial randomised 181 patients to usual care or 3
months of supervised exercise training followed by 9 months of home-based exercise
training (McKelvie et al., 2002). After 3 months, a 10% increase in peak VCE was
observed, rising to 14% after 12 months. However, adherence to training was poorer
during the home-based phase of the trial and there was no observed difference in
hospitalisation or mortality. This contrasts with Belardinelli, et al. (1999) which showed
a significantly lower combined end-point of hospitalisation and cardiac mortality (5 vs.
14 events, RR 0.29, p=0.02) and a separation of survival curves (9 vs. 20 events, RR
0.37, p=0.01) between trained and non-trained groups beyond 1 year. The issues of
population selection which will be explored further in chapter 8 may be of relevance
with respect to the disparity in results of these two trials.
Smart and Marwick have performed a meta-analysis of 81 trials of exercise training in
heart failure (Smart and Marwick, 2004). This encompassed 2387 patients and over 60
000 hours of training in total. 26 patients randomised to exercise group and 41
randomised to non-exercising groups died (OR 0.71 95% CI 0.37 to 1.02, p = 0.06). The
combined end-point of death or adverse event including hospitalisation rate was 56 in
the exercising groups and 75 in the control groups (OR 0.98, 95% CI 0.61 to 1.32, p =
0.60). As such, there is a suggestion of mortality benefit following training, but the
evidence is not concrete.
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A further meta-analysis of selected exercise training trials has also been reported
(Piepoli et al., 2004). This used individual patient data from 9 randomised parallel group
controlled trials with an exercise duration of at least 8 weeks and a follow-up period of
between 159 and 2284 days. Between 27 and 181 patients were participating in the
individual trials and a total of 801 patients' data-sets were analysed, 395 of whom had
been randomised to an exercise programme. 88 deaths were observed in the exercising
arm and 105 in the control arm (HR 0.65, 95% CI 0.46 - 0.92, p=0.015). The secondary
endpoint of death or hospital admission was also significantly lower in the exercising
arm (127 vs. 173 events, HR 0.72, 95% CI 0.56 - 0.93, p=0.011). Strictly speaking, this
was not a true meta-analysis as data were pooled and treated as a single study,
potentially introducing bias and over-precision. Additionally cox-regression was used to
correct for the individual trials which will potentially bias for the study with the longest
period of follow-up (Belardinelli et al., 1999) which had a large observed mortality
difference between trained and non-trained groups.
These data require confirmation in a larger trial before firm conclusions regarding the
potential mortality benefit with training can be drawn. HF-ACTION is a large study
which is currently underway and will attempt to address this question (Bensimhon et al.,
2007). This trial aims to recruit 3000 NYHA class II to IV CHF patients with an average
follow-up period of 2.5 years. The applicability of trial data to the wider CHF population
derived from this type of study is also a matter of debate in view of potential differences
between trial and general CHF populations. Despite this, there is an indication that
exercise training may confer a mortality benefit, which is an attractive prospect, and
hopefully we will have a better understanding of this when HF-ACTION reports.
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2.4 Rationale for studies in this thesis
2.4.1 Study 1. A randomised study of home-based neuromuscular
stimulation of the legs and conventional bicycle exercise training for
patients with chronic heart failure.
This trial was conceived at the time that recommendations for management of chronic
heart failure had been published (Hunt et al., 2001; Remme and Swedberg, 2002;
Scottish Intercollegiate Guidelines Network, 2002; Working Group on Cardiac
Rehabilitation & Exercise Physiology and WorkingGroup on Heart Failure of the
European Society of Cardiology, 2001). Exercise training / rehabilitation was included
in the recommendations but it is widely appreciated that the heart failure patient is both
detrained and often demotivated. As such, delivery of this therapy is difficult.
Neuromuscular electrical stimulation (NMS) of limbs has been shown to be effective in
the rehabilitation for patients detrained due to other conditions such as stroke disease.
Additionally, neuromuscular stimulators have become popular with healthy individuals
attempting to increase muscle performance / bulk either in addition to or instead of
conventional training in the gym. These units are commercially available for little cost
and are frequently advertised as a way of achieving improved performance with less
effort. Study 1 is the pilot study intended to explore the concept that these devices can be
used for CHF patients. The study is randomised for conventional bicycle training against
NMS training of quadriceps and gastrocnemius muscles but does not use a control
population. Patients exercise for six weeks using either conventional or NMS training
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with functional performance assessments before and after the training period. The main
aim of this study is to explore the effectiveness and safety of NMS training at home.
Issues such as motivation and compliance are also discussed.
2.4.2 Study 2. Maximum oxygen uptake corrected for skeletal muscle
mass accurately predicts functional improvements following
exercise training in chronic heart failure.
This study was designed to explore the effect of exercise training using NMS on skeletal
muscle in CHF patients. Dual energy X-ray absorptionometry (DEXA) can accurately
measure lean body mass and we proposed that small changes in skeletal muscle mass
following a period of training might be detectable using this technique. Alternatively,
qualitative changes in skeletal muscle following training have been demonstrated
previously (Adamopoulos et al., 1993) and the contribution of qualitative and
quantitative adaptations following exercise in CHF patients is as yet unknown. By
performing DEXA scanning before and after conventional and NMS training, we aimed
to explore this relationship. Finally, it is well recognised that lower muscle mass is
associated with a worse outcome in heart failure (Anker et al., 1997b; Anker et al.,
2003). Reversal of this cachectic state may improve prognosis. Identifying whether
patients with the lowest muscle mass prior to training experience the same or different
degrees of benefit from training with respect to exercise performance or muscle mass as
patients with higher baseline muscle mass or exercise capacity may have implications in
the selection of patients for rehabilitation and training in the future. It is as yet unclear
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whether patients with poorer baseline function have as much to gain from training as
their fitter counterparts.
2.4.3 Study 3. Change in circulating cytokines following two forms of
exercise training in chronic stable heart failure.
It is well recognised that a pro-inflammatory state exists in CHF patients and that the
degree to which this is present is associated with disease severity (Levine et al., 1990;
Torre-Amione et al., 1996a). The third study was designed to explore the association
between disease severity / exercise performance and markers of inflammation before and
after a period of training. Different training regimes may have differing effects on the
pro-inflammatory state which have not yet been identified. The study compares NMS
and conventional training with respect to high sensitivity C-reactive protein (hs-CRP),
interleukin 6 (IL-6), tumour necrosis factor alpha (TNFa) and the two soluble TNFa
receptors, sTNFri and sTNFr2. Patients exercise for 6 weeks using either conventional or
NMS training with functional capacity assessments and cytokine assays at the beginning
and the end of the training period.
2.4.4 Study 4. Neuromuscular and conventional exercise training in stable
and recently decompensated patients with chronic heart failure.
This study expands on the concepts explored in chapter 4 (study 1). Exercise training,
either conventionally performed or using NMS in CHF patients is studied, on this
occasion with the addition of a control CHF population to aid the interpretation of
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findings. Furthermore, in view of the fact that patients participating in studies,
particularly those involving exercise training, appear highly selected for their stability
and greater baseline fitness, this study includes patients who have recently been admitted
to hospital following an episode of decompensated heart failure. By including this
group, this study is designed to explore the hypothesis that early rehabilitation of
patients with recently decompensated symptoms is as safe and as effective as exercise
training in stable patients. The inclusion of these patients is challenging from a
methodological point of view and issues regarding drop-out from the study and patient
compliance are discussed. Patients are randomised to either control (no exercise),
conventional or NMS training regimes for 6 weeks with functional capacity assessments
and NT-pro BNP assay before and after the study period. A further assessment of
functional capacity is made after a further 6 weeks of detraining.
2.4.5 Study 5. Participants suitable for inclusion in exercise training trials
are substantially different from the general heart failure population.
Whilst study 4 had included a broader range of patients compared with other exercise
training trails in the literature, it is still apparent that many patients seen in hospital,
either in clinic or on the wards, are not eligible to participate in such trials based on
standard inclusion and exclusion criteria. Certain patients with orthopaedic, neurological
or simply severe heart failure symptoms who are unable to perform the necessary
performance assessments in clinical trials are automatically excluded from such studies.
Despite this, it is possible that they have much to gain from training, particularly
regimes which require less physical effort and / or less motivation to perform. As such,
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study 5 examines the characteristics of patients willing and able to participate in an
exercise training study and compares them to the population of heart failure patients
from which they are recruited. A comparison is also made between the characteristics of
stable patients, traditionally included in CHF exercise studies, recently decompensated
patients, i.e., those recently discharged following a hospital admission due to
decompensated heart failure, and patients examined as part of the ExTraMATCH
collaborative summary, a meta-analysis of several well-designed and frequently cited
CHF exercise training trials. No such data is yet available in the literature regarding this
subject.
The studies were carried out between 1999 and 2004. Scientific research is often
collaborative and multiple investigators are often involved in the prosecution of clinical
trials. Only the pilot study (study 1) involved significant collaboration with another
investigator. Dr S. Harris commenced this pilot trial collecting approximately 50% of
the data between 1999 and 2001. The remainder of the data collection for this and the
other four studies, along with all data analysis and manuscript preparation is my own
work, with the support of Ms S McKee, heart failure research nurse and under the
guidance of the two project supervisors, Professor KAA Fox and Dr MA Denvir. The
research was carried out at the Western General Hospital, Edinburgh and, latterly, at the
Wellcome Trust Clinical Fesearch Facility at the Western General Hospital. The studies





Patients included in studies l -3 were recruited from hospital out-patient clinics and were
classed as having stable chronic heart failure (S-CHF). This was defined as having been
diagnosed in the past with heart failure on the basis of symptoms of breathlessness and
exercise intolerance and impaired left ventricular systolic function with a calculated
ejection fraction of less than 40% using the modified Simpson biplane method. At the
time of recruitment, patients described NYHA class II or III symptoms. Stability was
defined as no alterations in medical therapy within one month and no myocardial
infarction within three months prior to inclusion. No weight loss of greater than 6% was
reported for any of the patients in the preceding 6 months. All patients were on
appropriate medical therapy including angiotensin converting enzyme inhibitors (ACEi)
or angiotensin II receptor blockers (ARB), loop diuretics, aldosterone antagonists,
digoxin and beta-blockers. None of the subjects was participating in an exercise
programme prior to inclusion in the studies. Patients were excluded if they had co¬
existing respiratory, neurological, orthopaedic or peripheral vascular disease that would
prevent either a bicycle exercise training programme or completion of the exercise
performance assessments throughout the course of the studies. None of the subjects
taking part in the study was known to have any intercurrent infective or malignant
disease.
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For study 2, an additional 20 healthy age-matched control subjects with no prior history
of cardiac or any other chronic illness were recruited from within the department and
were used as a comparison group.
3.1.2 Studies 4,5
Stable patients (S-CHF) for studies 4 and 5 were recruited and defined in the same way
as for studies 1-3 (section 3.1.1). Recently decompensated patients (RD-CHF) were also
recruited. All RD-CHF subjects with potential for inclusion had been previously
diagnosed with heart failure on the basis of clinical assessment and documented left
ventricular systolic dysfunction described as at least moderate in severity by
echocardiography prior to the current admission. Subjects were identified at the time of
their admission for decompensated heart failure, i.e., worsening and uncontrolled
peripheral oedema or pulmonary oedema defined clinically and on chest radiograph, and
approached towards the end of their hospital stay once they were deemed fit to provide
informed consent. They were treated for decompensated heart failure with standard
medical therapy and discharged from hospital once stable. Potentially suitable subjects
were invited to attend for a baseline screening visit between 2 and 4 weeks after their
discharge from hospital. Patient information leaflets were provided prior to discharge
and again at attendance for baseline assessment. Those patients who were eligible to
continue gave consent at this point and proceeded to carry out baseline performance
assessments prior to randomisation. Patients were excluded from the study if they were
aged <18 or >80 years, had a history of stroke or acute coronary syndrome within the
last 3 months, had uncontrolled anginal symptoms or had any respiratory, neurological
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or orthopaedic condition which would prevent their participation in either a conventional
bicycle exercise training programme or the physical exercise assessments during the
study. No subject was participating in any exercise training programme prior to
recruitment. At the time of first baseline assessment, participating patients were on
standard medical therapy that included ACEi or ARB, diuretic, aldosterone antagonists,
digoxin and/or beta-blockers.
3.2 Ethics and consent
Written informed consent was obtained from all subjects participating in studies 1-5.
Subjects signed three copies of a standard consent form after confirming that they had
read and understood the relavant patient information sheet for the particular study.
Consent was taken by myself and witnessed by a research nurse in all cases. The study
protocols were approved by the local research ethics committee and conformed to the
principles outlined in the Declaration of Helsinki.
3.3 Performance / disease severity assessments
3.3.1 Echocardiography
Echocardiography was performed for studies 1-3 to determine left ventricular ejection
fraction (EF). Several techniques are available to quantify LV ejection fraction and
include simple visual assessment, M-mode echo, modified 2D Simpson bi-plane method,
X-ray cineangiography, radionucleotide scanning and cardiac MRI. The most commonly
used assessment in clinical practice is a simple visual assessment on 2D echo which is
reproducible when performed by experienced sonographers. Visual assessments may
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underestimate the severity of LV dysfunction however, and this method along with M-
mode and 2D echo assessments of ejection fraction rely on the presence of satisfactory
imaging windows and good endocardial border definition (Bellenger et al., 2000).
Cardiac MRI may provide the most reproducible assessment of ejection fraction and
avoids the limitations of echocardiography with respect to image acquisition. It is not
uncommon, however, for patients to be unable to complete an MRI scan due to
claustrophobia. Additionally, cardiac MRI is more time consuming and costly at present
compared with echocardiography and is not universally available. Cardiac MRI was not
available locally at the time the studies were carried out and as such was not considered.
Equally, cineangiography and radionucleotide scanning were considered inappropriate
as part of our trial design in view of the necessity for radiation exposure.
Accepting the problems associated with image acquisition in 2D echo, studies 1-3
utilised the modified Simpson bi-plane technique to assess LV ejection fraction (Schiller
et al., 1989). This technique has been validated previously against radionucleotide
scanning and cineangiography (Folland et al., 1979). Each subject underwent two
separate scans performed on the same day by a single, experienced sonographer. The
mean EF value was used. Where endocardial border definition or apical echo windows
were not satisfactory, no assessment was made and the data treated as missing at the
time of statistical analysis. Commercial echo contrast agents were not available locally
at the time of the studies.
Every subject included in study 4 and every screened subject in study 5 underwent
echocardiography as part of their routine clinical care. A prior diagnosis of heart failure
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had been made on the basis of symptoms of breathlessness and exercise intolerance
accompanied by an echocardiogram repot ted as showing LV systolic impairment of at
least moderate severity. Although ejection fraction is correlated with outcome in heart
failure, the relationship between ejection fraction and exercise performance is very poor
and as such it was not felt at the time of trial design that a formal ejection fraction was
required for these studies as little additional information was likely to be gained.
Furthermore, a change in ejection fraction was unlikely to be observed following
training owing to the short period of training involved and the reproducibility of
measurements between scans - a much larger group of patients would need to be
enrolled in these studies to allow meaningful statistical interpretation of any data
generated from echo. As such, visual assessment of LV function was considered a valid
assessment to confirm that LV systolic dysfunction of at least moderate severity was
present.
3.3.2 6-minute walk
The 6-minute walk (6MW) test is a simple measure of how far a subject can walk in 6
minutes. It is well tolerated and theoretically easy to administer (Solway et al., 2001). It
is a measure of submaximal exercise performance with patients allowed to rest during
the period of the test if they wish. This mirrors daily activities and provides an
assessment of the global response to exercise, including cardiac, pulmonary, circulatory,
muscular and psychological aspects of exercise. The 6MW test has been used as an
outcome measure in chronic respiratory disease (Mackay et al., 2007; Paggiaro et al.,
1998; Spence et al., 1993) and heart failure trials of drugs (Barabino et al., 1991;
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Hutcheon et al., 2002), devices (Abraham et al., 2002; Higgins et al., 2003) and exercise
(Freimark et al., 2007; McKelvie et al., 2002). It is predictive of mortality in CHF
(Bittner et al., 1993). Although widely used as an outcome measure, however,
improvements in 6MW distance are not always seen, particularly in trials of
pharmacological agents which may have included patients with milder symptoms at
baseline with less relative improvement in exercise performance after intervention, or
the agents themselves having little effect on exercise performance (Olsson et al., 2005).
Furthermore, there is evidence that repetition of this test improves the participant's
performance making interpretation of test results before and after intervention unreliable
(Demers et al., 2001; O'Keeffe et al., 1998; Opasich et al., 1998; Yusuf and Tsuyuki,
1996). Few clinical trials state whether a familiarisation test is performed.
Safety aspects of the 6MW test and contraindications are discussed in the American
Thoracic Society guideline (American Thoracic Society, 2002). Patients should ideally
use an unobstructed corridor which is 30 metres long with the turn marked with a cone,
resulting in a 60 metre circuit. It has been shown that oval circuits may result in longer
distances achieved in patients with severe COPD (Sciurba et al., 2003).
No quiet length of corridor was available at the time of the studies and, as such, a 60m
square circuit was used. Although this may have resulted in longer distances achieved,
the circuit was not altered over the entire study period. The surface was smooth and
firm. Seating was arranged at regular intervals to allow the subject to rest, if required.
Subjects were rested for at least 10 minutes before the start of the test to allow
acclimatisation and to check resting heart rate, blood pressure and to exclude signs of
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pulmonary oedema. Subjects wore loose clothing and comfortable shoes. The test was
conducted at approximately the same time of the day on each occasion (around 9-10am).
Standardised instructions were given to each subject at the start of the test as follows:
"The object of this test is to walk as far as possible for 6 minutes. You will walk around
this hallway continuously turning to your left at each corner. Six minutes is a long time
to walk, so you will be exerting yourself. You will probably get out of breath or become
exhausted. You are allowed to slow down, to stop, and to rest as necessary. You may
lean against the wall or sit down while resting, but please resume walking as soon as you
are able. 1 am going to count the number of laps you complete. Remember that the
object is to walk as far as possible for 6 minutes, but do not run or jog. If you experience
any chest discomfort or dizziness during the test, please stop. Start now, or whenever
you are ready."
To maintain line-of-sight with the subject, one operator stood at one corner of the circuit
with the other operator at the opposite corner. The subject was not followed around the
circuit and was not encouraged in any way during the test. The subject was informed of
the time after 2 minutes, after 4 minutes and 15 seconds before the end of the test.
In view of the training effect seen with two repeated 6MW tests, the test was repeated at
least 24 hours later but within 1 week. No strong data exist regarding the effect of
performing further practice 6MW tests. Figure 3.1 shows Bland-Altman plots of 6
minute walk distance vs. absolute and percentage difference for 94 consecutive pairs of
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Figure 3.1. Bland-Altman plots for paired 6-minute walk distances. Top: absolute
difference; bottom: percentage difference.
performed according to the protocol described above. There is a bias of 25.8 ± 36.3 m or
5.00 ± 8.00 % increase for the second baseline test, respectively.1 For our study, the first
baseline test data was discarded and the second baseline data used as true baseline.
' Data presented according to the methods described by Bland and Altman (1999).
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3.3.3 Quadriceps strength and fatigue
The exercise training studies employ conventional training using either cycle ergometers
or neuromuscular stimulation of the quadriceps and gastrocnemius muscle. To assess
change in muscle strength and fatigability after a training period, an immobile
quadriceps bench was designed and constructed by the medical physics department at
the Western General Hospital, Edinburgh. This employed a piezoelectric strain gauge
attached to the bench and was calibrated to provide a measurement of equivalent weight
lifted during knee extension. Only the subject's dominant leg was studied (taken as the
same side as the hand they would use to write with). Care was taken to position the
subject comfortably in the apparatus with their back positioned to ensure a consistent
angle of the leg at the knee over the apex of the bench. The shin was placed behind a
second pad which was attached to the piezoelectric gauge. The gauge was calibrated by
the medical physics department every two months using standard masses. Data from the
gauge were analysed on a PC running Microsoft Windows 95™. A program was written
specifically for this task and a sample screen print of a demonstration trace is shown in
Figure 3.2. This sample simulates a fatiguing test of six-minute's duration. In fact, for
the studies presented here, a fatiguing protocol of 20-minutes duration was used, as
described by Buller, et al. (1991). Firstly, maximum strength was determined as the peak
equivalent weight lifted from three maximal voluntary contractions of the quadriceps of
the dominant leg and only contractions deemed to be maximal on the basis of the quality
of the visual trace were accepted. True maximal contractions demonstrated noise in the
visual trace representing fasciculation whereas sub-maximal contractions produced
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Figure 3.2. Screen print of fatigue protocol measurements.
smooth traces. Attempts were performed at least one minute apart and clear instructions
were given to each subject prior to each test. A fatiguing protocol was then performed
whereby patients applied a force to the isometric bench at 30% of the previously
determined maximum every 2 seconds for 40 seconds of every minute over a 20-minute
period. Maximum quadriceps strength was repeated at the end of the 20 minutes and
fatigability index expressed as the ratio between the first and second maximal
measurements.
Ideally, an instrument such as the Cybex dynamometer would have been used to
measure isokinetic strength as this would have removed the potential error introduced by
differing leg positions between subjects. Unfortunately, this equipment was not available
locally at the time the studies were carried out.
To exclude a training effect similar to that seen with 6MW tests, two baseline tests were
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Figure 3.3. Bland-Altman plots for paired fatigue index tests. Top: absolute difference;
bottom: percentage difference.
in the literature regarding possible training effects for this type of equipment. Bland-
Altman plots of consecutive pairs of strength and fatiguing tests performed on CHF
patients according to the protocol described above are shown in Figure 3.3 and Figure
3.4. There was a bias of 2.72 ± 6.21 kg or 6.36 ±15.1 % for the second test of maximal
quadriceps strength and a bias of 0.053 ± 0.144 or 6.15 ± 20.6 % for the second test of
fatigue index. Tests were performed at approximately the same time of the day (usually
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Figure 3.4. Bland-Altman plots for paired maximal quadriceps strength tests. Top:
absolute difference; bottom: percentage difference.
3.3.4 Cardiopulmonary data
3.3.4.1 Equipment
Maximum oxygen consumption (VO2 max) is regarded as the best objective assessment
of exercise capacity, integrating cardiac, respiratory, circulatory, skeletal, biochemical
and psychological performance. Patients rarely achieve a true maximum plateau VO2
with oxygen consumption limited by one or more variables, e.g., stroke volume, heart
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rate or cellular respiration, and so the peak VO2 attained during exercise is often used as
an interchangeable term although it should be appreciated that it is not a true maximal
value. Peak VO2 predicts survival in patients with CHF (Cohn et al., 1993; Francis et al.,
1982; Mancini et al., 1991). Oxygen uptake at the lungs directly mirrors tissue oxygen
consumption, as shown diagrammatically in Figure 3.5, with CO2 production at the
lungs mirroring cellular CO2 production under steady state conditions. VO2 can thus be
calculated if one can measure flow and the difference between oxygen inspired and
expired as shown in Equation 3.1, where VO2 is oxygen consumption, VI is the volume
of inspired gas (air), FIO2 is the proportion of oxygen in the inspired gas, VE is the
volume of expired gas and FEO2 is the proportion of oxygen in the expired gas:
VO2 = [(VI x F1Q2 ) - (VE x FEQ2)1 / t
Equation 3.1. Calculation of V02
V02 is usually expressed per unit time (t) e.g., 1/min or ml/kg/min. C02 is calculated
similarly (Equation 3.2) but with the simplification of removing the minimal quantity of
inspired C02 from the equation, where VC02 is carbon dioxide production, VE is the
volume of expired gas, FEC02 is the proportion of C02 in the expirate and t is time:
VCP2 = (VE x FECQ2) /1
Equation 3.2. Calculation of VC02
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Figure 3.5. Relationship between oxygen consumption and tissue utilisation. Adapted from
Wasserman, et al. (2004)
Accurate measurement of oxygen consumption and CO2 production at the mouth is
achieved using specialised cardiopulmonary exercise testing equipment. For studies 1-3,
a zirconia fuel cell oxygen analyser and infrared carbon dioxide analyser were used
(Benchmark system, Morgan Medical, Kent, UK). For studies 4 and 5 a mass
spectrometer system was used (Pulmolab Ex671, Morgan Medical, Kent, UK). Both
systems have been demonstrated to provide accurate measurements in the past and are in
routine clinical use. The change in equipment between studies 3 and 4 was due to
relocation of the studies to the Wellcome Trust Clinical Research Facility (WTCRF) at
the Western General Hospital. The previous Benchmark system was owned by the NHS
and was in routine clinical use. Due to the large number of patients anticipated to enrol
in study 4, it was elected to relocate to the WTCRF and purchase new equipment
dedicated to research studies. Cross-validation between the two systems was not
performed; however no data collected from either system was shared / pooled with data
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from the other as part of any study.
Flow was measured using a pneumotachograph with the Benchmark system (pressure
measurement across a low-resistance screen) and a turbine volume transducer with the
Pulmolab system (low inertia impeller blades which rotate in response to flow, rotational
speed measured by disruption of light beam within volume transducer by impeller
blades). Both systems are in routine use around the world and both have potential
advantages / disadvantages over the other. Pneumotachographs are cheaper but require
laminar flow to function properly and there is greater dead space involved downstream
which may affect gas analysis. Additionally, expired gas needs to be as dry as possible
as fluid (i.e., saliva) on the low-resistance screen can introduce flow errors. Gas
temperature affects this type of flow measuring device more than flow volume
transducers. The flow volume transducer is more expensive and less tolerant of damage.
Sterilisation is more difficult as hot water melts the impeller blades. There is a potential
for lag in flow measurement with this type of system due to the mass of the impeller
blades, but this was not encountered as a problem with the Pulmolab system. With both
systems, flow was calibrated with a standard 3 litre syringe of air prior to each test. Error
tolerance was less than 0.5% for flow calibration.
Prior to exercise, both the Benchmark and Pulmolab systems were calibrated against
known gases certified by the manufacturer as accurate in composition to <1%. Expirate
was drawn into the tip of the sample capillary tube which was inserted into the
mouthpiece at approximately 30ml per minute. This expirate was drawn approximately
2.5 metres along the capillary tube and into either the Benchmark or Pulmolab systems
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within a few hundred milliseconds by the vacuum generated by the instrument. A small
portion of the expirate was drawn into the vacuum chamber and analysed using a
zirconia fuel cell system for O2 and infrared CO2 analyser (Benchmark) or mass
specrtometer (Pulmolab). With the Pulmolab mass spectrometer system, the expirate is
subjected to electron bombardment ionisation and the subsequent ions formed are
projected across the quadrupole, under the influence of an electric charge which is
dynamically altered to select ions of similar masses. The selected ions carry a current
which is collected and measured and is proportional to the ionisation efficiency and
partial pressure of the parent molecule, in turn proportional to the concentration of the
associated gas. A sample screen print of a mass spectrometer recording for air is shown
in Figure 3.6.
Figure 3.6. Sample mass spectrometer output for room air, Pulmolab ex671.
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For both systems, patients exercised on a treadmill using a modified Bruce protocol
which consisted of a standard Bruce protocol with the addition of 2 stages occurring
before stage 1 of the standard Bruce test: stage 0 at 2.7km/h, 0% slope and stage V2 at
2.7km/hr and 5% slope. Heart rate was recorded continuously. Blood pressure was
recorded every 3 minutes, one minute prior to an increase in workload. Patients were
encouraged to exercise to the point of exhaustion and this was checked by ensuring that
they had achieved their anaerobic threshold (AT), i.e., the point at which metabolic
respiration becomes predominantly anaerobic. Assessment of AT is discussed more in
section 3.3.4.3.
During exercise, patients were monitored for arrhythmia and were asked to report any
symptoms of chest pain or dizziness. The only adverse event noted during over 250
cardiopulmonary exercise tests performed was one episode of non-sustained ventricular
tachycardia in a patient with ischaemic cardiomyopathy. The episode lasted less than 30
seconds and the test was terminated on this basis. This occurred at the final assessment
visit for a patient participating in study 4 and did not result in exclusion from the study.
Some technical problems were encountered with the purchase and installation of the
Pulmolab system which had a direct impact on study 4. There was a six-month delay
between ordering of the equipment and final installation and full integration with
treadmill, cycle ergometer exercise equipment and 12-lead ECG analysis equipment.
This in turn led to a delay in patient recruitment into study 4. Additionally, calibration
issues were identified relating primarily to the quadrupole mass spectrometer. Impurities
on the surface of the quadrupole resulted in inaccurate measurements of oxygen and
104
carbon dioxide. Cardiopulmonary testing was therefore unavailable for several weeks
during the course of study 4 further limiting patient recruitment. Finally, combination of
ECG and cardiopulmonary real-time data analysis on a single PC proved problematic.
The PC was considered state-of-the-art in 2002 but did not have sufficient multi-tasking
processing power to cope with the heavy demands placed upon it. Integration of flow
and gas data analysis is critical for generation of accurate cardiopulmonary data and
there were concerns at the beginning of study 4 regarding the validity of some results
obtained. These results were discarded and following discussion with the manufacturer,
a replacement PC was provided. Once these issues were resolved, the equipment proved
reliable and, with careful calibration, accurate. The accuracy and validity of
cardiopulmonary data presented in all of the below studies was not thought to have been
adversely affected by the commissioning issues.
3.3.4.2 Peak V02
Analysis of breath by breath data obtained by both systems was performed offline. Raw
data was not available from the Benchmark system; data was averaged over 8
retrospective rolling breaths. Peak VOt was taken as the maximal VO2 in the last 30
seconds of exercise. A similar system was employed for data obtained from the
Pulmolab system. Raw data was used and retrospectively analysed using the Morgan
Medical analysis suite software (MMAS). A rolling average of 8 breaths was used and
peak VO2 taken as the highest VO2 in the final 30 seconds of exercise.
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3.3.4.3 Anaerobic threshold
Anaerobic threshold (AT) is a submaximal exercise parameter which has been shown to
be associated with prognosis (Gitt et al., 2002) and which can increase following a
period of exercise training as discussed in section 2.3.2.4 (Hambrecht et al., 1995;
Wielenga et al., 1999). It is usually expressed as an absolute value referenced to the VO2
at which the threshold occurs, and as a percentage of predicted peak VO2. It is usually
around 50-60% of predicted VO2. It is the point at which cellular respiration becomes
predominantly anaerobic. During incremental exercise, a combination of oxygen
delivery and consumption mismatch plus probable recruitment of muscle fibres with a
predominantly glycolytic metabolism contribute to the generation of lactic acidosis. The
term lactate threshold is sometimes used when describing this phenomenon but should
be reserved for studies where lactic acid has been sampled invasively. Buffering of
lactate occurs with stimulation of respiration and increased CO2 exchange at the lungs.
This along with the contribution of anaerobic cellular metabolism leads to higher VCO2
compared to VO2. The point at which this occurs is the AT and it can be determined by
different techniques. The most commonly used technique is the modified V-slope
method (Sue et al., 1988) which simplifies the original complex V-slope method
(Beaver et al., 1986). VCO2 increases as a linear function of VO2 in early exercise below
the anaerobic threshold (SI). As exercise intensity increases with increased lactate
production, there is an increase in slope (S2). Plotting VO2 against VCO2 allows the
visual determination of AT, termed the break point (Figure 3.7).
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Figure 3.7. Measurement of anaerobic threshold by V-slope method. Adapted from Beaver et
al., 1986.
increase VCO2 disproportionately to VO2 in the absence of significant lactate buffering.
Abnormal breathing patterns will also invalidate the V-slope method of non-invasive
determination of anaerobic threshold. Additionally, computerised graphical displays of
VO2 vs. VCO2 allow manual positioning of trend lines across the data representing SI
and S2. The data is usually averaged which invalidates the concepts of linear regression
on which the automated trend lines are based. Secondly, the manual positioning is
arbitrary and frequently varies between operators and even with the same operator and
test when analysed on separate occasions. To counteract these problems, two solutions
were employed. Firstly, I designed an automated system allowing two linear regression
lines to be 'best-fit' plotted against raw data. Graphpad Prism 4.0 was programmed with
the following instruction set (Equation 3.3):
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Y1 = intercept + slopel*X
YatXO = slopel*XO + interceptl
Y2 = YatXO + slope2(X-X0)
Y = IF(X<XO, Yl, Y2)
Equation 3.3. Automated break-point calculation using 'bi-linear' regression to determine anaerobic
threshold.
This allowed linear regression equations to 'best-fit' above and below a break point in
the raw data which would otherwise have been difficult to determine visually. An
example of data produced is shown in Figure 3.8. Secondly, values obtained by this V-
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Figure 3.8. Example of 'bi-linear' regression fitting to calculate anaerobic threhold from raw
cardiopulmonary data.
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VE/VCOa were plotted and AT assessed as the VO2 where VE/VOa reaches a minimum
and begins to rise without a rise in VE/VCO2.
No data yet exist regarding the correlation between AT determined by the regression
technique described above and invasive measurement of lactate threshold, but this could
be included in future research.
3.3.4.4 VE/VCO2 slope
VE/VCO2 slope is a measure of ventilatory efficiency. It represents the amount of
ventilation required to eliminate CO2 produced during respiration. As discussed in
section 2.3.2.4, there is an exaggerated ventilatory response to exercise in CHF (Beaver
et al., 1986; Gitt et al., 2002) which is independently predictive of mortality (Arena et
al., 2003; Corra et al., 2002) and with beneficial change seen following exercise training
(Coats et al., 1992; Guazzi et al., 2004). At low levels of exertion and at rest, the
relationship between VE and VCO2 can be random, being influenced by situational and
psychological factors. At heavy exertion, the relationship is non-linear, being influenced
by the degree of lactate production and CO2 production / buffering. At moderate levels
of exercise, however, the relationship is linear and most investigators use the linear
portion of the slope prior to the AT to generate the data. This was the method used in
these studies. There is some data, however, to suggest that VE/VCO2 slope remains a
strong predictor ofmorbidity and mortality irrespective of the portion of the exercise test
data used (Arena et al., 2003). Raw data was analysed off-line using Microsoft Excel
version 2000™ after determination of the AT. Data after the onset of AT, resting pre-test
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data and data from the first 1-2 minutes of exercise which was clearly non-linear were
excluded.
3.3.4.5 Oxygen Uptake Efficiency Slope
The oxygen uptake efficiency slope (OUES) was originally proposed as a submaximal
measure of performance without the need for maximal effort tolerance (Baba et al.,
1996). It is the linear portion of the relationship between VO2 and the logarithmic plot of
VE and is defined by Equation 3.4, where a is the OUES and b is the intercept on the y
axis:
V02 = a.logioVE + b
Equation 3.4. Oxygen uptake efficiency slope (OUES).
It has been shown to be a predictor of mortality in univariate and multivariate analysis
models in a retrospective analysis, and values are significantly lower with worsening
NYHA functional class (Davies et al., 2006). Little data exist regarding the effects of
exercise training on OUES although a recent small study suggested an early beneficial
change (Van et al., 2007). There is no consensus regarding the use of data from the
entire test or truncated data, e.g. before the onset of AT, but it has been suggested that
values derived from truncated data vary little from those values derived from an entire
test (Davies et al., 2006). Raw data was not readily available for OUES determination
for studies 1 to 3. As such OUES was included as an analysis variable in studies 4 and 5
only. Raw data from the linear portion of the test prior to onset ofAT and excluding pre¬
test resting data and the first 60 seconds of exercise was used. Data was analysed using
Microsoft Excel version 2000™.
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3.3.5 DEXA scanning
Studies 1-3 use data derived from dual-energy x-ray absorptionometry. Patients
underwent DEXA scanning prior to randomisation and at the end of the studies. The
mean time from end of the exercise training period to the final scan was 1.53 ± 1.39
months, range 1 day to 5.32 months). The scanner was in routine NHS use and delay in
performing the second scan was due to limited scanner time availability. The Hologic
QDR 4500A DEXA scanner was used (Hologic, USA) which employs a whole-body
dual energy fan-beam scanning technique. Measurement of lean tissue mass and fat mass
by this technique has been validated previously (Salamone et al., 2000; Visser et al.,
1999).Two scans were performed on each occasion and analysed using Hologic
Software version 11.1. A mean of the two measurements was used to improve accuracy.
Whole body densitometry scanning was used to calculate fat free mass, skeletal muscle
mass and total body bone mineral density. Bone density is expressed as g/cm2 and as a
standardised t-score, which compares individual bone density values with those of a
young sex-matched population and a standardised z-score, which compares individual
values with those of an age and sex-matched population. According to World Health
Organisation criteria, t-scores less than -2.5 (indicating bone mineral densities more
than 2.5 standard deviations below the mean) represent osteoporosis, and t-scores
between -1 and -2.5 represent osteopenia.
Total radiation exposure for each pair of scans was approximately 7pSv, which is
equivalent to one day of normal background radiation in the UK.
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3.3.6 Cytokine analysis
For study 3, cytokine and high sensitivity C reactive protein (hs-CRP) analyses were
performed. Samples were drawn at the first baseline visit and at the time of post-training
assessment. Subjects rested in an armchair for at least 30 minutes in a quiet environment
before samples were drawn by an investigator experienced in phlebotomy. A tourniquet
was used. Samples were drawn prior to any exercise assessment and at approximately
the same time of day, i.e., usually at around 8:45am after completion of enrolment
paperwork. Venous blood was drawn into vacuum serum gel containers which were then
stored on ice prior to being centrifuged within 1 hour at 1000G and 4°C for 10 minutes.
Supernatant was stored at -80°C. Serum levels of TNFa, sTNFri, sTNFr2 and IL-6 were
measured locally using commercially available enzyme immunoassay kits according to
the manufacturer's recommendation (Quantikine, R&D Systems, USA). Precision and
sensitivity for the assays are as follows: IL-6 intra-assay precision 4.2%, inter-assay
precision 6.4%, sensitivity 0.7pg/ml; TNFa intra-assay precision 4.6%, inter-assay
precision 5.4%, sensitivity 4.4pg/ml; sTNFrl intra-assay precision 6.9%, inter-assay
precision 8.8%, sensitivity 3pg/ml; sTNFr2 intra-assay precision 2.5%, inter-assay
precision 5.1%, sensitivity lpg/ml. Hs-CRP was not analysed locally. This analysis was
performed by the Department of Biochemistry, Royal Victoria Hospital, Kirkcaldy, Fife.
Samples were held locally until the time of analysis and transported within one hour
insulated and on dry ice. The enhanced immunonephelometry technique was used for
analysis (Dade Behring, Marburg, Germany) (Montagne et al., 1992). Sample data
remained blinded until the time of final data analysis.
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3.3.7 NT-pro BNP analysis
Blood sampling for studies 4 and 5 was performed in a similar fashion to the cytokine
sampling described in section 3.3.6 above. Samples were drawn at the first baseline visit
and at the post-training period visit approximately six weeks later. Sampling was
performed after at least 30 minutes of rest in a quiet undisturbed room. Patients relaxed
in an arm chair during this period. The same time of the day was typically used, prior to
any exercise assessments (usually around 8:45am). A tourniquet was used. Samples
were collected into a non-vacuumed syringe and immediately spun using a centrifuge in
the adjacent room at 4 degrees centigrade for 20 minutes at 1000G. Supernatant was
collected and immediately stored at -80°C. Samples were sent in one batch at the end of
the study period to the Department of Biochemistry, Glasgow Royal Infirmary insulated
and on dry ice. N-terminal pro BNP (NT pro-BNP) analysis was performed using a
standard assay (Roche Diagnostics, Basel, Switzerland). Sample data remained blinded
until the time of final data analysis.
3.3.8 Quality of life
Patients participating in studies 1-3 completed a Minnesota 'living with heart failure'
questionnaire at the first baseline visit between exercise performance assessments and at
the end of the training period. A copy of this questionnaire and instructions for data
collection and storage are provided in Appendix A. This questionnaire has been widely
used for over 15 years as on outcome measure in heart failure and has been designed to
be representative of the ways in which CHF affects quality of life, including, physical,
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emotional, social and psychological aspects. In addition to questions regarding physical
functioning, such as the impact of breathlessness, fatigue, etc., other questions explore
issues such as ability to earn a living, social impact on carers, memory and concentration
and side effects of therapy. It has been demonstrated to be reliable and reproducible
(Bennett et al., 2003; Gorkin et al., 1993; Rector and Cohn, 1992). A number of clinical
trials have demonstrated changes in the treatment arm of the study but no change in the
placebo arm, indicating the responsiveness of the questionnaire to change, e.g., trials of
ACEi / ARB (Cohn and Tognoni, 2001; Rector et al., 1993), heart failure disease
management programmes (Harrison et al., 2002; Kasper et al., 2002), resynchronisation
therapy (Abraham et al., 2002; Young et al., 2003) and exercise training (Belardinelli et
al., 1999). The use of this questionnaire over a short period of exercise training has not
been tried before, however.
3.4 Exercise training
3.4.1 Randomisation
Patients enrolled in studies 1-3 were randomised after completing the second baseline
assessment. This was to ensure that they were able to complete the functional
performance assessments required in the study prior to randomisation. Randomisation
was performed according to a pre-defined schedule by a third party with the investigator
and subject having no prior knowledge of the schedule.
Patients enrolled in study 4 were randomised in a similar fashion with a predetermined
block schedule designed and administered by an independent statistician in the WTCRF.
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Again, patients were only randomised once the second baseline assessment visit was
complete, and no prior knowledge of the schedule was available for the subject,
investigator or research nurse. The block randomisation schedule was based on equal
randomisation between the three groups (control, bike and neuromuscular stimulation,
NMS) over the anticipated recruitment of 120 subjects.
3.4.2 Cycle ergometer training
The bicycle exercise regimes for studies 1-3 and studies 4 and 5 were similar, although
different equipment was used. Patients participating in studies 1-3 and assigned to the
bicycle group underwent a 1-hour instruction session in the use of a semi-recumbent
bicycle and a chest-strap/wrist heart rate monitor (Polar, UK). The bike was adjusted to
provide the maximum comfort for the subject. A peak heart rate was determined as the
mean of the peak heart rates from the two preceding maximal treadmill exercise tests.
Subjects were asked to exercise on the bike sufficiently to achieve 70% of this
maximum heart rate. To achieve this, they were asked to adjust the resistance of the bike
manually and alter their speed as necessary. Subjects were issued with a diary card to
record the duration and peak heart rate achieved whilst exercising. They were asked to
exercise for 30 minutes per day, five days per week for 6 weeks. The first 3 sessions
were of shorter duration to allow acclimatisation. Bicycles were delivered to the
subjects' homes and placed in a convenient position. The bikes were collected at the end
of the study.
Patients participating in studies 4 and 5 and assigned to the bicycle exercise group were
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assessed for their maximum heart rate in the same way, i.e., from the previous treadmill
tests. Rather than using Polar chest strap / wrist watch heart rate monitors, however, a
combined heart rate monitor / ergometer system was used. Patients were given
approximately 1 hour of training with a Kettler SX1 recumbent cycle (Kettler, UK). This
system monitored heart rate via sensors in the handles and could vary resistance at the
wheel electromagnetically. Bikes were programmed to automatically adjust workload to
maintain a constant heart rate of between 75 and 85% of the previously determined
maximum. Subjects were asked to exercise for 30 minutes per day, five days per week
for six weeks. The first 5 training sessions were shorter to allow acclimatisation. Patients
kept an exercise diary; additionally, odometer recordings from the equipment could be
checked to verify compliance at the end of the training period. Bikes were delivered by a
professional delivery company to the subjects' homes and collected at the end of the
training period.
No significant technical difficulties were experienced with either cycle type. Patients
appeared to prefer the Kettler system used in studies 4 and 5 as adjustment of workload
was performed by the bike automatically. The heart rate sensors in the Kettler bike
appeared to cope with atrial fibrillation adequately. The only adverse comments received
from patients regarding the bikes was that they were large and heavy - once it had been
positioned in the subject's house, it was difficult for a patient to move.
3.4.3 Neuromuscular electrical stimulation
The protocol for use of NMS was slightly different between studies 1-3 and studies 4
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and 5. For studies 1-3, patients randomised to the NMS group received approximately
one hour of hospital-based training in the use of the device, specifically relating to
adjustment of electrode position and stimulator output in order to achieve maximal
muscle recruitment. Commercially available muscle stimulators and electrodes were
used (Sports Pro, Boditek Ltd, UK). Each stimulator has 4 output channels, each
supplying a pair of electrodes. This allowed positioning of electrodes on the skin over
the upper-lateral and lower-medial aspects of the quadriceps muscle of both legs and
over the upper and lower portions of gastrocnemius muscles of both legs. Specifically,
the first electrode pair was positioned approximately 5cm below the inguinal fold and
approximately 5cm above the upper patella border; the second electrode pair was
positioned over the belly of the gastrocnemius muscle approximately 2cm below the
popliteal fossa and approximately 2cm above the junction between gastrocnemius and
achilles tendon. The stimulator was configured to deliver a direct electrical current at 25
Hertz (Hz) for 5 seconds followed by 5 seconds of rest. The intensity of the stimulation
was adjusted by the patient to achieve a visible muscle contraction that was not
sufficiently strong to cause discomfort or a significant movement at either the knee or
ankle joints. Due to acclimatisation, patients were required and encouraged to gradually
increase the stimulator output over 30 minutes of stimulation. At the end of the
stimulation period, the adhesive electrodes were stored to prevent drying of the
conductive gel and a diary of stimulator settings completed.
Patients participating in studies 4 and 5 used identical stimulator units with the same
electrode configuration. The also underwent the same period of training and were
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encouraged to maintain a diary. They used the stimulators for 30 minutes per day, 5
sessions per week for 6 weeks. Again, stimulation was applied for 5 seconds every 10
seconds. Signal frequency was adjusted to alternate between 25Hz and 50Hz daily. This
was performed as it is possible that stimulation at different frequencies may
preferentially recruit different muscle fibre types, possibly with the 50Hz cycle
frequency preferentially recruiting fast-twitch fibres. However, no data exist in the
literature to confirm this theory.
3.5 CHF population screening
To assess the characteristics of a large population of CHF patients and to enable their
follow-up, 1 designed and programmed a multi-relational database. This was created in
Microsoft Access version 10 (2000). The core dataset includes demographic data and
health-related data including medications and investigations. All patients admitted to the
Western General Hospital between October 2001 and December 2003 were screened in
hospital and those with a proven diagnosis of heart failure due to left ventricular systolic
impairment were entered into the registry. Screening was carried out by reviewing the
notes of patients admitted and by scrutinising discharge summaries. The diagnosis of
CHF was made on the basis of consistent symptoms and echocardiographic evidence of
LV systolic impairment. The patient was interviewed and where necessary examined by
either a heart failure specialist nurse or a cardiologist. Diagnosis may have been made on
a prior admission. The likely duration of heart failure prior to entry into the database was
recorded. Details were updated by the heart failure nurse liaison team when patients
reattended for clinic review, at home visits, for beta-blocker up-titration on the day-care
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unit, when attending for other research studies, at the time of readmission, and at the
time of death. Although the database is used across multiple sites in Lothian and Fife,
only data pertaining to patients admitted to the Western General Hospital in Edinburgh
was used for study 5. Permission was asked from patients before their data was included
in the registry. The database is registered under the data protection act, registration
number K4245548. The database relationships are depicted in Appendix B.
Data was extracted from the database with SQL queries designed in SPSS for Windows
version 13, at which point data were anonymised.
3.6 Statistical analysis
3.6.1 Power calculation
Study 1 was designed as a proof-of-concept pilot. No control group was included. The
sample size was estimated on the basis of improvement in peak VO2 following training.
From previous studies involving short programmes of training vs. control populations,
an increment of around 15-30% in peak VO2 has been observed (see Table 2.4).
Assuming a peak VO2 for a sample ofNYHA class II and class II patients of around 20
ml/kg/min, if only 10% improvement in peak VO2 following NMS training was
observed, but 20% improvement following bike training, this would result in post-
training peak VO2 measurements of 22 and 24 ml/kg/min, respectively. Hence, there
would be a difference between the two groups of around 2 ml/kg/min, potentially.
Taking an a of 0.05, a difference between the two group means of 2 ml/kg/min, a power
of 0.99 and an arbitrary standard deviation of difference between the two means of 3
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ml/kg/min, this results in a sample size of 44 required to reject the null hypothesis that
the two groups show no difference in the effect of training on peak VO2. If the projected
difference between the two groups is proved to be less, the sample size required would
be much larger. It is the nature of the pilot study, however, that these differences are
unknown at the outset.
Following the results of study 1, a further power calculation was performed to assess the
sample size required to show a difference between NMS, bike training and controls.
Assuming an increase of just 5% in peak VCF following training with either regime, an a
of 0.05, a standard deviation within groups of 2 ml/kg/min and a difference between
groups of 1 ml/kg/min, the power calculation based on an ANOVA model with 40
patients within each group results in a power of 0.598. Comparing combined data from
both exercise regimes with controls using the same parameters as above yields a
statistical power of 1.0. The actual difference between groups and standard difference
between group means may not be judged correctly, however, leading to an
underestimate of sample size.
3.6.2 Analysis
All analysis was performed using commercially-available software running on Microsoft
Windows™. Data remained blinded until the final analysis. Advice and assistance was
provided by professional statisticians working for the University of Edinburgh (studies
1-3) and the WTCRF (studies 4,5). SPSS for Windows version 13.0, GraphPad Prism
version 4.0 and Microsoft Excel version 11 (2003) were used where appropriate.
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Individual statistical tests vary between studies and are detailed in the methods section
of the relevant data chapters.
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4 Study 1. A randomised study of home-based
neuromuscular stimulation of the legs and
conventional bicycle exercise training for
patients with chronic heart failure.
4.1 Abstract
4.1.1 Aims
Recent guidelines recommend regular exercise in the management of patients with
chronic heart failure. This study was designed to compare the safety and efficacy of
conventional bicycle exercise and functional electrical stimulation of the legs as forms
of home-based exercise training for stable chronic heart failure patients and is the pilot
study for further work presented in this thesis.
4.1.2 Methods and Results
46 patients (38 male) with stable NYHA Class II/III heart failure underwent a six-week
training programme using either a bicycle ergometer or neuromuscular stimulation of the
quadriceps and gastrocnemius muscles. In the bike group significant increases were seen
in 6-minute walk (44.6m, 95%CI 29.3 to 60.9m), treadmill exercise time (110s, 95%CI
72.2-148.0s), maximum leg strength (5.32kg, 95%CI 3.18-7.45kg), and quadriceps
fatigue index (0.08, 95%CI 0.04-0.12) following training. In the stimulator group similar
significant increases were seen following training for 6-minute walk (40.6m, 95%CI
28.2 to 53.0m), treadmill exercise time (67s, 95%CI 11.8-121.8s), maximum leg
strength (5.35kg, 95%CI 1.53-9.17kg), and quadriceps fatigue index (0.10, 95%CI 0.04-
0.17). Peak VO2 did not change in either group following training, indicating a low-
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intensity regime. Quality of life scores were improved following training when the
bicycle and stimulator groups were considered together but not separately (-0.43, 95%CI
-8.13 to -0.56).
4.1.3 Conclusions
Neuromuscular stimulation produces beneficial changes in muscle performance and
exercise capacity in patients with chronic heart failure. Within this study, the benefits
were similar to those observed following bicycle training. Neuromuscular stimulation
could be offered to heart failure patients as an alternative to bicycle training as part of a
home-based rehabilitation programme and further work is required to clarify the benefits
of this form of training.
4.2 Introduction
A number of recently published guidelines recommend a regular programme of exercise
training for patients with CHF (Hunt et al., 2001; Remme and Swedberg, 2002; Scottish
Intercollegiate Guidelines Network, 2002; Working Group on Cardiac Rehabilitation &
Exercise Physiology and WorkingGroup on Heart Failure of the European Society of
Cardiology, 2001). The majority of previous studies of exercise training in CHF have
been hospital based (Belardinelli et al., 1995b; Belardinelli et al., 1995a; Belardinelli et
al., 1999; Dubach et al., 1997a; Jette et al., 1991; Wielenga et al., 1999) although there
are now a number of studies confirming the effectiveness of home-based programmes
(Adamopoulos et al., 1993; Coats et al., 1992; Hambrecht et al., 1995; Hambrecht et al.,
2000a). The ability to deliver such programmes within primary and secondary care is
limited by available resources and safety concerns. In addition, co-morbidities that limit
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the ability to perform exercise are common in CHF patients, particularly the elderly
(Lien et al., 2002) and some have such marked impairment of exercise capacity that they
may be unable to undertake physical training.
Neuromuscular stimulation (NMS) is a method of exercising which requires less
baseline functional capacity to perform. It has been studied in other patient groups who
cannot undertake conventional forms of exercise, e.g. patients with scoliosis (Grimby et
al., 1985; Wright et al., 1992), muscular dystrophy (Zupan, 1992) and paraplegia
(Hjeltnes and Lannem, 1990). It is recognised to improve muscle fatigue resistance and
muscle strength depending on the pattern and frequency of the electrical impulses used
(Bajd et al., 1989). NMS of the lower limb muscles is potentially attractive as a method
of training in chronic heart failure as it is home-based, requires less motivation to use
and could be performed by patients unable to undertake conventional training due to
their symptoms of heart failure or other co-morbidities. Additionally, the devices are
widely available and relatively inexpensive, typically costing around 160-250 Euros.
However, NMS has not been extensively investigated in patients with chronic heart
failure. Two small trials found NMS to produce improvements in muscle strength and
metabolic measures of exercise capacity in highly selected patients around the time of
cardiac transplantation (Quittan et al., 2001; Vaquero et al., 1998). One further small
uncontrolled trial in less symptomatic patients also demonstrated the safety of NMS and
suggested improvements in quality of life and exercise capacity (Maillefert et al., 1998).
I have therefore compared the usefulness and tolerability of NMS with conventional





Patients with stable heart failure and New York Heart Association class II-III symptoms
were recruited from out-patient clinics as described in section 3.1.1. All subjects were
limited in their ability to perform exercise by either breathlessness or fatigue as a
consequence of heart failure and were on appropriate medical therapy including
angiotensin converting enzyme inhibitors (ACEi), diuretic, digoxin and beta-blockers
(Table 4.1). None of the subjects was participating in an exercise programme prior to
inclusion in the study. Exclusion criteria as discussed in section 3.1.1 applied. Written
informed consent was obtained from all subjects and the protocol was approved by the
Bike group (n=24) NMS group (n=22) p value
Age ± SD, years 61.8± 10.8 63.0 ± 10.0 0.68
Sex, n (%)
Male 21 (87.5) 17(77.3) 0.30
Female 3 (12.5) 5 (22.7)
CHF aetiology, n (%)
IHD 16 (66.7) 13 (59.1) 0.60
DCM 8(33.3) 9 (40.9)
NYHA Functional class, n (%)
II 18(75) 17(77.3) 0.86
III 6(25) 5 (22.7)
Ejection fraction ± SD, % 32.0 ±9.3 28.3 ± 6.3 0.008
Medications, n (%)
Diuretic 17 (71) 20 (91) 0.09
ACEi 22 (92) 22 (100) 0.27
Spironolactone 1 (4) 3(14) 0.27
Digoxin 9(38) 10(45) 0.58
Beta-blocker 9 (38) 9(41) 0.81
Table 4.1. Patient characteristics at baseline.
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local research ethics committee.
4.3.2 Patient assessment
At baseline, patients underwent 6-minute walk test (section 3.3.2), cardiopulmonary
treadmill exercise test (section 3.3.4) and quadriceps strength and fatigue testing (section
3.3.3) on two separate occasions at least 24 hours apart to familiarise them with
assessments prior to randomisation. Results recorded at the second baseline visit were
used as the pre-training values in the final analysis. Ejection fraction was measured on
echocardiography by the Simpson biplane method at one of the baseline visits (section
3.3.1). The Minnesota 'living with heart failure' quality of life questionnaire was
completed at the first baseline visit prior to the exercise performance tests (section
3.3.8). All assessments other than echocardiography were repeated on one occasion after
the exercise training period.
4.3.3 Exercise training
Patients were randomised following baseline assessment to receive either a recumbent
bicycle ergometer or NMS for home use over a 6-week period as described in section
3.4.1. Those patients assigned to the bicycle group were trained to use the equipment
and asked to exercise for 30 minutes per day, 5 days per week for 6 weeks as described
in section 3.4.2. Patients allocated to use NMS were also trained in their use and asked
to use the devices for 30 minutes per day, 5 days per week for 6 weeks, as described in
section 3.4.3. There were no scheduled hospital visits during the training period.
Subjects from both groups maintained a diary indicating the duration and intensity of
exercise during each session over the training period. This diary was compared against
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subjects' verbal description of their experience with either the bike or muscle stimulator.
4.3.4 Statistical analysis
All data are expressed as mean ± SD unless otherwise stated. Normally distributed
paired data was compared using a paired t-test and unpaired data with an unpaired t-test
or a Pearson Chi-square test with Fisher's exact test where appropriate. A Mann-
Whitney U test was used to compare unpaired data that were not normally distributed.
One-way ANOVA was used to compare mean data at different time-points during the
study. Analysis was performed using SPSS for Windows version 13.0. A value of p <
0.05 was considered statistically significant.
4.4 Results
49 patients were recruited and 46 completed the exercise training programme. Of the
three who did not complete the study, one patient died following randomisation to the
NMS due to increasingly severe heart failure, one patient assigned to NMS dropped out
of the study due to worsening symptoms of heart failure and one patient assigned to the
bicycle group dropped out of the study due to back discomfort. Baseline data for these
patients were included in the final analysis with post-training data treated as missing
data. Of the remaining 46 patients, no adverse effects were reported and their medical
therapy remained unchanged for the duration of the study. Blood pressure and heart rate
was recorded in five patients who underwent a 30-minute period of electrical stimulation
of the quadriceps and gastrocnemius muscles and no acute changes were observed
during stimulation (data not shown). Baseline characteristics for those patients who






















































































Table 4.2. Training-induced changes in exercise capacity and quality of life.
group had a lower ejection fraction at baseline but otherwise there were no significant
differences between the two groups for age, sex, heart failure aetiology, NYHA
functional class or heart failure drug treatments. Additionally, no significant differences
for markers of functional capacity or quality of life were observed at baseline between
bicycle and NMS groups (Table 4.2).
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Baseline assessments were performed orr two separate oeeasions. To identify any effeel
of repeated exercise testing on subjects' performance, these two baseline assessments
were analysed in the context of the post training results using a one-way ANOVA with
post hoc Bonferroni analysis. Small increases were observed for 6-minute walk distance
and treadmill exercise time between first and second baseline measurements that did not
reach statistical significance (Figure 4.1). Peak VO2 did not increase between the first
and second baseline visits. The second baseline visit was used as the pre-training value
for subsequent analyses.
Significant changes were observed following both forms of exercise training for markers
of functional capacity (Table 4.2). Quality of life improved for the study group as a
whole, as indicated by a lower score on the Minnesota questionnaire, but changes did
not reach statistical significance when the training groups were examined independently.
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Figure 4.2. Mean absolute improvements in exercise variables and quality of life following
training. Error bars indicate 95% confidence intervals; p values refer to differences in mean
change between exercise groups.
The degree of change in indices of functional capacity observed following training was
compared between the two groups. Figure 4.2 shows the mean absolute change in
exercise capacity. Mean percentage increase in 6-minute walk was 10.3% (95%CI 6.59
to 14.1) for the bike group and 9.52% (95%CI 5.92 to 13.1) for the NMS group.
Treadmill exercise time mean percentage increase was 33.0% (95%CI 10.8 to 55.3) for
the bike group and 14.1% (95%CI 3.34 to 24.8) for the NMS group. Mean percentage
increase in maximum quadriceps strength was 11.9% (95%CI 6.67 to 17.0) for the bike
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group and 15.3% (95%CI 4.50 to 26.1) for the NMS group. Mean percentage
improvement in fatigue index was 12.2% (95%CI 4.48 to 19.9) for the bike group and
17.2% (95%CI 5.40 to 29.1) for the NMS group. Mean percentage change in quality of
life score was 2.47% (95%CI -28.8 to 33.8) for the bike group and -2.8% (95%CI -28.5
to 22.8) for the NMS group. Mean percentage increase in peak VO2 was 5.5% (95%CI -
1.48 to 12.5) for the bike group and 2.97% (95%CI —4.32 to 10.2) for the NMS group.
There were no significant differences seen between bike and NMS groups in the degree
of absolute or percentage change from baseline following training for any of the indices
of exercise capacity or quality of life.
4.5 Discussion
The safety of exercise training for stable CHF patients delivered in a supervised
environment is now well established (Belardinelli et al., 1995a; Belardinelli et al, 1999;
Belardinelli et al., 1995b; Dubach et al., 1997a; Jetteetal., 1991; Wielenga et al., 1999).
There are also studies suggesting that it can be delivered at home safely and effectively
(Adamopoulos et al., 1993; Coats et al., 1992; Hambrecht et al., 1995; Hambrecht et al.,
2000a). These studies have demonstrated significant benefits for a variety of outcome
measures including exercise capacity and quality of life and there is now preliminary
evidence that prolonged training may have favourable effects on admission rates and
mortality (Belardinelli et al., 1999; Piepoli et al., 2004). Recent guideline documents
have therefore recommended an exercise training programme as part of the
comprehensive rehabilitation and management of patients with chronic heart failure
(Hunt et al., 2001; Remme and Swedberg, 2002; Scottish Intercollegiate Guidelines
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Network, 2002; Working Group on Cardiac Rehabilitation & Exercise Physiology and
Working Group on Heart Failure of the European Society of Cardiology, 2001) and
there is a need to examine new ways to deliver exercise therapy to patients in the
community without the need for intense supervision.
This is the first randomised trial comparing NMS and conventional exercise training in a
group of stable chronic heart failure patients. We have demonstrated that NMS is well
tolerated, safe and results in significant improvement in markers of functional capacity.
There was improvement in quality of life for both groups when examined together and a
trend towards improved quality of life when NMS and bicycle groups were examined
separately. NMS appeared to produce similar improvements in exercise capacity as
bicycle training for the patients participating in our study and is a potentially attractive
form of therapy since it requires less motivation and can be performed whilst a subject is
sedentary. As such, it may be suitable for those patients who are either unwilling or
unable to perform more conventional forms of exercise. Conventional training and NMS
training are different, however. More muscle groups are utilised in conventional exercise
regimes and there are significant changes in central haemodynamic variables during
conventional exercise. Electrical muscle stimulation targets a smaller number of muscle
groups and I did not identify any significant change in haemodynamic variables during
periods of stimulation in five CHF patients. Although only a crude assessment of central
response to local muscle stimulation, it is in keeping with other investigators who have
identified no change in cardiac output (Maillefert et al., 1998) and only small changes in
heart rate during periods ofNMS (Quittan et al., 1999a). Whilst this supports the safety
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of this form of muscle training in CHF patients, further work to investigate both central
and local haemodynamic effects of muscle stimulation in a heart failure population is
required. Physical inactivity itself is a risk factor for cardiovascular disease and the
potential long-term benefits of training with NMS may be offset by this risk if it is the
only form of training undertaken, although NMS may be of benefit in combination with
conventional exercise or as a bridging therapy until a patient regains sufficient
functional capacity to exercise conventionally. Formal tests of equivalence need to be
performed in a larger trial to confirm that NMS is as effective as conventional exercise.
Peripheral muscle is abnormal in heart failure patients, with atrophy of both type I and
type II muscle fibres (Lipkin et al., 1988) and an apparent switch in fibre-type
proportion to the less fatigue resistant fast-twitch type IIB fibres (Magnusson et al.,
1996). The quantity of aerobic enzymes and the density of mitochondria are reduced
consistent with a decreased capacity for aerobic metabolism (Drexler et al., 1992b). As
such, the peripheral muscle is weaker with a decreased mass, reduced aerobic capacity
and increased susceptibility to fatigue. Chronic low frequency NMS, such as used in our
study, has previously been shown to produce an increase in oxidative capacity with
reduced fatigability but little improvement in muscle strength (Badylak et al., 1990;
Maillefert et al., 1998). Fligher frequency intermittent protocols are recognised to retain
fatigue resistance by improving aerobic capacity while also improving muscle strength
(Pournezam et al., 1988; Quittan et al., 2001). The frequency and pulse duration ofNMS
protocols may be important in determining the profile of changes obtained with training
and the use of a higher frequency protocol preferentially targeting type II fibres might
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account for more marked improvements in muscle strength compared with
improvements in fatigability. It is possible that in our study NMS training induced
improvements due to a partial reversal of the unfavourable fibre type distribution and
increased aerobic capacity but future studies with muscle biopsy before and after NMS
training are required to test this theory.
Peak VO2 did not improve following training in contrast to other studies (Adamopoulos
et al., 1993; Belardinelli et al., 1999; Coats et al., 1992; Dubach et al., 1997a; Jette et
al., 1991; Wielenga et al., 1999). The training period was short and of low intensity for
both groups and this may account for the lack of change in peak VO2. Verbal reports
from subjects were consistent with their training diaries, indicating compliance with the
training programme. Unfortunately, with home-based programmes it is difficult to be
absolutely certain about patient compliance and it is possible that poor compliance could
have been partly responsible for the lack of change in peak VO2. Compliance with a
prescription for exercise is an important issue for both clinical trials and clinical practice
and exercise regimes that are poorly tolerated during a trial are unlikely to be better
tolerated in practice. Future studies focussing on compliance with home-based training
regimes are required to investigate this area further. In the context of this trial, however,
functional improvement as determined by 6-minute walk, treadmill exercise time and
muscle strength and fatigability did occur, and this is important given that many patients
with chronic heart failure will be unwilling or unable to undertake more intensive forms
of training. In addition, we did observe an improvement in perceived quality of life
when the groups were considered together and this is also an important consideration in
135
patients with chronic symptoms and poor prognosis. Patients with the most severe
symptoms may even be prepared to trade duration of life for quality (Lewis et al., 2001)
and whilst the effects of exercise training on prognosis remain to be fully established,
improved quality of life remains a strong reason to recommend exercise therapy for
selected patients. Peak VCL is a marker of prognosis in heart failure, however (Likoff et
al., 1987), and whilst low-intensity training may improve other markers of functional
capacity or quality of life, lack of improvement in peak VO2 suggests that prognosis may
remain poor for these patients.
4.5.1 Conclusions
Exercise therapy reverses some of the peripheral changes seen in chronic heart failure
and improves muscle strength, exercise time and perceived quality of life.
Neuromuscular stimulation of the lower limbs is effective at improving functional
capacity and could be offered in the future as an alternative to conventional training as
part of a community based exercise training programme depending upon the results of
future studies.
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5 Study 2. Effect of exercise training on body




Chronic heart failure is associated with skeletal muscle atrophy and weight loss. Skeletal
muscle mass and peak oxygen uptake are important predictors of functional status and
outcome in patients with stable chronic heart failure. Exercise training may potentially
reverse some of these changes. This study was designed to assess changes in skeletal
muscle mass and peak oxygen uptake following conventional exercise and
neuromuscular stimulation of the legs.
5.1.2 Methods
36 patients with moderate stable chronic heart failure were randomly allocated to either
a bicycle ergometer (bike) or neuromuscular stimulators (NMS) applied to quadriceps
and gastrocnemius muscles to be used daily for six weeks. Assessment of patients before
and after training included symptom-limited cardiopulmonary exercise test, quadriceps




Both types of exercise training resulted in similar improvements in treadmill exercise
time, leg strength and 6-minute walk test. Bike training resulted in a slightly greater
mean increase in peak oxygen uptake per kilogram of lean muscle mass (Bike 7.5 (11.8)
vs. NMS 4.7 (10.4) ml/min/kg, p=0.45). Despite significant improvements in functional
capacity, there were no significant changes in body composition for total skeletal muscle
mass, leg muscle mass or total body fat content. Lean muscle mass was strongly
predictive of maximum oxygen uptake at baseline (r=0.69, p<0.001) and after exercise
training (r=0.63, p<0.001).
5.1.4 Conclusions
This study suggests that in stable chronic heart failure, exercise training using bicycle
ergometer or NMS results in favourable qualitative rather than quantitative changes in
skeletal muscle. Correction of maximum oxygen uptake for skeletal muscle mass rather
than total body mass is a more sensitive measure of changes associated with exercise
training.
5.2 Introduction
Chronic heart failure is characterised by breathlessness, fatigue and poor exercise
capacity. While circulatory insufficiency is the primary disorder it is now widely
accepted that skeletal muscle in these patients has reduced strength and is more readily
fatigued (Harrington et al., 1997; Mancini et al., 1992). A number of histological
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abnormalities have been described in the skeletal muscle of chronic heart failure
patients. A widely reported finding has been altered fibre type distribution with a change
from slow twitch aerobic fibres to fast twitch glycolytic fibre types (Drexler et al.,
1992b; Lipkin et al., 1988; Schaufelberger et al., 1997; Sullivan et al., 1990) although
this has not been reported by all authors (Lindsay et al., 1996). Molecular techniques
have also suggested changes in myosin heavy chain proteins to faster glycolytic myosin
types (Vescovo et al., 1998). Reduced levels of metabolic enzymes involved in oxidative
metabolism such as citrate synthase, succinate dehyrdrogenase and 3-hydroxyacyl CoA
dehydrogenase have also been reported (Lindsay et al., 1996; Mancini et al., 1989;
Mettauer et al., 2001). Magnetic resonance techniques have demonstrated a reduced
ability to replenish high energy phosphates, such as adenosine triphosphate (ATP),
which appears to be a key metabolic abnormality (Broqvist et al., 1992; Opasich et al.,
1996). The proposed mechanisms underlying these changes include reduced perfusion
due to myocardial insufficiency, simple disuse atrophy and apoptosis induced by
elevated local and circulating cytokines (Adamopoulos et al., 1993; Vescovo et al.,
2001). A number of exercise training programmes have been shown to significantly
improve functional capacity in CHF patients without significantly altering cardiac
performance (Belardinelli et al., 1995b; Coats et al., 1992; Gordon et al., 1996; Pu et al.,
2001). These studies have confirmed that although skeletal muscle has diminished
function in CHF it can regain strength and power despite persistence of circulatory
insufficiency.
Neuromuscular stimulation (NMS) differs from standard dynamic exercise training with
respect to muscle group recruitment and cardiovascular responses to exertion but has
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been shown to improve exercise performance in CHF patients (Maillefert et al., 1998).
This study aimed to examine whether NMS results in a distinctive change in the quality
of skeletal muscle or whether an increase in muscle mass is responsible for the observed
improvements in functional capacity. We therefore used dual energy x-ray
absorptionometry before and after exercise training to examine changes in body
composition and assessed the findings along with a detailed characterisation of
functional status including cardiopulmonary exercise testing.
5.3 Methods
5.3.1 Study Population
Thirty-six patients with stable chronic heart failure, New York Heart Association
(NYHA) class II to III, were recruited as described in section 3.1.1. Written informed
consent was obtained from all subjects and the local research ethics committee approved
the protocol. A series of age-matched men and women (9 female, 11 males) from the
local population with no history of cardiac disease or other co-morbidity were included
as a comparison group (Table 5.1, n=20).
5.3.2 Exercise-training regimes
Patients were randomised as described in section 3.4.1 to a training regime of either
conventional bicycle training or NMS as described in sections 3.4.2 and 3.4.3. Patients
underwent training 30 minutes per day, 5 days per week, for 6 weeks.
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5.3.3 Patient assessment
Prior to randomisation, patients underwent baseline testing on two separate occasions at
least 24 hours apart. The second baseline test used as the true baseline. Patients
underwent 6-minute walk test (section 3.3.2), cardiopulmonary treadmill exercise test
(section 3.3.4), and quadriceps strength and fatigue testing (section 3.3.3).
DEXA scanning was performed at one of the baseline visits and again after the end of
the training period, as described in section 3.3.5. Results are expressed as mean values
from two scans obtained on the same day using Hologic Software version 11.1 thus










Age (years) 60.7 ±2.6 63.9 ±2.6 61.4 ± 4.7 0.39*
Sex (Male: female) 15:4 12:5 11:9 0.39*
























Ejection fraction (%) 32.4 ±2.7 28.7 ± 1.7 - 0.24
Table 5.1. Baseline patient characteristics.
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body densitometry was used to calculate fat free mass, skeletal muscle mass and total
body bone mineral density.
5.3.4 Statistical analysis
Data analysis was performed using SPSS for Windows, version 13 as described in
section 3.6. A paired t-test and one way ANOVA were used to compare data with a
normal distribution, a Mann-Whitney U test was used to compare data with uneven
distribution. Data are presented as mean ± standard deviation (SD) unless otherwise
stated. Correlations are expressed as univariate analyses and include 95% confidence
intervals (95% CI). The Chi-square test was also used to compare groups. Significance
was accepted at the 5% level (p<0.05).
5.4 Results
The clinical characteristics of patients and controls are summarised in Table 5.1.
Exercise groups were well matched for a range of clinical features. Healthy controls




Bike NMS , «
(n=19) (n=17) P value
Baseline After training Baseline After training
:.3±5.1 19.8 ±5.1 17.7 ±4.9 18.6 ±4.7 0.60




520 ± 279 654 ± 271** 508 ± 201 568 ± 231 * 0.35
6-minute walk (m) 480 ± 109 540 ± 109** 486 ± 115 531 ±112** 0.68




0.77 ± 0.14 0.84 ± 0.13** 0.77 ± 0.12 0.87 ± 0.1** 0.50
Minnesota QoL score 39.0 ±21.0 31.0 ± 17.2 29.4 ±20.4 25.5 ± 20.6 0.15
30.2 ±4.9 30.6 ±5.1 26.4 ±4.8 25.8 ±4.6 0.39
Body fat (%) 30.1 ± 6.7 30.0 ±7.1 27.6 ± 5.5 28.0 ±5.6 0.29
Total skeletal muscle
(kg)
* p<0.05, ** p<0.01, comparing before and after training
s
p- value for comparison ofmean change between exercise groups
Table 5.2. Change in functional assessment and body composition after training.
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There were no significant differences observed in the body composition of male and
female CHF patients at baseline compared with age matched healthy controls for body
fat, lean muscle mass and leg muscle mass (Table 5.3). There were similar
improvements in treadmill exercise time, 6MW test, quadriceps muscle strength and
fatigue resistance index in both exercise groups (Table 5.2). Correcting absolute oxygen
uptake values for total body weight, there was no significant change in peak oxygen
uptake (peak VO2) in either group following training (bike 19.4 ± 1.4 to 19.8 ± 1.4
ml/kg/min, p=0.64, NMS 18.8 ± 1.6 to 18.5 ± 1.4 ml/kg/min, p=0.80). However, when
values for oxygen uptake were recalculated using lean body mass (and not total body
mass) there was a significant increase in peak VO2 in the bike group (49.5 ± 14.7 to 57.2
± 13.6 ml/kg/min, p=0.01) and a trend for an increase in the NMS group (48.6 ± 15.4 to
54.0 ±14.1 ml/kg/min, p=0.06). There were no significant changes in total body skeletal








Body weight (kg) 82.9 ± 12.2 68.4 ± 15.8 86.1 ± 17.5 72.2 ± 8.4 0.23
Body mass index 27.2 ±3.6 28.3 ±4.7 28.3 ±5.4 28.1 ±3.4 0.67
Total lean mass (kg) 57.5 ±7.7 44.4 ±6.5 59.7 ±6.9 42.6 ±4.9 0.33
Total skeletal muscle
mass (kg)
29.7 ±4.4 22.1 ±3.7 31.8 ± 3.8 24.6 ±3.9 0.33
Leg skeletal muscle
mass (kg)
17.7 ±2.0 13.3 ±2.5 18.9 ± 1.9 14.3 ±2.2 0.41
Body fat
(% body mass)
27.2 ±4.7 ■ 36.7 ±7.3 23.4 ±6.8 39.5 ±7.9 0.12
Bone mineral density
(g/cm3)
1.11 ±0.12 0.98 ±0.06 1.14 ± 0.05 1.00 ±0.10 0.37
Table 5.3. Baseline body composition: male and female CHF patients and controls.
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muscle mass or leg muscle mass and no significant change in total body fat after the
period of exercise training in either training group or when all CHF patients were
analysed together. There was no significant change in bone mineral density in either
group (Table 5.2) or when all patients (n=36) were considered together (1.072 ± 0.025 to
1.077 ± 0.026 g/cm3, p=0.25).
At baseline, total body weight was not related to peak VCF (r=-27, p=0.71) but was more
closely linked with peak VO2 after exercise training (r=0.67, p=0.02). Peak VO2
expressed as a percentage of age predicted VO2 was slightly lower in the bike group at
baseline and improved by only 4% after training while the NMS group started slightly
higher and demonstrated only a 1.5% improvement. Peak VO2 was strongly associated
with lean body mass (Figure 5.1) both before (r=0.69, 95% CI 0.46 to 0.83) and after
(r=0.63, 95% CI 0.35 to 0.71) exercise training for all CHF patients. There was no clear
Figure 5.1. Association between lean body mass and absolute V02 at baseline. r=0.69, p<0.001.
145
Figure 5.2. Relation between baseline peak V02 and increase in V02 (corrected for lean body
mass). r=-.43, p=0.01, CI -0.67 to -0.12.
relationship between improvements in peak VO2 and improvements in quadriceps
muscle strength (r=0.11) or fatigue resistance (r=0.05). There was a negative association
between baseline peak VO2 and the absolute change in peak VO2 (Figure 5.2) suggesting
that patients with lowest baseline peak oxygen uptake had a greater increase in peak
VO2 following exercise training. Improvements in 6MW test were not associated with
improvements in peak VO2 (r=0.17, 95% CI -0.13 to 0.44) but peak VO2 was correlated
with 6MW at baseline (r = 0.53, p<0.001, 95% CI 0.33 to 0.68) and this relation
strengthened after training (r = 0.60, p<0.001, 95% CI 0.36 to 0.77).
5.5 Discussion
In this study, exercise training using static bicycle and neuromuscular stimulation in
patients with chronic heart failure produced no measurable change in skeletal muscle
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mass, body fat content or bone mineral density. However, there was clear evidence of
improvements in quadriceps muscle strength and fatigue resistance, and significant
improvements in treadmill exercise time, 6MW test and peak VO2 (corrected for skeletal
muscle mass). In addition, in CHF patients we demonstrated that lean body mass was
closely associated with peak VO2 (expressed per unit lean muscle mass) at baseline but
that the increase in peak VO2 resulting from training was greatest in those patients with
the lowest baseline peak oxygen uptake. These findings suggest that exercise training
can result in significant improvements in functional capacity without increasing muscle
mass. Furthermore they confirm the close link between two important prognostic
markers in patients with CHF, namely, peak oxygen uptake and skeletal muscle mass
(Anker et al., 1997b; Anker et al., 2003; Stelken et al., 1996). This suggests that even
patients with low baseline functional status and low skeletal muscle mass are able to
benefit from exercise training. The question remains unanswered as to whether
improvements in either of these parameters, muscle mass or peak VO2, by exercise
training could alter mortality. There has been only one previous study suggesting that
exercise training can improve prognosis (Belardinelli et al., 1999) although a more
recent meta-analysis of 9 studies has also supported this possibility (Piepoli et al., 2004).
Our study would suggest that at least short term exercise training will improve oxygen
uptake but that this can occur without a concomitant increase in total skeletal muscle
mass, suggesting the potential for the uncoupling of these two factors. Furthermore, it
confirms the findings of other groups that patients with low baseline peak VO2 can gain
more from exercise training (Hambrecht et al., 1995) and could therefore potentially
achieve more prognostic benefit compared with CHF patients with higher baseline VCF.
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Bicycle training resulted in significant improvements in VCf in keeping with a greater
haemodynamic response to this form of training. NMS resulted in a smaller increase in
VO2 of borderline significance. I was able to detect a change in peak VO2 by expressing
absolute oxygen uptake per kilogram of skeletal mass but there was no significant
difference when this was expressed using total body mass. The reason for this difference
is likely to relate to the accuracy of the DEXA scan in measuring the tissue contributing
greatest to oxygen consumption during exercise, namely skeletal muscle mass. Since we
demonstrated a strong relationship between muscle mass and peak VO2 both at baseline
and after training (Figure 5.1), while total body mass was only related to peak VO2 after
training, correction of VO2 to muscle mass is clearly a more sensitive way to detect
change in oxygen consumption following training. This way of describing peak VO2 is
not widely used mainly because accurate measurement of lean body mass is only
possible with DEXA or magnetic resonance imaging. Other workers have suggested this
as a more accurate way of assessing cardiopulmonary function (Cicoira et al., 2001) and
there is some evidence that it may also have stronger prognostic value (Cicoira et al.,
2004). Bicycle training is more likely to result in improvement in peak VO2 compared
with NMS because of the larger muscle groups recruited, such as gluteus maximus and
rectus femoris. While there was no statistically significant differences in functional
capacity between the two forms of training, bicycle training did result in slightly greater
improvements in 6MW test and treadmill exercise time. This is likely to be a reflection
of the greater improvement in peak VO2 in the bike group since we did see a relationship
between improvements in peak VO2 and 6-minute walk test. The muscle-specific
assessments of function such as quadriceps strength and fatigue resistance, demonstrated
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very similar improvements for Bike and NMS. The patients in this study had a wide
range of functional capacity at baseline, with most patients in NYHA class II and some
having a peak VCB close to that predicted for their age. Such patients are less likely to
increase peak VO2 after exercise training and may also partly explain why we did not
see a significant improvement in this parameter when corrected for total body weight.
Since there was no significant change in body or leg muscle mass, the predominant
change responsible for improved functional capacity must be related to changes in the
quality of existing skeletal muscle. This further supports the notion of adaptability of
skeletal muscle despite persistent circulatory insufficiency in CHF. Previous studies both
in humans and in numerous animal models have demonstrated qualitative improvements
in oxidative metabolism and high energy phosphate supplies (Adamopoulos et al., 1993)
resulting from exercise training in heart failure. Our findings suggest that NMS may also
able to influence these processes but possibly to a lesser degree than bicycle training. A
limitation of this study is that it includes younger CHF patients than are typical of a
heart failure population. This may partly explain why our patients had a slightly higher
peak VO2 than that reported in other similar studies (Stelken et al., 1996). Further large
trials including more elderly patients would be needed to confirm our findings.
One additional important finding is that despite the potential risk of extended rest while
using the NMS there was no significant reduction in bone mineral density in patients
randomised to this treatment modality. This is probably related to the short duration of
daily use and improved activity levels in all patients during the study period as reflected
by the improvements in functional performance.
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Conclusions
This is the first study using DEXA scanning to follow-up heart failure patients that have
undergone an exercise training programme. The lack of change in body composition
observed in our study could reflect the short time period for training, the relatively low
intensity home-based programme and the small number of patients included. However,
the clear improvement in functional capacity observed for both forms of exercise,
despite no increase in muscle mass, confirms the ability of skeletal muscle to undergo
qualitative adaptation during exercise training in CHF.
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6 Study 3. Change in circulating cytokines
following two forms of exercise training in
chronic stable heart failure.
6.1 Abstract
6.1.1 Background
A pro-inflammatory state is recognised in chronic heart failure and the degree of
immune activation corresponds to disease severity and prognosis. Training is known to
improve symptoms in heart failure but less is known about the effects of specific forms
of training on the pro-inflammatory state.
6.1.2 Methods
46 patients with stable chronic heart failure underwent a home-based programme of
exercise training for 30 minutes a day, 5 days per week over a 6-week period. 24 used a
bicycle ergometer and 22 used an electrical muscle stimulator applied to quadriceps and
gastrocnemius muscles. Tumour necrosis factor a (TNFa), TNFa soluble receptors 1 and
2, interleukin 6 and high sensitivity C-reactive protein were measured before and after
the training period.
6.1.3 Results
Significant improvements in markers of exercise performance were seen in both training
groups. Soluble TNFa receptor 2 levels decreased following training in the bike group
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only (2900 ± 1069 pg/ml to 2625 ± 821 pg/ml, p=O.013). Trends towards a decrease in
levels of TNFa and soluble TNFa receptor 1 were also seen in the bike group only. No
change in circulating inflammatory markers was observed following stimulator training.
6.1.4 Conclusions
Physical training improves exercise capacity for patients with chronic heart failure but
degree of attenuation of the pro-inflammatory response may depend on the mode of
training despite similar improvements in exercise capacity.
6.2 Introduction
It is no longer accepted that heart failure is a syndrome solely dependent on the degree
of left ventricular systolic dysfunction. Pump inefficiency is a trigger for maladaptive
neurohormonal responses and endothelial dysfunction and despite modern
pharmacological treatments, heart failure continues to carry a high morbidity and
mortality (Cowie et al., 1997). Attention has therefore been directed towards other
possible mechanisms that may be responsible for disease progression and symptom
generation.
There is evidence of a state of heightened immune activation in chronic heart failure.
Pro-inflammatory cytokines interleukin 2 (IL-2) (Matsumori et al., 1994), interleukin 6
(IL-6) (Munger et al., 1996) and tumour necrosis factor a (TNFa) (Levine et al., 1990;
Torre-Amione et al., 1996a) are found in higher concentrations in the circulation of heart
failure patients compared with normal subjects and some reports demonstrate
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association between increased concentrations of cytokines and disease severity (Levine
et al., 1990; Torre-Amione et al., 1996a). The reason for the heightened immune
response in heart failure is not clear although possibilities include tissue hypoxia
(Hasper et al., 1998; Leeper-Woodford and Detmer, 1999; Matsui et al., 1999),
myocardial production (Kapadia et al., 1997; Torre-Amione et al., 1996b) and
endotoxin-mediated stimulation following bacterial translocation across an oedematous
gut wall (Anker et al., 1997a; Niebauer et al., 1999). It is most likely, however, that
there is a diffuse source of cytokine activation and activation of the immune response
may involve different pathways for different individuals.
Exercise training can partially reverse skeletal muscle abnormalities observed in heart
failure and improves symptoms (Adamopoulos et al., 1993; Belardinelli et al., 1999;
Coats et al., 1992; Hambrecht et al., 1997; Magnusson et al., 1996; Sullivan et al., 1991;
Wielenga et al., 1999) but the optimal form of exercise training and the effect of
training on the inflammatory response remains unclear. Additionally, the influence of
different forms of physical training on cytokine expression has not been established. As
such, this study was designed to explore the relationship between the pro-inflammatory
cytokines IL-6, TNFa, the two soluble receptors for TNFa, sTNFrl and sTNFr2, and the
inflammatory marker C-reactive protein (CRP), with exercise performance. The changes
in these inflammatory markers following a home-based programme of either bicycle




46 subjects with stable chronic heart failure and New York Heart Association (NYHA)
class II-III symptoms were recruited as described in section 3.1.1. Baseline
characteristics are shown in Table 6.1. All subjects were on appropriate medical therapy
that included angiotensin converting enzyme inhibitors (ACEi), diuretic, aldosterone
antagonist, digoxin or beta-blockers. None of the subjects were participating in a
specific exercise programme prior to inclusion in the study. Exclusion criteria outlined
in section 3.1.1 applied. None of the subjects taking part in the study was known to have
any intercurrent infective or malignant disease. One subject did not complete the
exercise training programme due to back discomfort. All patients randomised were
included in the final analysis.
n=46
Age, years 62 ± 10.3
Sex, male, n (%) 38 (83)
CHF aetiology, IHD / DCM, n (%) 29 / 17 (63 /37)
NYHA Functional class, II / III, n (%) 35 / 11 (76 / 24)







Table 6.1. Patient characteristics.
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Written informed consent was obtained from all subjects prior to randomisation and the
protocol was approved by the local research ethics committee.
6.3.2 Patient assessment
Subjects underwent assessment on three occasions. Two baseline assessments were
performed at least 24 hours apart prior to randomisation and one assessment was
performed following the exercise training period. At each visit subjects performed a 6-
minute walk test (section 3.3.2), a symptom-limited cardiopulmonary treadmill exercise
test (section 3.3.4) and an isometric quadriceps strength and fatigue test (section 3.3.3).
Data from the second baseline assessment were used as the true baseline.
At one of the baseline visits and following the training period each patient completed a
Minnesota 'living with heart failure' quality of life questionnaire (section 3.3.8).
6.3.3 Cytokine analyses
Venous blood was collected at one of the baseline visits and after the end of the 6-week
training period, as described in section 3.3.6 for analysis of TNFa, sTNFri, sTNFr2, IL-6
and hs-CRP.
6.3.4 Exercise training
Following baseline assessment, subjects were randomised to receive either a recumbent
bicycle ergometer or a neuromuscular stimulator for home use 30 minutes per day, five
days per week over a 6-week training period, as described in section 3.4.
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6.3.5 Statistical Analyses
Data were analysed using SPSSfor Windows version 13 as described in section 3.6. Data
are presented as mean ± standard deviation unless otherwise stated. Normally distributed
paired data were analysed using the paired /-test. Paired data that were not normally
distributed were analysed using the Mann Whitney U test where appropriate.
Correlations between variables were calculated using the Pearsons bivariate correlation
test for normally distributed data and the Kendall tau-b test for non-normally distributed
data. A p value of <0.05 was considered statistically significant.
6.4 Results
Improvements in 6-minute walk test distance, treadmill exercise time, maximal
quadriceps leg strength and quadriceps fatigue index were observed in the group as a







6MW (m) 42.7 ±30.7 <0.001 44.6 ±34.6 <0.001 40.6 ±26.5 <0.001
QoL -4.29 ± 11.8 0.02 -5.27 ± 14.6 0.11 -3.20 ± 8.11 0.090
Treadmill time(s) 90.1 ± 101 <0.001 110 ± 85.5 <0.001 66.8 ± 114 0.020
Peak V02
(ml/kg/min)
0.43 ± 3.05 0.38 0.76 ±3.12 0.276 0.060 ±3.01 0.932
Max quad
strength(kg)
5.33 ±6.54 <0.001 5.32 ±4.82 <0.001 5.35 ±8.16 0.009
Fatigue index 0.09 ±0.12 <0.001 0.079 ±0.090 0.001 0.10 ± 0.15 0.005
Table 6.2. Mean changes in functional capacity following training.
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variance indicated that the mode of exercise training was unimportant in determining the
degree of change seen. Improvement in quality of life score following training was
observed for the whole group (p=0.02) but not when the groups were considered
separately. Increase in peak VO2 following exercise training did not reach statistical
significance for either training group.
Pre-training concentrations of circulating inflammatory markers are shown in Table 6.3.
Although no normal control subjects were included in this study, levels of IL-6, TNFa,
sTNFri, sTNFr2 and hs-CRP are all elevated in comparison with the assay
manufacturers' data and previously published data (Chenillot et al., 2000; Herbeth et a!.,
2001). No relationship between concentrations of individual inflammatory markers and
NYHA functional class or left ventricular ejection fraction was observed. No significant
changes were detected in circulating inflammatory markers following training in the
study group as a whole although a trend towards lower levels of sTNFr2 was seen
(p=0.052, Table 6.3). sTNFr2 levels decreased significantly in the bike training group
(p=0.013) but not in the NMS group. Trends towards lower concentrations of TNFa and
sTNFrl were seen in the bike group but not in the NMS group. hs-CRP and IL-6 did not
change significantly following training in the bike group and no changes for any
inflammatory marker were observed in the NMS training group.
Correlations were seen at baseline between individual inflammatory markers (Table
6.4). A weak negative correlation was observed between IL-6 and treadmill exercise
time (coefficient = -0.223, p = 0.05); TNFa correlated weakly with treadmill exercise
time (coefficient = 0.242, p = 0.037). sTNFri correlated with age (coefficient = 0.277, p
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= 0.016).


































































Table 6.3. Training-induced changes in circulating inflammatory markers.




















Table 6.4. Relationship between inflammatory markers at baseline.
158
6.5 Discussion
Whilst the beneficial effects of physical training in chronic heart failure for markers of
exercise performance (Belardinelli et al., 1999; Coats et al., 1992; Wielenga et al.,
1999), muscle metabolism (Adamopoulos et al., 1993), endothelial function (Hambrecht
et al., 1998; Linke et al., 2001) and perhaps prognosis (Belardinelli et al., 1999) are
documented, less is known about the effects of physical training on the pro¬
inflammatory state. Larsen et al. have demonstrated modest reductions in circulating
TNFa following a 12-week training period (Larsen et al., 2001) and Adamopoulos et al.
have shown reduction in TNFa, soluble TNFa receptors 1 and 2, soluble IL-6 receptor
and markers of apoptosis with correlations between cytokine reductions and
improvements in markers of exercise performance (Adamopoulos et al., 2002). This
study confirms high levels of circulating pro-inflammatory cytokines in a group of
patients with chronic heart failure although I did not demonstrate a convincing
relationship between cytokine concentrations and severity of heart failure based on
NYHA class or exercise performance. This may be due to the stability of symptoms for
the whole study group and the small number of NYHA class III patients (11 subjects). I
did not demonstrate a reduction in levels of circulating TNFa or IL-6 following training
as other workers have done, although there was a trend towards lower circulating levels
of sTNFr2 following training in the whole study group. The fall in sTNFr2 was significant
in the bike training group only. A trend towards lower concentrations of TNFa and
sTNFri was seen in the bike training group although results did not reach statistical
significance. The fact that TNFa, IL-6 and CRP did not change significantly could
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reflect the sensitivity of these markers to short-term changes in immune state, for
example, changes occurring with intercurrent infection or physical exertion and, as such,
the relatively small population size in this study may limit the ability to resolve changes
for these markers. The differential changes seen following stimulator and bike training
need to be confirmed in a larger trial.
The existence of a heightened immune response in chronic heart failure is now accepted
but its possible role in the pathogenesis of the heart failure syndrome is a subject for
debate. Recent clinical trials have not shown benefit from treatments which target TNFa
(Chung et al., 2003; Mann et al., 2004) and this has raised the possibility that elevated
levels of circulating cytokines are markers of disease severity rather than causative
agents. The results of these trials which target single cytokine pathways do not
absolutely rule out a role for inflammation in the progression of heart failure, however.
Certainly TNFa levels have been found to be elevated in patients with left ventricular
systolic dysfunction (Levine et al., 1990; Matsumori et al., 1994), and in higher
concentrations in those with more severe heart failure (Torre-Amione et al., 1996a).
Animal studies have demonstrated that TNFa can depress myocardial contractility and
induce cardiomyopathy (Bryant et al., 1998; Finkel et al., 1992; Hegewisch et al., 1990),
and cytokines including TNFa can promote over-expression of inducible nitric oxide
synthase (iNOS) (Forstermann et al., 1994) which may cause elevated levels of intra¬
cellular nitric oxide sufficient to depress oxidative capacity and myocardial function.
Additionally, cytokines including TNFa are stimulators of apoptotic cell death (Ware et
al., 1996). 1L-6 is elevated in chronic heart failure (Munger et al., 1996) with higher
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concentrations found in patients with more severe symptoms and left ventricular systolic
dysfunction (Torre-Amione et al., 1996a), and high concentrations have been linked to
prognosis (Kell et al., 2002; Tsutamoto et al., 1998). The two receptors for the TNFa
homotrimer, TNFri and TNFr2, are widely expressed and mediate the actions of TNFa
(Sack et al., 2000) - the soluble forms of both subtypes which were measured in our
study are found in the circulation in higher concentrations in chronic heart failure with
concentration closely correlated with mortality (Deswal et al., 2001; Ferrari et al., 1995;
Rauchhaus et al., 2000). The precise role of the circulating TNF receptors is uncertain,
however. Receptors are up-regulated on exposure to TNFa and shed into the circulation.
The soluble receptors can bind to TNFa in the circulation and may buffer its action,
either attenuating its bioavailability or, alternatively, acting as a reservoir of TNFa,
thereby prolonging its normally short half-life (Aderka et al., 1992). As such,
concentrations of soluble TNFa receptors may reflect the overall level of TNFa
exposure irrespective of whether the soluble receptors limit or potentiate TNFa
bioactivity, and although TNFa levels may vary over time, soluble TNFa receptors may
represent the overall state of immune activation. As such, the reduction in circulating
levels of sTNFr2 following training in the bike group may reflect a reduction in the
overall state of immune activation.
In contrast, changes in circulating cytokine levels following training with neuromuscular
stimulation were not observed, despite improvements in functional capacity in both
training groups. Peak VO2 did not increase following training for either group indicating
either low intensity training regimes or poor patient compliance. Although patients
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maintained exercise diaries, it is difficult to be absolutely certain of compliance with any
home-based training programme and the lack of change in cytokine levels in the NMS
group may have been due to poor compliance with this form of training. Alternatively,
the absence of change in circulating inflammatory markers in the NMS group may be
due to less muscle bulk having been exercised over the six-week period for those
subjects in view of the likely more limited muscle recruitment by these devices
compared with conventional bicycle exercise. Whilst changes in muscle structure
promoting improved oxygen delivery following conventional training regimes have been
studied in heart failure patients previously, with beneficial changes in capillary density
(Scarpelli et al., 1999), flow dependent flow (Hornig et al., 1996) and peak leg blood
flow (Sullivan et al., 1988a), the long term effects of training with neuromuscular
stimulation have not been studied. Additionally, the acute effect of exercise with
electrical stimulation on muscle metabolism and deoxygenation in heart failure has not
been investigated. We did not observe any acute increase in heart rate or blood pressure
for five patients undergoing leg stimulation (data not shown), but further work
examining the acute haemodynamic effects of NMS in a heart failure population is
required. Since tissue hypoxia is a stimulus for TNFa production (Leeper-Woodford and
Detmer, 1999; Matsui et al., 1999) and the degree of oxygen delivery and tissue hypoxia
both during exercise and following training may be different for conventional training
regimes and electrical stimulation, there may be differing effects on inflammatory
response. Further work clarifying the mechanisms by which the pro-inflammatory state
is attenuated following different modes of physical training is required. Training regimes
may have differing peripheral effects, which may result in differing functional outcomes.
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If the pro-inflammatory state in heart failure is partly responsible for disease progression
rather than merely a surrogate marker of disease severity, then the mode of exercise
training chosen may be important in determining prognostic benefit despite similar
changes in exercise performance.
Conclusions
Exercise training with both neuromuscular stimulation and conventional cycle ergometer
results in beneficial changes in exercise performance in stable chronic heart failure
patients. However, the pro-inflammatory state appears to be attenuated in a group
receiving conventional training but not in a group receiving training with NMS. It will
be important to identify the source of immune activation and the mechanisms by which
training affects this inflammatory state, as it may be possible to tailor training regimes to
produce maximal benefit both for symptoms of heart failure and perhaps also prognosis.
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7 Study 4. Neuromuscular and conventional
exercise training in stable and recently




Previous studies have highlighted the benefits of exercise training in stable chronic heart
failure (CHF) but no data exist regarding patients with recently decompensated CHF.
Poor effort tolerance and demotivation may be more pronounced in this patient group
making delivery of conventional training difficult. We examined bicycle ergometer
exercise and neuromuscular stimulation (NMS) in stable and recently decompensated
groups.
7.1.2 Methods
15 patients, NYF1A class 1I-III with stable CHF (S-CHF) and no admission within the
preceding 3 months and 25 patients with recently decompensated CHF (RD-CHF) were
recruited. NT-pro BNP, 6-minute walk (6MW), quadriceps strength and fatigue test and
cardiopulmonary exercise test were assessed at baseline and after exercise training.
Patients were randomised to either no exercise (control), bike or NMS exercise daily for
30 minutes five days per week for 6 weeks.
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7.1.3 Results
In 23 patients completing the study, exercise training resulted in improvement in NYHA
class (2.13 ± 0.352 to 1.87 ± 0.516, p= 0.041), 6MW (553 ± 131 to 569 ± 139 m,
p=0.046), VO2 at anaerobic threshold (AT, 12.6 ± 3.05 to 13.8 ± 3.10 ml/kg/min,
p=0.036), OUES (oxygen uptake efficiency slope, 1.86 ± 0.699 to 2.11 ± 0.560,
p=0.032), VE/VCO2 slope (NMS only, 30.1 ± 3.80 to 24.6 ± 3.89, p=0.043), NT-pro
BNP (1721 ± 1752 to 1209 ±1248 pg/ml, p=0.005), quadriceps strength (34.2 ± 13.5 to
39.2 ± 16.0 kg, p=0.002) and treadmill exercise time (599 ± 207 to 683 ± 188 s
(p=0.002). NT-pro BNP fell significantly in the RD-CHF group receiving NMS training
(2859 ± 2352 pg/ml tol865 ± 1791 pg/ml, p=0.043) but not in the bike (1949 ± 1628 to
1086 ± 1369 pg/ml, p=0.18) or control group (1367 ± 1352 to 921 ± 1404, p=0.073). No
change in NT-pro BNP was seen in S-CHF patients. A trend for increased VO2 at AT
was seen in RD-CHF and S-CHF patients in NMS and bike groups but not controls.
7.1.4 Conclusions
For RD-CHF patients able to undertake an exercise programme, significant
improvements in symptoms and functional capacity are observed. NMS appears to be
effective in this group and could be a useful mode of delivery of exercise where
conventional training is not practicable.
7.2 Introduction
The syndrome of chronic heart failure (CHF) due to left ventricular systolic dysfunction
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is a complex interaction between poor cardiac output, neurohormonal maladaptations
and chronic peripheral changes in skeletal muscle. Meta-analyses have identified the
benefit of exercise training in improving morbidity, mortality and quality of life in
patients predominantly with stable chronic heart failure (S-CHF) (Piepoli et al, 2004;
Rees et al., 2004; van Tol et al., 2006). These studies have also explored different
modalities of training including dynamic and static regimens alone and in combination.
More recently, neuromuscular electrical stimulation (NMS) has emerged as a training
modality which may provide equivalent benefits to static bicycle training while being
potentially better tolerated by a wider range of patients (Dobsak et al., 2006; Nuhr et al.,
2004; Quittan et al., 2001). However, a number of important issues remain poorly
understood with regard to exercise training in heart failure. Firstly, patients included in
previous exercise training studies appear to be highly selected on the basis of greater
baseline physical fitness and motivation, hence they may not be truly representative of
the spectrum of CHF patients seen in hospital and community practice. Secondly,
patients with the most severe symptoms may have the most to gain from training but
maintenance of an exercise training programme in this group is often difficult due to
problems of motivation, comorbidities and limiting symptoms. As such, these patients
have not been well studied. Thirdly, the ideal timing of an exercise training programme
in the course of a patient's illness pathway is unknown, and in particular the safety and
efficacy of exercise training in recently decompensated heart failure patients is
unknown. We therefore sought to compare conventional bicycle ergometer exercise
training with NMS of quadriceps / gastrocnemius muscles in a group of patients selected
from a well defined hospital-based population with either stable heart failure (S-CHF) or
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40 patients with NYHA class II to III symptoms of heart failure were recruited in a
university teaching hospital setting. 15 of the patients were recruited from outpatient
clinics and were classed as having stable chronic heart failure (S-CHF) as described in
section 3.1.1. 25 patients were recruited following an admission with a primary
diagnosis of recently decompensated chronic heart failure (RD-CHF), i.e. worsening and
uncontrolled peripheral oedema or pulmonary oedema defined clinically and on chest
radiograph, as described in section 3.1.2. RD-CHF patients were invited to participate in
the study during their in-patient admission once they were deemed fit to provide
informed consent. They were treated for decompensated heart failure with standard
medical therapy and discharged from hospital once stable. They returned for initial
physical assessment between 2 and 4 weeks post-discharge. All patients recruited had
been previously diagnosed with heart failure on the basis of clinical assessment and
documented left ventricular systolic dysfunction described as at least moderate in
severity on echocardiography. Exclusion criteria outlined in section 3.1.2 applied. No
subject was participating in any exercise training programme prior to recruitment. At the
time of first baseline assessment, participating patients were on standard medical therapy
that included angiotensin converting enzyme inhibitors (ACEi) or angiotensin 2 receptor
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blockers (ARB), diuretic, aldosterone antagonists, digoxin or beta-blockers. Baseline
characteristics for recruited patients are shown in Table 7.1. Written informed consent
was obtained from all subjects prior to randomisation. The protocol was approved by the









64.6 ± 11.8 62.3 ± 6.87 0.49
Sex Male:Female, n (%)
31:9
(78:22)







124/75.3 ± 116/73.4 ± 134/77.4 ±
0.015/0.32
22.1/10.1 17.7/11.6 24.1/7.43






Aspirin 18 (45) 12 (48) 6(40) 0.622
ACEi / ARB 33 (83) 19(76) 14(93) 0.162
Beta-blocker 20 (50) 10(40) 10(67) 0.102
Loop diuretic 37 (92) 23 (92) 14(93) 0.877
Spironolactone 18(45) 13 (52) 5(33) 0.251
Digoxin 27 (68) 17(68) 10(67) 0.931
Statin 21 (52) 11 (44) 10(67) 0.165
Table 7.1. Baseline characteristics prior to randomisation.
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7.3.2 Assessment
Subjects underwent assessment on four occasions. Two initial assessments were
performed at least 24 hours apart prior to randomisation. Data from the first assessment
were discarded and the second assessment data were used as baseline. A third
assessment was performed within five days of the end of a 6-week training period. A
final assessment was then made after a further 6-week period of "detraining" during
which patients were neither encouraged nor discouraged from taking part in any form of
physical training.
At each visit subjects performed a 6-minute walk test (6MW, section 3.3.2), a symptom-
limited cardiopulmonary treadmill exercise test (section 3.3.4) and an isometric
quadriceps strength and fatigue test (section 3.3.3). Blood was collected for N-terminal
pro BNP (NT-pro BNP) analysis at baseline assessment and within five days of
completing the exercise training programme using a standard assay (section 3.3.7, Roche
Diagnostics, Basel, Switzerland).
7.3.3 Randomisation
Patients were randomised by an independent third party according to a pre-defined block
schedule to one of three groups as discussed in section 3.4.1. Group A underwent the
same performance assessment and follow-up as the two training groups but without any
formal training programme. Group B underwent conventional cycle ergometer training
as described below. Group C underwent training with NMS as described below.
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7.3.4 Exercise training programmes
Following baseline assessment and randomisation, patients undertook a six-week
programme of either usual activity (Group A), home-based cycle ergometer training
(group B, bike) or home-based neuromuscular electrical stimulation of the
quadriceps/gastrocnemius muscles of the legs (group C, NMS). Bike and NMS training
regimes are discussed in detail in sections 3.4.2 and 3.4.3, respectively. Patients
participating in all three groups were visited at home after two weeks and contacted by
telephone after four weeks to monitor progress.
7.3.5 Statistical analysis
Data for randomised patients were analysed using SPSS for Windows version 13 on an
intention to treat basis, as discussed in section 3.6. Data are presented as mean ±
standard deviation unless otherwise stated. Normally distributed paired data were
analysed using the paired /-test. Paired data that were not normally distributed were
analysed using the Mann Whitney U test where appropriate. Repeated measure data
were analysed using one-way ANOVA with post hoc Bonferroni test. A p value of <0.05
was considered statistically significant.
7.4 Results
At baseline, S-CHF and RD-CHF groups were not significantly different for NYHA
class, age, sex, CHF aetiology or drug use (Table 7.1). Drug dosages were not
significantly different between groups (data not shown). Systolic BP was significantly
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lower in the RD-CHF group.
7.4.1 Recently decompensated CHF vs. stable CHF groups
In total, from 40 patients initially recruited, 17 dropped out of the study. The majority of
these were patients in the RD-CHF group (n=ll). 6 patients (5 RD-CHF) dropped out
during the baseline assessment phase prior to randomisation due to severity of symptoms
and inability to complete the baseline performance assessments. 5 (4 RD-CHF patients)
dropped out during the exercise programme - 3 from group B (Bike) and 2 from group
C (NMS). A further 6 dropped out before the final assessment could be undertaken, 3 S-
CHF and 3 RD-CHF. Dropout following randomisation was due to worsening of heart
failure symptoms and no patient reported a specific intolerance of either exercise regime
as a precipitating factor. One RD-CHF patient was readmitted due to worsening
symptoms prior to the final visit.
Figure 7.1 and Figure 7.2 show changes observed following the training period for
groups A, B and C when combined or separated between RD-CHF and S-CHF. NMS
and BIKE patients show similar improvements in NT-pro BNP in the RD-CHF group
only, with NMS (group C) reaching statistical significance (Figure 7.1). The small
improvement observed in peak VO2 at AT observed for NMS and Bike groups together
(B and C combined) did not reach statistical significance when S-CHF and RD-CHF
patients were analysed separately (Figure 7.2). No significant changes were observed in
NYHA class, 6MW distance, treadmill exercise time, quadriceps strength and peak VCB
when S-CHF and RD-CHF data were analysed separately (data not shown).
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7.4.2 NMS vs bicycle regimes
Examining bicycle and NMS exercise modalities separately, NMS (group C) resulted in
significant improvements in treadmill exercise time, quadriceps strength, NT-pro BNP
and VE/VCO2 slope as shown in Table 7.2 and Table 7.3. A trend for improvement in
NYHA class, 6MW distance, treadmill exercise time and quadriceps strength was
observed in the bike training group (B). No change in peak VO2 or VO2 at AT was




















RD-CHF and S-CHF combined
N.S. N.S. p=0.021 p=0.005
T I
ABC B+C
Group (baseline to post-training change)
Figure 7.1. NT pro BNP between baseline and after training for control and exercising groups. A,
control group; B, bike group; C, NMS group, B+C, all exercising. RD-CHF, recently decompensated




























RD-CHF and S-CHF combined
20-i N.S. N.S. N.S. p=0.036
T
10-
A B C B+C
Group (Baseline to post-training change)
Figure 7.2. V02 at anaerobic threshold at baseline and after training for control and exercising
groups. A, control group; B, bike group; C, NMS group, B+C, all exercising. RD-CHF,
recently decompensated patients; S-CHF, stable patients only. N.S., not significant.
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Group Baseline After training
NYHA A 2.14 ± 0.363 2.14 ±0.363
B 2.0 ±0 1.5 ± 0.548 0.076
C 2.22 ±0.441 2.11 ± 0.333 0.347

















Treadmill time (s) A 546 ±181 581±188 0.194
B 647±170 722± 198 0.055
C 563 ±235 655±187 0.030
B±C 599 ±207 683 ±188 0.002
Quadriceps strength (kg) A 33.6 ±11.1 34.4 ±9.33 0.58
B 42.8 ± 9.70 47.8 ± 10.8 0.067
C 28.6 ± 12.9 33.4 ± 16.7 0.027
B±C 34.2 ± 13.5 39.2 ± 16.0 0.002
Fatigue index A 0.62 ±0.182 0.60 ±0.121 0.607
B 0.70 ±0.184 0.68 ± 0.158 0.825
C 0.79 ± 0.205 0.8 ± 0.085 0.917
B±C 0.75 ± 0.196 0.75 ± 0.130 0.943
















Table 7.2. Pre and post training performance and NT-pro BNP data for combined recently
decompensated and stable patients. A, Control group, n=14; B, Bike group, n=7; C, NMS group,
n=10; B±C, all exercising, n=17.
7.4.3 Exercise training vs. controls
When the exercise training groups were combined, significant improvements in NYHA
functional class, 6MW distance, treadmill exercise time, quadriceps strength, NT-pro
BNP, VO2 at AT and OUES were observed following the training period (Table 7.2 and
Table 7.3). Interestingly, a significant deterioration in OUES and VE/VCO2 slope was
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observed in group A (controls) for the same period; the remaining assessment
parameters were unchanged in this group.
7.4.4 Effects of detraining
Change in assessment parameters over the entire course of the study, including the
detraining period, were also examined (Figure 7.3). No significant differences were
observed in parameters measured immediately post-training and following the detraining
period. The most noticeable changes were observed in the bike group for treadmill
exercise time, peak VO2, VO2 at AT and NYHA functional class. Although these
Baseline After training P
pV02 (ml/kg/min) A 18.6 + 3.65 18.7 + 4.67 0.78
B 20.5 + 6.75 22.8 + 8.62 0.109
C 18.7 + 4.47 18.8 + 3.69 0.93
B+C 19.6 + 5.54 20.8 + 6.66 0.15
V02 at AT (ml/kg/min) A 12.6 + 2.75 12.8 + 3.43 0.78
B 13.2 + 3.97 14.7 + 3.53 0.159
C 11.9+ 1.90 12.9 + 2.57 0.15
B+C 12.6 + 3.05 13.8 + 3.10 0.036
ve/vco2 A 26.2 + 4.83 31.0 + 8.65 0.034
B 27.3 ± 6.27 28.2 + 8.09 0.633
C 30.1+3.80 24.6 + 3.89 0.043
B+C 28.7 + 5.15 26.4 + 6.34 0.161
oues A 2.33 + 0.699 1.78 + 0.437 0.023
B 1.93 + 0.596 2.04 + 0.604 0.307
C 1.78 + 0.840 2.17 + 0.560 0.067
B+C 1.86 + 0.699 2.11 ±0.560 0.032
Table 7.3. Pre and post training cardiopulmonary data for combined recently decompensated and
stable patients. A, Control group, n=14; B, Bike group, n=7; C, NMS group, n=10; B+C, all
exercising, n=17.
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measures were not statistically significant between visit dates for the bike group with the
exception of NYHA class, there is a trend for more sustained improvement in the bike
group compared with NMS and controls. Only NHYA class was significantly improved
in the bike group after detraining as compared with controls (control 2.1 ± 0.316, bike
1.6 ± 0.548, p=0.041).
7.5 Discussion
Previous studies of exercise training in chronic heart failure have focussed on patients
with stable symptoms (Belardinelli et al., 1999; Dubach et al., 1997a; Hambrecht et al.,
1995; Wielenga et al., 1999). To our knowledge, no study has yet investigated the effect
of exercise training in patients with recently decompensated symptoms. There is
evidence that the RD-CHF patients in this study were more unwell than S-CHF and
control patients: NT-pro BNP levels were higher at baseline, blood pressure was lower
and there was a higher drop-out rate from the study in the RD-CHF group. Despite this
finding, significant improvement in NT-pro BNP was observed in the RD-CHF group
following training. The majority of this effect was due to changes observed in the NMS
group. Further work is required to clarify whether this reflects a genuine improvement in
heart failure as a beneficial effect of NMS or whether this is a statistical anomaly since
NT-pro BNP also fell to a lesser degree in RD-CHF control patients. Up-titration of
ACEi and beta-blocker therapy occurred in few RD-CHF patients during the exercise
training period but equally between control, bike and NMS subjects, and in no patients
from the S-CHF group. However it is difficult to altogether exclude the possibility that
improvement observed following training with NMS in NT-pro BNP was not due to the
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increases in medical therapy concomitant with the training regime.
It is not clear whether training in RD-CHF patients is safe owing to the small number of
participants in this study. However, no adverse events were noted in the RD-CHF group,
either with training or during performance assessment, although one patient was
readmitted to hospital with worsening CHF. Additionally, 44% of the RD-CHF group
dropped out of the study, 6 prior to randomisation, and, as such, were excluded from the
final analysis. Further studies involving larger numbers of RD-CHF patients would be
required to clarify the tolerability of exercise training in recently decompensated
patients.
Patient motivation was poorer following a recent admission with decompensated
symptoms. Their decreased functional status was reflected in the number of subjects
who were recruited to the study initially but who were unable to complete baseline
exercise assessments and were subsequently excluded - 5 in this group compared with 1
in the stable group. 3 further patients dropped out of the study prior to the post training
period assessment, all from the recently decompensated group. 2 of these patients were
using conventional bike training, 1 NMS and none from the control group. This indicates
that in a more severely affected patient population, exercise training is much more
difficult to provide in a sustained way. Overall, 32% of the recently decompensated
group as a whole and 37.5% of the recently decompensated group randomised to
exercise therapy were unable to complete the exercise training period. However, the
overall numbers of patients randomised were too small to draw any firm conclusions at













































NMS has previously been shown to improve exercise performance including
cardiopulmonary parameters, muscle strength and fatigability (Dobsak et ah, 2006) and
to induce beneficial changes in muscle fibre composition and oxidative capacity (Nuhr
et al., 2003; Theriault et al., 1994), pro-inflammatory state and endothelial function
(Karavidas et ah, 2006). In this study we demonstrated improvements in 6MW distance,
quadriceps strength, treadmill exercise time, NT-pro BNP, OUES and VCf at AT when
data from the NMS and bicycle groups were combined. A trend for improvement in
6MW distance was observed for the bike group, and OUES for the NMS group when
exercise regimes were examined separately. The lack of statistical significance seen may
have been due to the low number of patients who completed the exercise training period.
Improvements remained significant for the NMS group in treadmill exercise time, quad
strength, NT-pro BNP and VE/VCO2 slope when exercise regimes were examined
separately. It is interesting that VE/VCO2 slope significantly deteriorated in the control
group, was apparently unaltered in the bike group and significantly improved in the
NMS group. Whilst these data do not prove that NMS is any better or worse than
conventional training, they do indicate that NMS is superior to no exercise therapy and
is worthy of further investigation.
Data obtained following a 6-week period of detraining is limited by the small number of
patients completing this part of the study. There is a trend for sustained improvement in
peak VO2 and VO2 at AT seen in the bike group, and treadmill exercise time in the NMS
group. However, none of the data from assessment after detraining reached statistical
significance compared with controls. This is likely to be due to the small numbers of
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subjects in each group completing this section of the study and so no firm conclusions
about this can be made. One recent study has examined the role of detraining in the CHF
patient (Tenenbaum et al., 2006). In this study, patients exercised for either 1.6 years or
3 years and were reassessed at 3 years. Results suggest that continued exercise therapy is
required to maintain the benefits that result from conventional training. No data yet
exists for detraining following NMS but it is likely that continued therapy will be
required, or NMS used as a bridging therapy until conventional training can be
performed.
Training regimes used in heart failure exercise trials usually involve aerobic exercise
which requires an increase in cardiac work. Although we have not encountered adverse
events during conventional training programmes or during cardiopulmonary exercise
testing, exercise-induced arrhythmia is a theoretical concern and may limit the
acceptability of exercise rehabilitation to prescribing clinicians. Additionally, the target
population that may benefit from exercise training are generally less well motivated and
have more comorbidities than trial populations previously studied. As such, we designed
this study to include patients who had recently been admitted to hospital with an acute
decompensation of their heart failure. Exercise rehabilitation in this setting would more
closely mirror, in timing of introduction, rehabilitation that is offered following acute
myocardial infarction. Neuromuscular stimulation is an alternative to conventional
aerobic or resistance training. Although the degree of patient motivation required to use
NMS due to discomfort and adjustments necessary should not be underestimated, it is
easier to perform than conventional exercise and may be more suitable to use in the
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deconditioned and demotivated heart failure population.
7.6 Conclusions
Improvements in symptoms and functional capacity are observed when RD-CHF
patients are included in an exercise training programme, a group previously excluded
from studies. However, these patients have a higher drop-out rate from exercise
programmes compared with stable CHF patients. Neuromuscular stimulation appears to
be effective in patients with recently decompensated heart failure and may be a useful
mode of delivery of exercise where conventional training is not practicable.
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8 Study 5. Participants suitable for inclusion in
exercise training trials are substantially




Exercise training in stable chronic heart failure (CHF) is safe and beneficial. However,
patients included in previous studies appear to be highly selected in terms of age,
comorbidities and motivation. This study compares characteristics of patients able to
undertake a clinical trial of exercise training with the population of CHF patients they
were recruited from. Similar data has not been previously reported in the literature.
8.1.2 Methods.
672 patients were screened in a tertiary centre, either following acute admission or
following outpatient attendance. Patients included in the register had documented left
ventricular systolic dysfunction and clinical evidence of CHF not attributable to an
alternative cause. Standard exercise trial inclusion and exclusion criteria were applied to
assess suitability to participate. Patients were subdivided into those with a recent
hospital admission due to decompensated CHF within the previous month (RD-CHF)




Only 45 (6.70%) of the screened patients were eligible to participate based on age,
ability to exercise and perform functional status tests required for the exercise training
study. 34 patients (5.06%) were subsequently randomised. 23 patients (3.42%)
completed the entire study protocol. 68.3% of eligible patients were taking at least
weekly exercise prior to recruitment compared to 18.0% of non-eligible patients
(p<0.001). Eligible patients were younger, had similar NYHA class, had fewer
comorbidities and were more likely to be treated with ACEi, B-blockers, aldosterone
antagonists and digoxin (p<0.05 in all cases) compared with non-eligible patients. After
inclusion, a trend for earlier dropout from the study was observed for RD-
CHF (p=0.077). In addition, O2 uptake efficiency was lower (p=0.027) and VE/VCO?
slope (p=0.002) and NT-pro BNP (p=0.014) were higher in patients who dropped out
from the study.
8.1.4 Discussion.
Recruitment of CHF patients representative of the population seen in the clinical setting
to participate in exercise training studies is difficult and standard exclusion criteria select
younger, fitter patients, commonly already participating in regular exercise. Trial
patients were younger and were on more specific CHF therapies. RD-CHF patients more
closely represent the wider CHF population but drop-out rate from the exercise training
study was high. Alternative trial designs are needed to investigate the role of training in
the general CHF population who may have much to gain from this therapy.
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8.2 Introduction
Exercise training in chronic heart failure (CHF) has been demonstrated to be safe and to
produce beneficial effects for exercise performance, neurohormonal imbalance,
inflammation and quality of life (Adamopoulos et al., 2002; Belardinelli et al., 1999;
Coats et al., 1992; Tyni-Lenne et al., 2001). There may also be a mortality benefit
(Piepoli et al., 2004). Guidelines relating to exercise training limit recommendation to
stable CHF patients (Swedberg et al., 2005) and no randomised controlled study has to
our knowledge explored exercise training in the recently-decompensated heart failure
group. As such, no data for this subset of CHF patients exist. There is a concern that the
characteristics of CHF patients previously included in trials do not accurately reflect the
wider CHF population. This limits the applicability of exercise training programmes and
may be one reason why some guidelines do not recommend exercise training
programmes as strongly as others (Hunt et al., 2005; Scottish Intercollegiate Guidelines
Network, 1999). In most studies, males are over-represented, patients are younger than
the peak incident age of heart failure and have fewer co-morbid conditions.
Additionally, study patients need to be highly motivated in order to participate in
exercise programmes of up to 3 years in duration and this may not be representative of
the general heart failure population who tend to be demotivated, detrained and often
depressed (Faris et al., 2002; Jiang et al., 2007). Medical management of trial patients is
usually stabilised and optimal, again not reflecting real-world practice in all cases.
This issue highlights an additional limitation of published trial evidence relating to
exercise training. Most trials have included patients that have been stable for at least 3
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months prior to randomisation. There are no published randomised controlled studies, to
our knowledge, that have attempted to explore exercise training in recently
decompensated heart failure patients and, as such, no safety or efficacy data for this
subset of patients exist.
In attempting to explore these issues further, we screened CHF patients in a tertiary
centre and explored the relationship between eligible patients able and willing to
participate in a training study with the non-eligible heart failure population. The
differing characteristics and ability to complete a simple exercise training study of stable
heart failure patients (S-CHF) and patients recently admitted to hospital with
decompensated symptoms (RD-CHF) were also examined. This is important since if
exercise training programmes are to be introduced more widely in clinical practice, the




Patients were screened in a tertiary centre teaching hospital, either following acute
admission or following attendance at an outpatient clinic as discussed in section 3.1.2.
Consent for details to be included in the registry was obtained verbally from each
patient. Case notes were reviewed and the patient was interviewed and, where necessary,
examined by either a heart failure specialist nurse or a cardiologist. Patients were
included in the register only if they had symptoms and signs consistent with heart
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failure, including breathlessness and/or evidence of salt/water retention not attributable
to an alternative cause. Data were entered into a multi-relational database (Microsoft
Access 2000) as described in section 3.5. Information in the register was updated with
each new attendance e.g. readmission, clinic visit, home visit or attendance at a
specialised beta-blocker up-titration clinic. The screening period was from October 2001
until December 2003.
8.3.2 Study inclusion
Patients from the registry were screened for their suitability for inclusion in an exercise
training research study. Inclusion and exclusion criteria for participating in the exercise
training programme are discussed in section 3.1. Inclusion criteria included age between
18 and 80 years, symptomatic heart failure NYHA grade II or above and documented
left ventricular systolic dysfunction graded at least moderate on previous
echocardiography or LV angiography. Exclusion criteria included any current active
participation in an exercise programme, a history of stroke or acute coronary syndrome
within the 3 months prior to recruitment, uncontrolled anginal symptoms and any
respiratory, neurological or orthopaedic condition which would prevent their
participation in either a conventional bicycle exercise training programme or the
physical performance assessments during the study. Two categories of patient were
recruited - recently decompensated heart failure patients (RD-CHF, section 3.1.2) and
stable heart failure patients (S-CHF, section 3.1.1). RD-CHF patients were recruited
following a hospital admission with worsening symptoms of heart failure and worsening
and uncontrolled peripheral oedema or pulmonary oedema defined clinically and on
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chest radiograph. Following agreement to participate if the study, they were seen
between 2 and 4 weeks following discharge and baseline performance assessments were
made. S-CHF patients were recruited from the outpatient setting and were defined as
having had no admission with heart failure, no change in their symptom status and no
adjustment of their heart failure medication over the 3 months prior to recruitment.
8.3.3 Comparison group
The ExTraMATCH pooled data is used as a comparison group. The studies from which
the dataset was identified were selected according to the criteria in Table 8.1. The
criteria are similar to the inclusion and exclusion criteria used for the S-CF1F study
patients. Individualised patient data are not available from the ExTraMATCFl
publication and, as such, it is not possible to merge the published data split between
training and control group patients presented in the paper. There were no differences at
baseline between the two groups and, as such, the trained patients' data are used for
comparison (n=395).
8.3.4 Study protocol
Study subjects underwent assessment on four occasions. Two initial assessments were
Randomised parallel group controlled trials
Evaluation of exercise training only with no other intervention studied simultaneously
Stable heart failure only (3 months or more)
Left ventricular systolic impairment with ejection fraction less than 50%
At least 8 weeks of exercise training
Training regimes targeting at least both legs
Survival data available of at least 3 months duration
Table 8.1. Inclusion criteria for ExTraMATCH meta-analysis datasets.
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performed at least 24 hours apart prior to randomisation with data from the first
assessment discarded and the second assessment data used as baseline. Patients were
randomised to one of three groups as described in section 3.4.1. Group A acted as
controls and undertook usual activity with no specific exercise training regime. Group B
exercised 5 days per week for 30 minutes per day using a recumbent bicycle. Group C
exercised for 30 minutes per day, five days per week using neuromuscular stimulation of
the quadriceps and gastrocnemius muscles. A third assessment was performed within 5
days of the end of a 6-week training period. A final assessment was then made after a
further 6-week period of "detraining" during which patients were neither encouraged nor
discouraged from taking part in any form of physical training. At each visit subjects
performed a 6-minute walk test (section 3.3.2), a symptom-limited cardiopulmonary
treadmill exercise test (section 3.3.4) and an isometric quadriceps strength and fatigue
test (section 3.3.3). Cardiopulmonary exercise data were collected during a symptom-
limited modified Bruce treadmill exercise test and patients were encouraged to exercise
to the point of exhaustion beyond their anaerobic threshold. Anaerobic threshold (AT)
was determined by the V-slope method (section 3.3.4.3). Oxygen uptake efficiency slope
(OUES) was calculated as described in section 3.3.4.5. VE/VCO2 slope was calculated
as described in section 3.3.4.4. Blood was collected for N-terminal pro-BNP analysis at
baseline assessment and within 5 days of completing the exercise training programme as
described in section 3.3.7.
8.3.5 Data analysis
Data were analysed as described in section 3.6 with SPSSfor Windows version 13.0 and
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a p value of <0.05 was considered statistically significant. Data are presented as mean ±
standard deviation unless otherwise stated. Nominal data were analysed using the
Pearson Chi-square test with Fisher's exact test where appropriate. Scale data were
analysed using independent t-test or one-way ANOVA with post-hoc Bonferroni test for
normally distributed data and the Mann-Whitney U test for non-parametric data.
Survival analysis was performed using the Kaplan-Meier method with subsequent log-
rank analysis of survival curves.
8.4 Results
8.4.1 Population characteristics
672 patients were screened over a 26-month period between October 2001 and
December 2003. Table 8.2 shows baseline characteristics of the screened group. 115
(17.1%) patients died during the screening period. Of the screened patients, only 413
(61.5%) were eligible for inclusion on age criteria. Applying the additional exclusion
criteria as detailed in the methods section above, 45 (6.70%) were eligible for inclusion
Mean
Age (years) 74.7 ±11.6 Range 31.1 - 102.6





Sex M:F 377:295 56.1 : 43.9 (%
Table 8.2. Screened population characteristics.
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and were contacted for further assessment. Of these patients, 5 did not perforin baseline
tests due to worsening of heart failure symptoms resulting in readmission. A further 6
attended for baseline assessment but were excluded from the study before being
randomised due to an inability to complete baseline performance assessments due to
physical limitation from either heart failure symptoms or angina. 34 patients (5.06%)
were randomised. 5 patients dropped out of the study during the exercise phase (4 RD-
CHF) patients, 3 from group B (Bike) and 2 from group C (NMS). 29 patients (4.31%)
therefore completed the exercise training programme. A further 6 dropped out before the
final assessment could be undertaken, 3 S-CHF and 3 RD-CHF, leaving a final sample
of 23 patients from the original 672, representing 3.42% of the originally screened
population.
Table 8.3 shows the characteristics of patients originally considered eligible for











344 : 283 (54.9 : 45.1)
33 : 12 (73.3 : 26.7)
0.011
Non-eligible 352 : 217 (61.9 : 38.1)
0.104/\euoiogy, n \/o)
Eligible 23 : 22 (51.1 : 48.9)
Table 8.3. Differing characteristics of study population vs. patients not suitable for study
based on inclusion and exclusion criteria.*Ischaemic vs. non-ischaemic patients.
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patients had similarly severe symptoms of heart failure - 56.0% of non-eligible patients
were in NYHA functional class 3 compared with 44.4% of eligible patients (p=0.093).
72.8% of non-eligible patients had LV systolic dysfunction graded as moderate or severe
compared with 91.1% of eligible patients (p=0.003). 18.0% of non-eligible patients
volunteered that they took at least weekly exercise prior to inclusion in the registry
compared with 68.3% of eligible patients (p<0.001).
Differences between non-eligible, RD-CHF, S-CHF and ExTraMATCH patients are
shown in Table 8.4. RD-CHF, S-CHF and ExTraMATCH patients were significantly
younger than the non-eligible population (p<0.001 in all cases). Age of RD-CHF and S-
CHF patients was not significantly different (p=0.193). ExTraMATCH patients were
significantly younger than the RD-CHF group (p=0.001). NYHA class was similar for
all four groups with no statistically significant differences observed between them. Mean
duration of heart failure since initial diagnosis was significantly longer for S-CHF
patients compared with non-eligible patients (p<0.001) and there was a trend for longer
duration of heart failure since diagnosis in S-CHF patients compared with RD-CHF
patients (p=0.054). RD-CHF patients did not have a statistically longer duration of CHF
Non-eligible RD-CHF S-CHF ExTraMATCH
Age (years) 74.5 ± 11.5 66.2 ±11.9 61.9 ± 7.00 60.5 ± 9.30
NYHA status 2.60 ± 0.59 2.48 ±0.51 2.33 ± 0.49 2.60 ±0.60
Duration ofCHF since
2.38 ± 3.38 3.03 ±3.66 4.45 ± 3.39 N/A
diagnosis
Table 8.4. Differences between non-eligible, RD-CHF, S-CHF and ExTraMATCH patients.
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Non-eligible RD-CHF S-CHF ExTraMMCH Non-eligible RD-CHF S-CHF ExTraM&lCH
Figure 8.1. Age, NYHA class, proportion of male and ischaemic patients for non-eligible, S-
CHF, RD-CHF and ExTraMATCH patients.
compared with non-eligible patients (p=0.149). No data from ExTraMATCH regarding
duration of CHF since diagnosis were available.
Age, NYHA class and percentage of male patients and those with an ischaemic
aetiology for their CHF are shown in Figure 8.1. The sex ratio was similar between non-
eligible patients and S-CHF patients (p=0.262). Males were over-represented in the RD-
CHF group compared with non-eligible patients (p=0.014) and in the ExTraMATCH
group compared with non-eligible patients (p<0.001). There was a trend for over-
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representation of non-ischaemic patients in the RD-CHF group compared with non-
eligible patients (p=0.072) but S-CHF and ExTraMatch had similar ratios on non-
ischaemic to ischaemic patients as the non-eligible population (p=0.54 and p=0.28,
respectively).
8.4.2 Comorbid conditions
Comorbid conditions were recorded in the database for 661 patients. A total of 207
different diagnoses were logged in the register (see Appendix C). The mean number of
additional comorbid conditions between non-eligible, RD-CHF and S-CHF patients was
not significantly different: for non-eligible heart failure patients the mean number of
comorbidities was 4.93 ± 2.64, for RD-CHF patients was 5.53 ± 2.65 and for S-CHF
patients was 5.71 ± 3.02. However, differences between the three populations were
observed when comorbidities were grouped into the following categories: valvular heart
disease, atrial arrhythmias, ventricular arrhythmias, significant respiratory disease,
peripheral vascular disease, renal impairment, diabetes, cerebrovascular disease and
carcinoma. Mean comorbidities when grouped in this way were 1.64 ± 1.28 for non-
eligible patients, 1.67 ± 1.03 for RD-CHF patients and 1.07 ± 0.88 for S-CHF patients;
RD-CHF and non-eligible patients were not significantly different (p=0.884), the smaller
number of comorbid conditions approached significance between RD-CHF and S-CHF
(p=0.051) and was significantly different between non-eligible and S-CHF patients
(p=0.027). No single comorbid condition was significantly more prevalent between the
three populations when individual conditions were examined separately (data not
shown). No data on co-morbid conditions for the ExTraMATCH group were available.
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8.4.3 Hospital admissions
The number of admissions during the screening period was examined. For the entire
registry the mean number of admissions was 1.21 ± 0.57, range 1-5. Mean number of
admissions of non-eligible patients was 1.18 ± 0.55, for RD-CHF patients was 1.63 ±
0.76 and for S-CHF was 1.27 ± 0.46. The number of admissions in the RD-CHF group
was significantly more then the non-eligible population (p=0.003) and approached
significance for the increased number of admissions compared with the S-CHF group
(p=0.052). Non-eligible and S-CHF patients were not significantly different (p=0.503).
8.4.4 Medications
Total number of prescriptions for each patient entered into the registry was examined
along with prescriptions for individual classes of drug. Mean number of medications was
4.89 ± 1.87, range 1-10. Interestingly male patients were on significantly more
medications than female patients (5.18 ± 1.91 and 4.52 ± 1.76, respectively, p<0.001).
CHF patients with an ischaemic aetiology were on more medications than those with a
non-ischaemic aetiology (5.41 ± 1.82 and 4.17 ± 1.69, respectively, p<0.001). Total
number of prescribed medications differed between non-eligible and eligible patients.
Non-eligible patients were on fewer medications than RD-CHF patients (mean 4.82 ±
1.87 and 5.73 ± 1.66, respectively, p=0.006) and S-CHF patients (5.93 ± 1.77, p=0.037).
RD-CHF and S-CHF were not on significantly different numbers of medications
(p=0.732).
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Table 8.5 shows prescription of individual classes of medication between non-eligible,
RD-CHF, S-CHF and ExTraMATCH training group patients; these data are represented
in Figure 8.2. In the ExTraMATCH group, antiplatelet usage was significantly lower
compared with non-eligible patients (p<0.001) and with RD-CHF patients (p=0.009), but
no differences were observed between non-eligible and RD-CHF or S-CHF patients.
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Figure 8.2. Medication prescription between non-eligible, RD-CHF, S-CHF and ExTraMATCH
patient groups. Combined cardioselective and non-cardioselective B-blocker use is shown.
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(p<0.001). RD-CHF, S-CHF and ExTraMATCH patients were more likely to be on
ACEi / ARB therapy compared with the non-eligible group (p=0.019, p=0.002 and
p<0.001, respectively). RD-CHF, S-CHF and ExTraMATCH patients did not differ
amongst themselves for ACEi/ARB usage. S-CHF patients were more likely to be on a
heart-failure specific beta-blocker than non-eligible patients (p=0.004) and all beta-
blocker usage in the ExTraMATCH group was significantly lower than all 3 other
groups (p<0.001 in all cases). No difference in loop diuretic use was seen between non-
eligible, RD-CHF and S-CHF patients. Loop diuretic use was significantly lower in the
ExTraMATCH patients compared with non-eligible, RD-CHF and S-CHF patients
(p<0.001 in all cases). Digoxin was used more for RD-CHF, S-CHF and ExTraMATCH
patients compared with non-eligible patients (p=0.011, p=0.038, p=0.001, respectively).
Medication class Non-eligible
(n=627)
RD-CHF (n=30) S-CHF (n=15) ExTraMATCH
Anti-platelet 375 (59.8) 16(53.3) 7 (46.7) 119(30.1)
Warfarin 126 (20.1) 10(33.3) 4 (26.7) 158 (40)
ACEi/ARB 352 (56.1) 23 (76.7) 14(93.3) 290 (73.4)
Non-CS B-
B locker
35 (5.82) 1 (3.33) 1 (6.67)
CS B-blocker 155 (24.7) 11 (36.7) 9 (60.0) 48 (12.2)
Loop diuretic 500 (79.7) 27 (90.0) 14(93.3) 272 (68.9)
Thiazide diuretic 46 (7.33) 4(13.3) 2(13.3)
Aldosterone
antagonist
151 (24.1) 15 (50.0) 5 (33.3)
Digoxin 253 (40.4) 19(63.3) 10(66.7) 199 (50.4)
Statin 187 (29.8) 15 (50.0) 10(66.7)
Table 8.5. Pearson Chi-square test for number of prescriptions of individual classes of medications.
Total n = 672. Data expressed as n (%). CS - cardioselective.
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No data from ExTraMATCH were available for thiazide, aldosterone antagonist or statin
use. No difference in thiazide usage was seen between non-eligible, RD-CHF and S-
CHF groups. RD-CHF patients were more likely than non-eligible patients to be using
aldosterone antagonists (p=0.002) but there was no difference between non-eligible and
S-CHF patients. Statin usage was higher in RD-CHF patients and S-CHF patients
compared to non-eligible patients (p=0.019 and p=0.004, respectively).






























Figure 8.3. Kaplan-Meier survival curve for RD-CHF and S-CHF study patients - time until
dropout from study.
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Figure 8.3 shows the Kaplan-Meier survival curve for dropout from the exercise training
study for RD-CHF and S-CHF groups. Although there is a trend for earlier dropout in
the RD-CHF group, this difference did not reach statistical significance (log-rank
p=0.077).
40 patients undertook performance testing and serum collection for NT-pro BNP
analysis. Differences were observed for physical performance between patients who
were and were not able to complete the study (Figure 8.4). Differences between dropout
groups by one-way ANOVA were not significant for treadmill exercise time (p=0.776),
peak VO2 (p=0.172), VO2 at anaerobic threshold (p=0.533), 6MW (p=0.158), maximal
leg strength (p=0.521) and fatigue index (p=0.304). Significant differences by one-way
Figure 8.4. One-way ANOVA comparison of performance between patients completing study and patients
dropping out pre-randomisation (pre-rand.), prior to end of training period (<6w) and prior to end of detraining
period (>6w).
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ANOVA were observed for VE/VCCf slope (p=0.002), OUES (p=0.027) and NT-pro
BNP (p=0.014). VE/VCO2 slope for patients who dropped out prior to randomisation
was significantly higher than those patients who completed the study (40.5 ± 3.08 and
28.0 ± 4.56, respectively, p=0.002), those who dropped out before the end of the training
period (27.2 ± 4.96, p=0.009) and those who dropped out prior to the end of the
detraining period (25.2 ± 7.34, p=0.009). OUES for patients who dropped out prior to
randomisation was significantly lower than those patients who completed the training
period but dropped out prior to the detraining period (0.714 ± 0.542 and 2.19 ± 0.370,
respectively, p=0.023) and a trend for lower OUES between those dropping out prior to
randomisation and those completing the study was observed (0.714 ± 0.542 and 1.72 ±
0.640, respectively, p=0.080). NT-pro BNP was higher in patients who dropped out prior
to randomisation compared with patients who completed the entire study (6302 ± 7651
pg/ml and 1401 ± 1664 pg/ml, respectively) and patients who completed the exercise
training period but who dropped out prior to the end of the detraining period (926 ±
1445 pg/ml). Non-parametric post-hoc tests did not reach significance, however.
Figure 8.5 shows the survival curve for the 34 patients who were subsequently
randomised to training or control groups. No difference in time to dropout from study
was observed between training groups and controls (log-rank p=0.589).
8.5 Discussion
Current guidelines recommend exercise training as part of the treatment of stable
chronic heart failure (Hunt et al., 2005; Swedberg et al., 2005). Previous studies have
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used differing training regimes and as such no single training modality is recognised to
be superior to another (Rees et al., 2004). Rehabilitation services similar to those offered
to survivors of acute myocardial infarction are not routinely in place for heart failure
patients outside of clinical trials and this may be due to the differing characteristics of
trial and general CHF populations.
Despite a substantial burden of heart failure both in the community and resulting from
hospitalisation (Alia et al., 2007; Rodeheffer, 2003; Thomas and Rich, 2007), few
patients screened were suitable for this exercise training trial based on standard inclusion
and exclusion criteria. Of the 6.7% suitable, only 4.3% completed the exercise training
Figure 8.5. Kaplan-Meier survival curve for randomised study patients - time until dropout
from study. n=34. A, control group; B, bike group; C, NMS group.
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section and only 3.42% were still participating at the end of the study.
Although symptoms of heart failure were similar between eligible and non-eligible
groups, eligible patients were younger, more likely to have a non-ischaemic aetiology
and had a higher degree of LV systolic impairment. RD-CHF patients more closely
mirrored the screened population with S-CHF patients having less severe symptoms,
younger age and a longer duration of heart failure since original diagnosis compared
with RD-CF1F patients.
RD-CHF and S-CHF study patients were more likely to be on ACEi or ARB,
cardioselective beta-blockers, aldosterone antagonists or digoxin compared with non-
eligible patients. Interestingly, although CHF patients with an ischaemic aetiology were
not over-represented in the study population compared to the non-study population,
study patients were more likely to be on a statin. In contrast, despite a high proportion of
ischaemic patients in the ExTraMATCH training group, there was relatively little aspirin
use. There was a relatively low usage of beta-blocking agents in ExTraMATCH (no
detail is given to indicate whether the agents used were cardioselective or non-
cardioselective), and the high usage of warfarin and digoxin in the ExTraMATCH group
suggests a high proportion of patients with atrial fibrillation. Alternatively, the lower
usage of beta-blockers and higher usage of digoxin may reflect the era in which the trials
comprising the pooled ExTraMATCH data were undertaken. No details regarding
thiazide diuretic, aldosterone antagonist or statin use are given in the ExTraMATCH
publication, p-values given in Table 8.5 refer to within group comparisons of non-
eligible, RD-CHF and S-CHF patients only.
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S-CHF patients were more likely to be on ACE inhibitor / angiotensin II receptor
blocker therapy, cardioselective beta-blockers and aldosterone antagonists than RD-CHF
or non-study patients. Interesingly, statin use was higher in the S-CHF group despite a
higher proportion of patients with a non-ischaemic aetiology of CHF.
Comorbid conditions were similar between RD-CHF and non-study populations. S-CHF
patients had significantly fewer comorbid conditions than non-study patients when co¬
morbidities were grouped. S-CHF and RD-CHF patients were also on more medications
than non-study patients.
Overall, S-CHF patients typical of those normally recruited for heart failure exercise
training studies were fitter, younger and were on better pharmacological therapy for
heart failure than the much larger group of non-study patients. Although RD-CHF
patients were more closely related to non-study patients, their recruitment into a training
study was difficult and there was a trend for earlier dropout from the study in this group.
Dropout was associated with more severe ventilatory inefficiency (higher VE/VCO2
slope, lower OUES) and raised NT-pro BNP levels, all surrogate markers of heart failure
severity. A larger sample size in future may allow prediction of which patient is likely to
be able to complete or maintain a training programme. For now, although training is an
attractive adjunct in the treatment of CHF, the applicability of trial results the general
CHF population is uncertain in view of the differing characteristics between the two
groups. Most CHF patients previously included in trials of exercise training are likely to
be highly selected and the applicability of this evidence to the wider CHF population is
questionable. Until further data exist for the older, less fit CHF patient, training will
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9.1 NMS as a training modality
Study 1 was designed as a pilot experiment to explore the concept ofNMS and assess its
safety. In these respects, this study was successful. Improvement in functional capacity
was observed for both training groups. Findings are consistent with those of other
investigators who have observed improvement in functional performance following this
form of training although these have been small trials of between 14 and 30 patients with
no control group included in the designs (Deley et al., 2005; Dobsak et al., 2006;
Maillefert et al., 1998). With this uncontrolled trial design, it is impossible to be certain
that improvement is due to the intervention itself as improvement may have been
observed as part of the natural course of these patients illness. As such, firm conclusions
regarding the efficacy of NMS and the interchangability with conventional training
regimes cannot be drawn pending controlled studies. Care was taken to ensure that the
change in performance seen between baseline and post-training in study 1 was not due to
increased familiarity with the assessments themselves, however. One study investigating
the effects of NMS in a transplant population was controlled and showed improvement
in peak VO2 following NMS training for 8 weeks with baseline peak VO2 slightly lower
at around 17 ml/kg/min compared with those observed in study 1 of around 19
ml/kg/min (Vaquero et al., 1998). Knee extensor muscle strength has been shown to
increase following NMS in both an uncontrolled and a controlled study design (Quittan
et al., 2001; Quittan et al., 1999a) and improvements have been observed in muscle
mass although beneficial changes in oxidative capacity are less obvious (Maillefert et
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al., 1998) compared with those seen following conventional training (Adamopoulos et
al., 1993). The findings in study 1 suggest that NMS is effective as a training modality
as is conventional training, although the degree of benefit will probably differ between
the two modalities and that the systemic and local effects may be different. Certainly,
NMS has been identified as a useful form of rehabilitation / training in other populations
such as spinal cord injury (Hillegass and Dudley, 1999) although the conditions relating
to impaired performance in this patient population and the CHF population differ (i.e.
denervation and disuse atrophy compared with maladaptive fibre type distribution,
disuse, cachexia). The protocol used for stimulation varies markedly between studies
also. Previous investigators have suggested that low frequency (25Hz) NMS, such as
that used in study 1, reduces fatigability and results in improvement in muscle strength
in human and animal subjects (Badylak et al., 1990; Maillefert et al., 1998) although
higher frequency protocols (50Hz) have also been used (Quittan et al., 2001; Quittan et
al., 1999a). Stimulation frequency has been explored more fully in animal models. Low
frequency stimulation protocols using frequencies of between 10 and 20 Hz have been
shown to result in increased fatigue resistance at the expense of decreased muscle
strength and oxidative capacity (Donselaar et al., 1987; Eerbeek et al., 1984; Kernell et
al., 1987b; Kernell et al., 1987a). Little information is available regarding higher
frequency regimes in humans, although in a cat model, intermittent use of a high
frequency stimulation period during low-frequency training largely prevented the loss of
strength seen with low frequency regimes alone (Kernell et al., 1987b). The use of an
alternating high frequency / low frequency protocol in study 4 was used to specifically
avoid the theoretical problems which may be associated with purely low-frequency
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protocols.
There is evidence to suggest that a combination ofNMS with resistance loading is more
effective in generating improvement in human muscle fatigue resistance and strength
(Bajd et al., 1989; Peckham et al., 1976) and further studies to assess the role of
conventional training facilitated by NMS are required.
No improvement in peak VO2 was seen in study 1 following NMS training or indeed
conventional training, despite improvement in 6MW, treadmill exercise time and muscle
strength and fatigue. This may have been due to methodological problems with the
assessment of peak VO2 using the original Morgan Benchmark equipment, or due to
problems with compliance with the training regimes, or with the training regimes
themselves. It is not possible to assess the contribution of each of these potential
problems. Compliance could not be reliably checked in study 1, other than by verbal
report from the study patients. This may be unreliable, of course, as patients may have
been eager to be helpful with the study and unwittingly give the impression that they
have exercised, either with NMS or the bike, more than is actually the case. This issue
was partially addressed in study 4 with the post-training check of the bike odometers.
NMS diaries and verbal reports from patients using NMS remain the only assessment of
compliance with NMS usage in a home environment, however, which is unsatisfactory.
Similarly, the adjustment of stimulator output (amplitude) during the course of a training
session is vital as adaptation occurs over the 30-minute period with visibly less
contraction occurring after every 5-10 minutes. Increasing the output can be potentially
uncomfortable for the subject which introduces a conflict - in a demotivated patient
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group whom we think are unlikely to tolerate conventional training programmes, the
tolerability and acceptability to the patient of a training programme which introduces
some discomfort to the patient cannot be underestimated.
I suspect that for NMS to be truly effective in improving muscle strength, fatigue
resistance and oxidative capacity, some form of resistance element needs to be
introduced. This could take the form of conventional bike exercise coupled with low
frequency NMS although a more comfortable and secure method of affixing the
electrodes would be required, e.g. a modified pair of shorts with electrodes pre-
positioned. Alternatively, resistance training using a modified quadriceps bench could be
used. Finally, although not strictly-speaking resistance training, a more practical
alternative would be to use extended periods ofNMS combined with walking. Using this
method combined with secure electrode placement may allow extended periods ofNMS
use and would allow a better trial using sham NMS vs. true NMS. Unfortunately,
extended periods of NMS may be less comfortable as the electrode interface gel dries
out. Furthermore, precise positioning of the electrodes to encourage maximal fibre
recruitment could be problematic.
9.2 Safety of NMS
One final aim of study 1 was to assess the safety of NMS. I did not encounter any
adverse events with NMS use and this is consistent with the findings of other
investigators. I could find no report in the literature regarding injury relating to NMS
and no adverse cardiovascular effects were observed when NMS was performed in
hospital on a small series of 5 patients. Equally, pulse and blood pressure were checked
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for every patient being instructed in the use of NMS prior to the start of their exercise
period in studies 1-4. No changes were observed. Case reports have suggested possible
inappropriate discharge of implantable defibrillators due to electromagnetic interference
during NMS therapy (Wayar et al., 2003) but other preliminary data exist suggesting
that NMS protocols utilising electrode positions distant from implantable devices do not
cause sufficient interference to induce pacemaker or ICD malfunction, an issue which
will become increasingly relevant over the next decade as more patients undergo device
therapy for CHF (Crevenna et al., 2004; Crevenna et al., 2003). Overall, 1 conclude that
NMS is safe for patients without implantable devices, but the safety for those with
devices remains uncertain and further study is required in this area.
9.3 Body composition
Study 2 examined whether NMS and conventional exercise training regimes were
associated with alterations in body composition assessed by DEXA scanning. Although
changes in functional capacity were seen, including an improvement in peak VO2 for
conventional exercise and a trend in peak VO2 for NMS exercise when corrected for
skeletal muscle mass, no change in body composition was observed. The hypothesis that
NMS would result in increased muscle mass following training was rejected. The
changes in muscle mass and oxidative capacity following conventional training are well
documented already (Nuhr et al., 2004; Quittan et al., 2001), but few data exist
regarding changes in muscle composition following NMS in a heart failure population.
The improvement in peak VO2 following this form of training may be due to increased
muscle mass, beneficial fibre type shift or improved oxidative capacity, and it is unclear
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what the relative contribution of each is. Unsurprisingly, in study 2, a strong correlation
between peak VCb and lean muscle mass was observed. Little improvement was seen in
peak VO2 following training, with peak VO2 increasing only in the bike training group
and only when corrected for skeletal muscle mass. This is likely to be due to a number
of factors, including the greater level of physical fitness seen in the predominantly
NYHA II group, reflected by higher baseline peak VO2S, limiting the potential gains and
the larger muscle groups exercised with the bike training regime compared with NMS.
Compliance may have been better with conventional exercise - there was no reliable
way to check compliance in studies 1-3. No change in muscle mass was observed
following training and this may have been due to a number of factors, including
underpowering of the study to detect a change using DEXA scanning, potentially
ineffective training, or qualitative changes in muscle function rather than quantitative
changes in muscle mass. Improvement was seen in treadmill exercise time, 6MW and
leg strength / fatigue, and as such, I think that training was effective to an extent. It may
be that longer NMS training regimes result in quantitative changes in muscle mass and
this could be the focus for further research. As yet, no similar data exist in the literature
using DEXA scanning following NMS training, and little data after any form of training
in CHF, so it is difficult to put the findings of this study in the context of others' work.
9.4 Inflammatory indices
There is no doubt that a pro-inflammatory state exists in heart failure with the degree of
inflammatory response closely associated with disease severity and progression, as
discussed in section 6.2. It is not yet absolutely certain whether inflammation is
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causative or reflective of disease severity / progression. For instance, mast cell density
and propensity for degranulation and release of vasoactive and pro-inflammatory
mediators from mast cells is elevated in human cardiomyopathy (Patella et al., 1998).
The pro-inflammatory mediators released may be responsible for endomyocardial
fibrosis seen in heart failure and there is evidence in a mouse model that mast cell
deficient animals do not develop myocardial dilatation decompensated heart failure in
response to pressure overload following aortic banding (Hara et al., 2002). TNFa is
negatively inotropic and induces cardiomyopathy (Bryant et al., 1998; Finkel et al.,
1992; Hara et al., 2002; Hegewisch et al., 1990). As such, the pro-inflammatory state
may be causative in the progression of heart failure and limiting / reversing this state
may have functional and prognostic benefits. The hypothesis of study 3 was that the pro¬
inflammatory state observed in CHF could be attenuated by neuromuscular electrical
stimulation. This effect was not observed following NMS training, however. As
discussed in section 6.5, a reduction in TNFa an d IL-6 was not seen following either
method of training in this study in contrast to other studies which have utilised
conventional exercise training methods (Adamopoulos et al., 2002; Larsen et al., 2001).
sTNF,-2 fell in the bike training group but not the NMS group. The discrepancy between
this and other studies includes underpowering of the study although Adamopoulos, et al.
(2002) exercised only 24 heart failure patients. These patients were less well, however,
with slightly lower peak VO2S at baseline and lower ejection fractions but the most
likely explanation for the difference in findings for conventional exercise is the shorter
exercise training duration in our study. With only 6 weeks of training, potential gains in
functional performance and fall in levels of circulating cytokines may not have had time
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to develop. Again, compliance may have been a contributing factor and the smaller
muscle mass exercised with NMS will have influenced the results when compared to
conventional training. Additionally, sTNFr2 is probably less vulnerable to acute changes
in inflammatory state induced by exercise or intercurrent illness for reasons already
discussed in section 6.5 and this may explain the change seen on the bike group only.
With a small group of study patients, sampling blood in a quiet, relaxed environment
may not be sufficient to remove the 'noise' seen with measurement of cytokines
sensitive to acute changes in clinical state, such as TNFa.
Overall, the hypothesis that NMS attenuates the pro-inflammatory response in heart
failure was rejected. However, a larger trial could be designed to investigate this further
as it is unclear whether the lack of change seen was simply due to under-powering as
there was some evidence of change following conventional training. If sufficient patients
could be recruited to a larger trial, it would be interesting to measure pro-inflammatory
cytokines throughout the training period allowing any trends for change with training to
emerge. This type of trial would have to include an appropriate control population of
similarly sick CHF patients, perhaps in a crossover design. Although it is unclear
whether the pro-inflammatory state is directly causative in the pathogenesis of CHF or
simply a surrogate marker of disease activity, measurement of cytokines and other
markers appears to be a marker of efficacy following an intervention in heart failure and
on this basis, NMS as used in this study was less effective than conventional exercise;
this may have important prognostic implications.
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9.5 NMS and decompensated heart failure
Study 4 was designed to investigate the hypothesis that patients with recently
decompensated symptoms would show an increment in peak VO2 and other markers of
severity / functional capacity including NT-pro BNP following NMS training. The
safety and tolerability was compared to conventional training and also overall with NMS
and conventional training in stable CHF patients. A control group of RD-CHF and S-
CHF patients was also included for comparison. Recruitment for this study was
challenging for reasons which were explored further in chapter 8. Following
randomisation, 32% of the RD-CHF group as a whole and 37.5% of RD-CHF patients
randomised to undertake some form of exercise training discontinued the study
prematurely. This high dropout rate significantly limits the interpretation of the study,
but some inferences can be made. RD-CHF patients had more severe CHF symptoms
and higher levels of circulating NT-pro BNP, as expected, but there was attenuation of
NT-pro BNP following NMS exercise in the RD-CHF group above that seen in the
control group, and this finding was repeated when S-CHF patients were included, with
no reduction in NT-pro BNP being seen in the bike training group when RD-CHF and S-
CHF patients were analysed separately or together. Treadmill exercise time improved
for NMS training as did quadriceps strength when RD-CHF and S-CHF patients were
analysed together. This is in keeping with the findings from study 1 and also implies that
selected RD-CHF patients do have something to gain from training. No previous study
has explored the effects of exercise in the recently decompensated patient group and as
such this study forms the basis for future research. Early rehabilitation is offered to
survivors of myocardial infarction and I believe that appropriate exercise training could
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be offered safely to survivors of decompensated heart failure. A major barrier to this
however is the patient's functional status and motivation. Although 1 believe that NMS
is better tolerated and easier to perform than bike exercise, a degree of motivation is
required to perform it properly and consistently. A better way of applying the electrodes
is required to maximise muscle recruitment and to reduce patient discomfort. At present,
quite small electrodes have been used which deliver current to a relatively small area
over the skin (approximately 4cm2). This requires quite accurate placement of electrodes
over quadriceps and gastrocnemius to ensure maximal recruitment with minimal
discomfort. 1 know from my experience that such optimal electrode position varied
between patients and that movement from one position to another tended to degrade the
electrode gel, resulting in more patient discomfort during stimulation. Compliance
would be poorer if the patient experienced more discomfort than was necessary and was
required to increase the stimulator output more frequently to observe an effect.
Therefore, a better system to use larger electrodes and would have better skin contact.
For a subsequent study, 1 think a better system would use an elastic material containing
large electrodes, such as lycra shorts, with a liberal application of conductive liquid/gel
applied before the shorts are put on. For the purposes of patient comfort, I do not think
gastrocnemius stimulation should be used in a further trial as the muscle mass recruited
in comparison to quadriceps is small and it would be important to limit the complexity
of the intervention in order to make it more acceptable to the patient.
A further trial of NMS in the recently decompensated patient would be worthwhile on
the basis of the results from study 4. The benefits of conventional training in patients
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with stable symptoms is well established but delivery of conventional training to RD-
CHF patients is difficult and the benefits are not obvious from study 4. The next trial
should look at NMS in isolation in order to simplify the design. Exclusion criteria in
study 4 primarily relate to the ability to perform some of the functional assessments and
to perform bicycle exercise training. A simplified study ofNMS vs. control patients with
recently decompensated symptoms would be less prone to patient drop-out if simple
functional assessments were made, such as 6MW, quality of life score, leg strength and
fatigue and cycle ergometer VO2 assessment. My experience has been that patients find
cycle ergometer cardiopulmonary exercise tests easier to perform, accepting that there
are some methodological differences in the interpretation of the results. Patients with
minor orthopaedic or neurological disease, or simply severe heart failure who would
have been unable to perform a symptom-limited treadmill cardiopulmonary exercise test
would not necessarily be excluded by such a trial design.
9.6 Influence of training duration
A longer duration of exercise training, e.g. 20 weeks, should also be used. One of the
reasons that studies 1 and 4 show less beneficial change for markers of functional
capacity than other investigators have found is likely to be the short period of exercise -
15 hours in total over a six-week period. The Cochrane review of 29 randomised
controlled trials of exercise training in CHF infers that longer therapy durations results
in greater improvement in functional capacity (Rees et al., 2004). A longer exercise
period would allow more exploration of the tolerability and safety of NMS and would
allow the effect of alteration of medication to be diminished. Large numbers of patients
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with CHF experience a decompensation of their symptoms and require intervention by a
heart failure nurse in the community or hospital admission. At the time of discharge,
adjustments are made to medical therapy and a criticism of study 4 is that adjustments of
ACEi and diuretic dose did occur in the immediate post-discharge period for RD-CHF
patients, although these alterations occurred equally between NMS, bike and control
groups. It cannot be said with certainty, however, that the beneficial effects ofNMS seen
could not have been compounded by changes in medical therapy. In a large metanalysis
of exercise training in CHF, only six out of the nine studies examined were able to
provide information regarding changes in medical therapy during the study period
representing approximately two thirds of the patients studied (Piepoli et al., 2004). It
was stated that there were no alterations in ACEi, B-blocker or aldosterone antagonist
prescription / dosage during the trial period but that patients were permitted to alter the
dosage of their loop diuretic therapy as required. No information was available from the
other three studies and it is impossible to altogether exclude an effect of medical therapy
on outcome during these trials.
A criticism of a longer exercise period for recently decompensated patients of course is
that after a few weeks if they continue to participate in the study, they are effectively
stable. As such, the only truly unstable patients are the ones who drop out of the study.
This concept makes statistical analysis to determine the benefits of NMS in recently
decompensated patients very difficult and so there is an argument for simply trialling
NMS in stable patients first over a long period to demonstrate efficacy, and trialling
NMS over a short period in recently decompensated patients to demonstrate safety.
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Some patients are discharged with a degree of peripheral oedema remaining. My
experience (with patients not included in any of the above studies) has been that NMS in
the presence of oedema results in current shunting and discomfort with no meaningful
muscle recruitment. As such, a delay of only two weeks following hospital discharge
may not be sufficient to allow time for removal of all oedema in the current climate of
early nurse-supported hospital discharge. This may be a factor in future trial design and
also in the clinical utilisation of NMS - if a small number of patients report adverse
experiences with NMS due to discomfort secondary to such shunting, clinicians will be
unlikely to recommend it routinely to many patients.
9.7 Recruitment challenges
Recruitment for clinical trials is recognised to be difficult (Lovato et al., 1997),
particularly amoungst the older population (Ory et al., 2002) and in those patients who
live at a greater distance from the trial centre (Lovato et al., 1997; Petrovitch et al.,
1991). There is no reason for CHF to be an exception. Although the National Service
Framework recommends rehabilitation for patients with CHF (Department of Health,
2000), it is recognised that this is a service infrequently available in the UK and uptake
may be poor. Uptake of rehabilitation following myocardial infarction is lower in the
elderly, in female and in ethnic minority groups (Evenson et al., 1998; Evenson and
Fleury, 2000; McGee and Horgan, 1992; Parks et al., 2000) and as discussed in section
2.2, females and elderly patients are over-represented in the general CHF population.
Limited data exist regarding the difficulties in CHF exercise training trial recruitment,
unfortunately. Only two published papers investigate this issue. In the first, a
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randomised American trial of behavioural therapy in CHF (Chang et al., 2004), similar
exclusion and inclusion criteria to those in study 5 were used - patients were in NHYA
functional class II-III, ejection fraction was <40% indicating at least moderate
impairment of LV systolic function, and they were not participating in an exercise /
rehabilitation programme prior to enrolment. Patients were screened from an outpatient
database and patients with ejection fractions <40% on the basis of results from either
cardiac catheterisation, radionucleotide scanning or echocardiography were flagged.
Patients were invited to participate by letter and subsequently by telephone. They were
required to attend the study centre once per week for 90 minutes for 15 weeks if
randomised to the education arm; in addition they were to use relaxation tapes lasting
15-20 minutes twice per day if randomised to the relaxation arm. Those randomised to
usual care were not required to attend the study centre. Those required to attend were
reimbursed for travel expenses and all patients were given a total of $100 if they
completed the entire study period. This contrasts with the patients in study 5 who were
screened following hospital admission and who were offered no financial incentives to
participate in the study. The recruitment period was 2 years, 3 months, similar to that in
study 5. Of the 1920 patients screened in this study, only 29% were eligible, with high or
unknown EF sited as the reason for exclusion. This is very similar to the number
excluded during our screening process - from 672 patients, 192 (28.6%) were excluded
in view of no, mild or an unknown degree of LV systolic dysfunction. Of the eligible
patients, 65 out of 551 did not turn up for assessment and a further 315 declined to
participate. Of the 126 consenting to participate, 36 were ineligible because their heart
failure symptoms were either too mild or too severe, or they were already participating
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in a similar rehabilitation or relaxation programme. A further 46 either did not complete
the screening or did not turn up for the baseline assessment. Ultimately only 18% (85) of
the 482 eligible patients were enrolled. Transportation problems and lack of willingness
to participate in the study accounted for 56% of those people who declined to continue
following screening. Little additional information regarding the characteristics of non-
eligible patients are presented in this study with most of the data pertaining to those who
were eligible but declined. Of those who declined, symptoms and medications were
similar to those who participated, but those who declined were older.
The second published study is a trial of relatively low-intensity exercise training in a
CHF population. This trial is currently underway but the difficulties encountered in
patient recruitment have recently been published (Jolly et al., 2007). This is a trial
designed to assess the benefits of low intensity exercise in a group of CHF patients in
addition to their enrolment in a heart failure nurse liaison programme. The outcomes of
this trial are yet to be reported. Patients have been recruited after referral to the heart
failure nurse liaison service and considered eligible based on the following inclusion
criteria - at least moderate LV systolic impairment as judged visually or based on a
measured EF of <40%, previous NHYA functional class II-III symptoms or an
admission due to decompensated CHF within the previous two years and stable
symptoms over the previous four weeks. Patients were excluded if they had NYHA class
IV symptoms, were unable to speak English, were hypotensive, had significant angina or
structural heart disease, had had a recent stroke or MI or recent involvement with a
rehabilitation programme, had any psychiatric or dementing illness, had significant
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respiratory compromise or any mechanical reason for not being able to exercise. As
such, inclusion and exclusion criteria were very similar to the S-CHF patients recruited
in study 5. Of the 1639 patients screened, only 39% were eligible based on the above
criteria. In fact 468 patients did not have sufficiently severe heart failure symptoms,
significantly impaired EF or a recent admission with decompensation. This is different
from our screening process as all patients had either been admitted or had had a previous
symptomatic episode. Of the remaining 529 non-eligible patients, 204 had non-cardiac
comorbidities and 153 had cardiac reasons for exclusion. 54 (10%) were excluded due to
problems with remote residence and transport issues which contrasts with the higher
percentage of drop-out due to this reason sited in the relaxation therapy study above
(Chang et al., 2004). Of the remaining 642, 289 declined to participate or failed to attend
for assessment and 184 were excluded following more detailed clinical assessment.
It will be interesting to see the baseline characteristics of patients recruited to this study
when it is published and compare the participants with the original eligible group. 169
(10%) patients were eventually randomised following a 19-month screening process in
this study, a similar duration to ours, but targeting patients who were stable - over half
of our recruitment was directed at patients with a recent decompensation. There is no
doubt that recruitment of RD-CHF patients was more difficult and this is reflected in the
lower proportion of the original screened group who eventually participated. No
information is recorded, unfortunately, regarding the reasons sited by patients in our
study for not wishing to be involved in the study. However, it is clear from the above 2
studies and from study 5 presented here that it is difficult to recruit these patients into
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clinical trials of exercise training. Additionally, the population of CHF patients recruited
into studies of exercise training, whether they are stable or recently decompensated
patients, are significantly different from the screened population from which they are
drawn. The RD-CHF patients do seem to more closely resemble the general heart failure
population in terms of age and severity, but recruiting this group and maintaining their
involvement within an exercise training study is particularly challenging.
Low rates of patient recruitment over the course of the study resulted in statistical under-
powering of study 4 and has limited the interpretation of the findings. To further assess
the benefits of early rehabilitation for RD-CHF patients a longer recruitment period
would be required. Measuring the benefits of training over a short period as was
performed in study 4 is, 1 think, still valid as a longer period of training would blur the
distinction between recently decompensated and stable patients. However, a much larger
trial will be needed to assess the effects of early rehabilitation and it may be that this sort
of trial will never be performed owing to the methodological problems 1 have
encountered. A simpler trial design will be needed, as discussed above, perhaps simply
investigating NMS vs. usual care and using simple assessments such as quality of life,
6MW, neurohormonal markers of severity of CHF, and possibly not including
cardiopulmonary data. Of note is that relatively few trials of exercise training in CHF
have included specific reference to the involvement of heart failure specialist nurse
involvement. It is well recognised that CHF nurse liaison is an effective intervention in
CHF with respect to hospital admission rates and survival (Blue et ah, 2001; Rich et al.,
1995; Stewart et ah, 1999). CHF nurses provide education, motivation and close
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monitoring of clinical state for CHF patients. We were careful to control for this by
including nurse support in study 4. It is not clear whether the additional monitoring
provided by study investigators during CHF exercise-training trials is equivalent, better
or less useful than CHF specialist nurse support, but it will be important to remember
that the control group's usual care for some research studies may in fact be less good
than the current gold standard which includes heart failure nurse liaison support.
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10 Conclusions
There is no doubt that in selected CHF patients, exercise training is safe, beneficial and
worthwhile. The major conceptual hurdle, though, is that the heart failure population is
elderly, symptomatic and demotivated. Exercise training trials are by necessity of an
open design and there may of course be a large placebo effect following exercise
regimes and this should be considered when interpreting the results of quality of life
measures and submaximal exercise performance parameters, e.g., 6MW. There is little
question, however, that qualitative changes do occur following training, such as
improvement in aerobic capacity and attenuation of the pro-inflammatory response. How
do we translate these potential gains from the highly selected CHF trial patient to the
wider CHF population? I know from my own data, presented in chapter 8, that the CHF
trial patient is younger, more likely to be male and likely already to be taking some form
of regular exercise prior to enrolment in the study when compared with the very much
larger group of non-eligible patients. This makes extrapolation of data difficult and it is
hard to recommend training to, for instance, elderly female CHF patients on this basis.
NMS may be an effective option to provide exercise training to the wider CHF
population as, 1 believe, it is easier to perform than conventional exercise and, as can be
seen from studies 1, 3 and 4, beneficial changes following NMS training are observed. I
do not think that the stimulation protocol used or duration of training performed was
optimal and this is reflected by the minimal change in peak VO2 observed following
NMS and indeed with conventional training. Additionally, a wider CHF population
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needs to be targeted to allow sensible extrapolation of these findings before
recommendation ofNMS training can be made.
The recruitment of recently decompensated patients in study 4 (chapter 7) was ambitious
but, as it subsequently proved, useful. The high rate of dropout emphasised that a much
larger trial would be required to assess the effect of NMS in this population. Since this
type of trial is unlikely to be repeated even on a small scale, however, training will
continue to be recommended for stable patients only. This is unfortunate as NMS
training may be effective in this population and may indeed serve as a bridging therapy
before a more conventional regime can be undertaken.
I sincerely hope that work in this area continues. Trials of exercise training have tended
to recruit small numbers of patients in the past and in the era of modern CHF
management, pharmacological and device therapy will dilute the potential benefits seen
in such small trials. Additionally, non-patentable treatments such as NMS (and exercise
in general) will struggle to attract funding for large scale clinical trials. Without the large
trials, we will not be able to confirm the new concepts in exercise therapy that emerge
with the smaller, ambitious study.
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Appendix A. Minnesota Living with Heart Failure
Questionnaire
The following questions ask how much your heart failure (heart condition) affected your life during the
past month (4 weeks). After each question, circle the 0, 1, 2, 3, 4 or 5 to show how much your life was
affected. If a question does not apply to you, circle the 0 after that question.
Did your heart failure prevent you from living as you










making you sit or lie down to rest during the
day?
making your walking about or climbing stairs
difficult?
making your working around the house or yard
difficult?


























6 making your sleeping well at night difficult? 0 1 2 3 4 5
7 making your relating to or doing things with
your friends or family difficult?
0 1 2 3 4 5
8 making your working to earn a living difficult? 0 1 2 3 4 5
9 making your recreational pastimes, sports or
hobbies difficult?
0 1 2 3 4 5
10 making your sexual activities difficult? 0 1 2 3 4 5
11 making you eat less of the foods you like? 0 1 2 3 4 5
12 making you short of breath? 0 1 2 3 4 5
13 making you tired, fatigued, or low on energy? 0 1 2 3 4 5
14 making you stay in a hospital? 0 1 2 3 4 5
15 costing you money for medical care? 0 1 2 3 4 5
16 giving you side effects from treatments? 0 1 2 3 4 5
17
18
making you feel you are a burden to your family
or friends?














19 making you worry? 0 1 2 3 4 5
20 making it difficult for you to concentrate or
remember things?
0 1 2 3 4 5
21 making you feel depressed? 0 1 2 3 4 5
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Instructions for Data Collection and Scoring
1. Patients should respond to the questionnaire prior to other assessments and
interactions that may bias their responses. You might tell the patient that you
would like to get his or her opinion before doing your medical assessment.
2. Ample, uninterrupted time should be provided for the patient to complete the
questionnaire. We recommend that the patient answer the questions without being
influenced by others such as their spouse or family members. Studies show that
patient proxies often have different perspectives.
3. We recommend that you use the first question to give the respondent more detailed
instructions as follows.
a. Read the introductory paragraph at the top of the questionnaire.
b. Read the first question with the respondent - "Did your heart failure prevent you
living as you wanted during the last month (4 weeks) by causing swelling in your
ankles or legs?" Then tell the respondent -
• If you did not have any ankle or leg swelling during the past month (4
weeks) you should circle the zero (0) after this question.
• If you did have swelling that was caused by a sprained ankle or some
other cause that you are sure was not related to heart failure, you should
circle the zero (0) after this question.
• If you had swelling that might be related to your heart condition, then
rate how much the swelling prevented you from doing things you
wanted to do or feeling the way you would like to feel. In other words,
how much did the swelling affect your life? Circle either the 0, 1,2, 3,
4 or 5 to indicate how much the swelling affected your life during the
past month - zero (0) means not at all, one (1) means very little and five
(5) very much.
4. Ask the patient read and respond to all 21 questions. The entire questionnaire may
be read directly to the patient if one is careful not to influence responses by verbal
or physical cues.
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5. Check to make sure the patient has responded to each question. If a question does
not apply to the patient they should circle the zero (0). Make sure there is only one
answer clearly marked for each question.
6. Score the questionnaire by summating the responses to all 21 questions. In
addition, a physical dimension score (items 2, 3, 4, 5, 6, 7, 12, 13 on the version
sent with these instructions) and emotional dimension score (items 17, 18, 19, 20,
21) have been identified by factor analysis and may be scored by simple
summation to further characterize the effect of heart failure on a patient's life.
7. Partially complete questionnaires do occur despite best efforts to minimize missing
data. However, missing data can greatly bias the data and complicate analysis. To
reiterate, you need to make sure the respondents understand to mark zero for any
items that do not apply to them, rather than leave a blank. Whenever possible
review the questionnaire before the respondent leaves to make sure there are no
unanswered questions or questions with more than one answer.
1 28. Several methods to impute missing data are discussed in the literature. ' Multiple
imputation using completed questions and perhaps other study variables to predict
missing responses should be considered.3 If a missing response is not imputed, the
item will be eliminated from that person's score (the sum of responses). Since
intermittently missing data can greatly affect within-person changes in scores, you
might want to use the same subset of questions to represent a person at all times by
omitting questions that have missing data at any point in time. We do not have any
recommendations about when missing data become too extensive to render the
information being collected useless.
1
Fayers PM et al. Incomplete quality of life data in randomized trails: missing items. Statistics in
Medicine 1998;17:679-696.
2 Schaffer JL and Graham JW. Missing data: our view of the state of the art. Psychological Methods
2002;7:147-177.
3
Raghunathan TE, et al. A multivariate technique for multiply imputing missing values using a sequence
of regression models. Survey Methodology 2001;27:85-95.
277
OPcontact Hospitalnumber Contactlinenumtx Location Contact Profession Dateofcon act CarerPresent Memo Datenextdu DischargedFromNL BPsystolic BPdiastolic Recommendations LVD36Score CreationDate
Studylnclusi
consultant
Contactode Firs:name Surname Tide Profession HOSDltal Contactnumber FaxNumber
Hospitalnumbe" Studycontactnam Researchernam Datecontacted Comments
Consultantcode Consultanttitle Consultantfir tai Consultantsurnam Departmentcod Hospitalcode Consultantsecreta
Departmen
UserNumber UserName UserTitle UserDepartment UserHospital UserPhcne UserFax UserBleep
Departmentcode Departmentn e
Hospitaltable Hospitalcode Hospitalname Hospitaladdress Hospitaltown/city Hospitalpostc de Hospitalphonenur FaxNumber
Medication. Medeventlinur Hospitalnumber NSVCode Dose Administrationfre ToBeTaken Startdate Datelastmodifi d Discontinuedda Activedrug Drugcomments
Weights Weighteven2 Hospitalnumber Weightdate Weight
Admission Admissionkey Admissionnuirj Hospitalnumbc Dateofadmiss HFadmission?; AdmissionNYH! DischargeNYH, NightsnCCU Requiredinotrci Hoursnin trc: NewECGChan 1stdegreeblo 2nddegree(ty; 2nddegree(ty 3rddegreebio
Studycode Hospitalnumbt NYHApreadmi; NYHA2/52 NYHA8/52 NYHA12/52 Weight2/52 Weight8/52 Weioht12/5?
Medicalhis.
Pharmacy
CXRcomments* Angiogram Lastangiogram Angiogramc n Exercise Alcohol Agefinished/t Occupation Emloymentsta Mainc rer Carerproximity Carervisitfreq CIDiuretic CISpiro CIACEi CIAGII CIDig CIB-Blocker Contra-indicatH
IVfunrhnno
NSVCode DrugDescription DrugName DrugForm PrintForm ReorderPackSize cost ContractPrice DrugClass UnitDose Units Used
BBuptitrati Hospitalnumber Datereferr d Source Finaltitrationda e
GPREF GPID GMCNumber GPReferenceNum GPSurname GPForename GPInitials PracticeCode
BBUptritati.
Diagnosise.
B8evertlin Hospitalnumbt Visitdate1 BBname Dose Active Datestopp d-
Diagnosisevertl Hospitalnumber Diagnosiscode Diagnosisd te Diagnosiscommen
bloodeven Bloodevertbr> Hospitalnumb< Date Haemoglobin Urea Creatinine




























































































42 Carcinoma - melanoma
43 Carcinoma - oesophagus
44 Carcinoma - ovary
45 Carcinoma - pancreas
46 Carcinoma - prostate





52 Cardiomyopathy - dilated
53 Cardiomyopathy - hypertrophic
54 Cardiomyopathy - restrictive
55 Cardioversion - successful
56 Cardioversion - unsuccessful
57 Carotid Endarterectomy
58 Chest infection
59 Chronic fatigue syndrome
60 Chronic lymphatic leukaemia
61 Chronic myeloid leukaemia
62 Chronic renal failure
63 Chronic renal impairment (mild)
64 Chronic renal impairment (moderate)
65 Chronic renal impairment (severe)




70 Coronary artery bypass
71 Coronary artery bypass, 1 vessel
72 Coronary artery bypass, 2 vessels
73 Coronary artery bypass, 3 vessels
74 Coronary artery bypass, 4 vessels
75 Coronary artery bypass, 5 vessels









85 Diabetes mellitus type I















100 Femoral popliteal bypass
101 Gastric angio-dysplasia
102 Giant cell arteritis
103 Glaucoma
104 Glomerulonephrits
105 Glucocortoid suppressible hyperaldosteronism
106 GORD
107 Gout
108 Heart block (complete)
109 Heart block (type I second degree)














124 Implantable cardiac defibrillator
125 Infective endocarditis
126 Intermittent Claudication
127 Intracranial Acoustic Neuroma
128 Irritable bowel syndrome
129 Ischaemic Heart Disease
130 Ischaemic heart disease - angina
131 Kaposis sarcoma
132 Knee Replacement
133 Left Ventricular Systolic Dysfunction
134 Left Ventricular Systolic Dysfunction - Mild

















































Left Ventricular Systolic Dysfunction - Mod/Severe
Left Ventricular Systolic Dysfunction - Moderate











Mixed aortic valve disease
Mixed connective tissue disease






Myocardial infarction - non Q wave










































































Permanent pacemaker (dual chamber)










Pulmonary embolisim - single

























Thrombus - left ventricle
Thrombus - right ventricle
Transient ischaemic attack





Urinary tract infection - recurrent
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231 Valvuloplasty - mitral





237 VF / VT arrest
238 VSD
